AU2005212399B2 - Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof - Google Patents

Abstract

Compounds represented by the following structure (I) are disclosed: as are methods for making such compounds, wherein said methods comprise reacting a diacyldiketopiperazine with a first aldehyde to produce an intermediate compound; and reacting the intermediate compound with a second aldehyde to produce the class of compounds with the generic structure, where the first aldehyde and the second aldehydes are selected from the group consisting of an oxazolecarboxaldeyhyde, imidazolecarboxaldehyde, a benzaldehyde, imidazolecarboxaldehyde derivatives, and benzaldehyde derivatives, thereby forming the above compound wherein R, R', R'', R, R, R, R, and R, X and X, Y, Z, Z, Z, Z, and Z may each be separately defined in a manner consistent with the accompanying description. Compositions and methods for treating vascular proliferation are also disclosed.

Description

WO 2005/077940 PCT/US2005/003636 DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF AND THE SYNTHESIS OF DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF Related Applications [00011 This application is a continuation-in-part of U.S. Patent Application No. 10/632,531 filed on August 1, 2003, and claims priority to U.S. Provisional Application No. 60/542,073 filed February 4, 2004 and to U.S. Provisional Application No. 60/624,262 filed November 1, 2004, all of which are entitled DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF AND THE SYNTHESIS OF DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF; and each of which is incorporated herein by reference in its entirety. Background of the Invention Field of the Invention [0002] The present invention relates to compounds and methods of synthetic preparation in the fields of chemistry and medicine. More specifically, the present invention relates to compounds and procedures for making compounds useful in the treatment of cancer and the treatment of fungal infections. Brief Description of the Related Art [0003] It is thought that a single, universal cellular mechanism controls the regulation of the eukaryotic cell cycle process. See, e.g., Hartwell, L.H. et al., Science (1989), 246: 629-34. It is also known that when an abnormality arises in the control mechanism of the cell cycle, cancer or an immune disorder may occur. Accordingly, as is also known, antitumor agents and immune suppressors may be among the substances that regulate the cell cycle. Thus, new methods for producing eukaryotic cell cycle inhibitors are needed as antitumor and immune-enhancing compounds, and should be useful in the treatment of human cancer as chemotherapeutic, anti-tumor agents. See, e.g., Roberge, M. et al., Cancer Res. (1994), 54, 6115-21. [0004] Fungi, especially pathogenic fungi and related infections, represent an increasing clinical challenge. Existing antifungal agents are of limited efficacy and toxicity, -1- WO 2005/077940 PCT/US2005/003636 and the development and/or discovery of strains of pathogenic fungi that are resistant to drugs curTently available or under development. By way of example, fungi that are pathogenic in humans include among others Candida spp. including C. albicans, C. tropicalis, C. kefyr, C. krusei and C. galbrata; Aspergillus spp. including A. fumigatus and A. flavus; CIyptococcus neoformans; Blastomyces spp. including Blastomyces dermatitidis; Pneumocystis carinii; Coccidioides immitis; Basidiobolus ranarum; Conidiobolus spp.; Histoplasma capsulatum; Rhizopus spp. including R. oryzae and R. microsporus; Cunninghamella spp.; Rhizomucor spp.; Paracoccidioides brasiliensis; Pseudallescheria boydii; Rhinosporidium seeberi; and Sporothrix schenckii (Kwon-Chung, K.J. & Bennett, J.E. 1992 Medical Mycology, Lea and Febiger, Malvern, PA). [00051 Recently, it has been reported that tryprostatins A and B (which are diketopiperazines consisting of proline and isoprenylated tryptophan residues), and five other structurally-related diketopiperazines, inhibited cell cycle progression in the M phase, see Cui, C. et al., 1996 JAntibiotics 49:527-33; Cui, C. et al. 1996 JAntibiotics 49:534-40, and that these compounds also affect the microtubule assembly, see Usui, T. et al. 1998 Biochem J 333:543-48; Kondon, M. et al. 1998 J Antibiotics 51:801-04. Furthermore, natural and synthetic compounds have been reported to inhibit mitosis, thus inhibit the eukaryotic cell cycle, by binding to the colchicine binding-site (CLC-site) on tubulin, which is a macromolecule that consists of two 50 kDa subunits (a- and p--tubulin) and is the major constituent of microtubules. See, e.g., Iwasaki, S., 1993 Med Res Rev 13:183-198; Hamel, E. 1996 Med Res Rev 16:207-31; Weisenberg, R.C. et al., 1969 Biochemistiy 7:4466-79. Microtubules are thought to be involved in several essential cell functions, such as axonal transport, cell motility and determination of cell morphology. Therefore, inhibitors of microtubule function may have broad biological activity, and be applicable to medicinal and agrochemical purposes. It is also possible that colchicine (CLC)-site ligands such as CLC, steganacin, see Kupchan, S.M. et al., 1973 JAm Chem Soc 95:1335-36, podophyllotoxin, see Sackett, D.L., 1993 Pharmacol Ther 59:163-228, and combretastatins, see Pettit, G.R. et al., 1995 J Med Chem 38:166-67, may prove to be valuable as eukaryotic cell cycle inhibitors and, thus, may be useful as chemotherapeutic agents. -2- WO 2005/077940 PCT/US2005/003636 [00061 Although diketopiperazine-type metabolites have been isolated from various fungi as mycotoxins, see Horak R.M. et al., 1981 JCS Chem Comm 1265-67; Ali M. et al, 1898 Toxicology Letters 48:235-41, or as secondary metabolites, see Smedsgaard J. et al., 1996 J Microbiol Meth 25:5-17, little is known about the specific structure of the diketopiperazine-type metabolites or their derivatives and their antitumor activity, particularly in vivo. Not only have these compounds been isolated as mycotoxins, the chemical synthesis of one type of diketopiperazine-type metabolite, phenylahistin, has been described by Hayashi et al. in J. Org. Chem. (2000) 65, page 8402. In the art, one such diketopiperazine-type metabolite derivative, dehydrophenylahistin, has been prepared by enzymatic dehydrogenation of its parent phenylahistin. With the incidences of cancer on the rise, there exists a particular need for chemically producing a class of substantially purified diketopiperazine-type metabolite-derivatives having animal cell-specific proliferation inhibiting activity and high antitumor activity and selectivity. There is therefore a particular need for an efficient method of synthetically producing substantially purified, and structurally and biologically characterized, diketopiperazine-type metabolite-derivatives. [0007] Also, PCT Publication WO/0153290 (July 26, 2001) describes a non synthetic method of producing dehydrophenylahistin by exposing phenylahistin or a particular phenylahistin analog to a dehydrogenase obtained from Streptomyces albulus. Summary of the Invention [0008] Compounds, and methods for the synthetic manufacture of compounds, are disclosed for a class of compounds having the structure of Formula (I): R 1 ' Z R 2 N y - X2 ZN N

R

1

Z

4 X2 R 3 (1) [00091 The disclosed compounds have the structure of Formula (I) wherein: -3- WO 2005/077940 PCT/US2005/003636 [00101 R 1 , R 4 , and R 6 , are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C-C 24 alkyl, unsaturated C-C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, -CO-0-R 7 , cyano, alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl -CCO-R 7 , wherein R 7 is selected from a hydrogen atom, a halogen atom, and saturated C-C 24 alkyl, unsaturated Cr-C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups; [00111 Ri' and R 1 " are independently selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C-C 24 alkyl, unsaturated Ce-C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, -CO-0-R 7 , cyano, alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl -CCO-R 7 , wherein R 7 is selected from a hydrogen atom, a halogen atom, and saturated C-C 24 alkyl, unsaturated CI-C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups; [00121 R 2 , R 3 , and R 5 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C -C1 2 alkyl, unsaturated I -C 1 2 alkenyl, acyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups, sulfonyl and substituted sulfonyl groups; [00131 X, and X 2 are separately selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom, each either unsubstituted or substituted with a RS group, as defined above; -4- WO 2005/077940 PCT/US2005/003636 [00141 Y is selected from the group consisting of a nitrogen atom, a substituted nitrogen atom with a R 5 group from above, an oxygen atom, a sulfur atom, a oxidized sulfur atom, a methylene group and a substituted methylene group; [00151 n is an integer equal to zero, one or two; [00161 Z, for each separate n, if non-zero, and Z 1 , Z 2 , Z 3 and Z 4 are each separately selected from a carbon atom, a sulfur atom, a nitrogen atom or an oxygen atom; and [0017] the dashed bonds may be either single or double bonds; [00181 with the proviso that, in a particular compound, if R 1 , R 1 ', R 2 , R 3 , R 4 and

R

5 are each a hydrogen atom, then it is not true that X 1 and X 2 are each an oxygen atom and

R

6 is either 3,3 -dimethylbutyl- 1 -ene or a hydrogen atom. 100191 The methods comprise the steps of: [00201 reacting a diacyldiketopiperazine with a first aldehyde to produce an intermediate compound; and [00211 reacting said intermediate compound with a second aldehyde to produce said class of compounds with said generic structure, wherein [00221 said first aldehyde and said second aldehydes are selected from the group consisting of an oxazolecarboxaldeyhyde, imidazolecarboxaldehyde, a benzaldehyde, imidazolecarboxaldehyde derivatives, and benzaldehyde derivatives, thereby forming a compound wherein [00231 The disclosed compounds have the structure of Formula (I) wherein: [0024] R 1 , R 4 , and R 6 , are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1

-C

24 alkyl, unsaturated C 1

-C

24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, -CO-0-R 7 , cyano, alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl -CCO-R 7 , wherein R 7 is selected from a hydrogen atom, a halogen atom, and saturated C1-C 24 alkyl, unsaturated C 1

-C

24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, -5- WO 2005/077940 PCT/US2005/003636 substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups; [0025] R 1 ' and R 1 " are independently selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C-C 24 alkyl, unsaturated C-C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, -CO-0-R 7 , cyano, alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl -CCO-R 7 , wherein R 7 is selected from a hydrogen atom, a halogen atom, and saturated C-C 24 alkyl, unsaturated C-C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups; [00261 R 2 , R 3 , and R5 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1

-C

1 2 alkyl, unsaturated C-C 12 alkenyl, acyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups, sulfonyl and substituted sulfonyl groups; [0027] X 1 and X 2 are separately selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom, each either unsubstituted or substituted with a Rs group, as defined above; [00281 Y is selected from the group consisting of a nitrogen atom, a substituted nitrogen atom with a R5 group from above, an oxygen atom, a sulfur atom, a oxidized sulfur atom, a methylene group and a substituted methylene group; [00291 n is an integer equal to zero, one or two; [00301 Z, for each separate n, if non-zero, and Z 1 , Z 2 , Z 3 and Z 4 are each separately selected from a carbon atom, a sulfur atom, a nitrogen atom or an oxygen atom; and [0031] the dashed bonds may be either single or double bonds. [0032] In preferred embodiments of the compound and method, the imidazolecarboxaldehyde is 5-(1,1-dimethyl-2-ethyl)imidazole-4-carboxaldehyde and the -6- WO 2005/077940 PCT/US2005/003636 benzaldehyde comprises a single methoxy group. Additional preferred embodiments of the compounds described herein include compounds having a t-butyl group, a dimethoxy group, a chloro- group, and a methylthiophen group, and methods of making such compounds, as well as the compounds described in Tables 2, 3 and 4, as well as methods of making such compounds. [0033] Also disclosed are methods and materials for treating neoplastic tissue or preventing cancers or infection by a pathogenic fungus. These methods and materials are particularly well suited for treatment of mammalian subjects, more particularly humans, and involve administering to the subject a dehydrophenylahistin or its. analog. The method comprises administering to the subject a composition comprising an effective antitumor or antifungal amount of a dehydrophenylahistin or its analog. [00341 Further embodiments relate to methods for treating a condition in an animal, which methods can include administering to the animal a compound as described herein in an amount that is effective to reduce vascular proliferation or in an amount that is effective to reduce vascular density. Exemplary conditions include neoplasms, such as cancers, as well as other conditions associated with or which rely upon vascularization, including for example, immune and non-immune inflammation, rheumatoid arthritis, chronic articular rheumatism, psoriasis, diabetic retinopathy, neovascular glaucoma, retinopathy of prematurity, macular degeneration, corneal graft rejection, retrolental fibroplasia, rubeosis, capillary proliferation in atherosclerotic plaques, osteoporosis, and the like. In some embodiments, the disease is not cancer. [0035] Other embodiments relate to methods of inducing vascular collapse in an animal. The methods can include treating said animal with a therapeutically effective amount of a compound of the Formula (I) as described herein, for example. The therapeutically effective amount of said compound can cause tubulin depolymerization in the vasculature. [0036] Preferably the animal can be a human. Preferably the disease can be a tumor, a diabetic retinopathy, an age-related macular degeneration, and the like. In some aspects the disease is not cancer or cancer can be specifically excluded from the methods and uses. Preferably, the compound is KPU-02. -7- WO 2005/077940 PCT/US2005/003636 [0037] Still further embodiments relate to pharmaceutical compositions for treating or preventing vascular proliferation comprising a pharmaceutically effective amount of a compound disclosed herein together with a pharmaceutically acceptable carrier therefor. The vascular proliferation can be a symptom of a disease, for example, cancer, age-related macular degeneration and diabetic retinopathy. . [00381 Some embodiments relate to methods of preferentially targeting tumor vasculature over non-tumor tissue vasculature. The methods can include the step of administering to an animal, preferably a human, a compound having the structure of Formula (I) as described herein. The non-tumor tissue can be, for example, skin, muscle, brain, kidney, heart, spleen, gut, and the like. The tumor vasculature can be preferentially targeted over non-tumor tissue vasculature, for example, by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% and 90%. [0039] Other embodiments relate to methods of preferentially targeting tumor vasculature over non-tumor tissue vasculature, which methods can include administering to an animal an agent that preferentially targets tumor vasculature over non-tumor tissue vasculature. [00401 Further embodiments relate to uses of a compound having the structure of Formula (I) in the preparation of a medicament for the treatment of a condition associated with increased vasculature or which relies upon vasculature. In some aspects the condition can be cancer, while in others, cancers particular types or all cancers are specifically excluded. The condition can be any other that is associated with hypervascularization, associated with vasculature or which relies upon vasculature. Examples include immune and non-immune inflammation, rheumatoid arthritis, chronic articular rheumatism, psoriasis, diabetic retinopathy, neovascular glaucoma, retinopathy of prematurity, macular degeneration, corneal graft rejection, retrolental fibroplasia, rubeosis, capillary proliferation in atherosclerotic plaques, osteoporosis, and the like. Brief Description of the Drawings [0041] The accompanying drawings, which are incorporated in and form part of the specification, merely illustrate certain preferred embodiments of the present invention. Together with the remainder of the specification, they are meant to serve to explain preferred -8- WO 2005/077940 PCT/US2005/003636 modes of making certain compounds of the invention to those of skilled in the art. In the drawings: [0042] Figure 1 illustrates a reaction scheme for producing dehydrophenylahistins by reacting a diacyldiketopiperazine 1 with an imidazolecarboxaldeheyde 2 to yield an intermediate compound 3 which is reacted with a benzaldehyde 4 to -produce a dehydrophenylahistin. [0043] Figure 2 depicts the HPLC profile of the synthetic crude dehydrophenylahistin. [0044] Figure 3 illustrates a reaction scheme for producing dehydrophenylahistins by reacting a diacyldiketopiperazine 1 with a benzaldehyde 4 to yield an intermediate compound 17 which is reacted with an imidazolecarboxaldeheyde 15 to produce a dehydrophenylahistin. [0045] Figure 4 depicts the HPLC profiles of the crude synthetic tBu dehyrophenylahistin produced from Route A and from Route B. [0046] Figure 5 illustrates two modification strategies for dehydroPLH for potent cytotoxic activity. [00471 Figure 6 depicts the putative active conformation of dehydroPLH at the phenyl moiety. [00481 Figure 7 depicts Cytochrome P450 metabolism of phenylahistin. [00491 Figure 8 illustrates the Z-E migration of tBu-dehydroPLH. [00501 Figure 9 depicts the synthesis and prodrug image of acyl-E-tBu dehydroPLH. [00511 Figure 10 depicts the temperature gradient of 3-Z-Benzylidene-6-[5"-(1,1 dimethylallyl)-lH-imidazol-4"-Z-ylmethylene]-piperazine-2,5-dione. [0052] Figure 11 depicts the temperature gradient of 3-Z-benzylidene-6-(5"-tert butyl-lH-imidazol-4"-Z-ylmethylene)-piperazine-2,5-dione. [00531 Figure 12 depicts the effect of KPU-2, KPU-35 and t-butyl-phenylahistin in comparison to colchicine and taxol on HuVEC monolayer permeability to FITC-Dextran. [0054] Figure 13 depicts the effect of KPU-2 alone and in combination with CPT 11 on estimated tumor growth in the HT-29 Human Colon Tumor Xenograft model. -9- WO 2005/077940 PCT/US2005/003636 [00551 Figure 14 depicts the effect of KPU-2 alone and in combination with CPT 11 on the weight of tumors excised at autopsy in individual mice in the HT-29 Human Colon Tumor Xenograft model. [0056] Figure 15 depicts the effect of KPU-2 alone and in combination with CPT 11 on estimated tumor growth in the HT-29 Human Colon Tumor Xenograft model. [00571 Figure 16 depicts the effect of KPU-2 alone and in combination with CPT 11 on the weight of tumors excised at autopsy in individual mice in the HT-29 Human Colon Tumor Xenograft model. [0058] Figure 17 depicts the effects of: A. KPU-2, B. KPU-35 and C. t-butyl phenylahistin alone and in combination with CPT- 11 on estimated tumor growth in the HT 29 human colon tumor xenograft model. [0059] Figure 18 depicts the effects of A. KPU-2, B. KPU-35 and C. t-butyl phenylahistin alone and in combination with CPT-11 on the weight of tumors excised at autopsy in individual mice in the HT-29 Human Colon Tumor Xenograft model. [0060] Figure 19 depicts the effects of KPU-2 alone and in combination with CPT- 11 on tumor growth in the HT-29 human colon tumor xenograft model: comparison of three studies. [0061] Figure 20 depicts the effects of KPU-2 alone and in combination with CPT-11 on final tumor weights in the HT-29 human colon tumor xenograft model: comparison of three studies. [00621 Figure 21 depicts the effects of KPU-2 alone or in combination with Taxotere on estimated tumor growth in the DU-145 Human Prostate Tumor Xenograft Model. [0063] Figure 22 depicts the effects of A. KPU-2, B. KPU-35 and C. t-butyl phenylahistin alone and in combination with Taxotere on the estimated tumor growth based on observations made during the in-life portion of the DU-145 Human Prostate Tumor Xenograft Model. [0064] Figure 23 depicts the effects of KPU-2 alone and in combination with Taxotere on the individual excised tumor weights at autopsy in the DU-145 Human Prostate Tumor Xenograft Model. -10- WO 2005/077940 PCT/US2005/003636 [00651 Figure 24 depicts the effects of KPU-35 alone and in combination with Taxotere on the individual excised tumor weights at autopsy in the DU-145 Human Prostate Tumor Xenograft Model. [0066] Figure 25 depicts the effects of A. KPU-2, B. KPU-35 and C. t-butyl phenylahistin alone and in combination with Taxotere in MCF-7 Human Breast Tumor Xenograft model. [0067] Figure 26 depicts the effects of KPU-2 alone and in combination with Taxotere on estimated tumor growth in the A549 Human Lung Tumor Xenograft model. [0068] Figure 27 depicts the effects of KPU-2 alone and in combination with Taxotere on the excised tumor weights at autopsy in the A549 Human Lung Tumor Xenograft model. [00691 Figure 28 depicts the effects of KPU-2 alone and in combination with Paclitaxel on estimated tumor weight in the murine mammary fat pad implanted MDA-231 Human Breast Tumor model. [0070] Figure 29 depicts effects of A. KPU-2, B. KPU-35 and C. t-butyl phenylahistin alone and in combination with Paclitaxel in the Murine Melanoma B16 F10 Metastatic Tumor Model. [0071] Figure 30 depicts effects of KPU-35 and KPU-02 on tumor vasculature in the dorsal skinfold chamber of Figure 30. [0072] Figure 31 depicts effect of KPU-02 in combination with CPT-1 1 on the estimated tumor weight in the HT-29 human colon tumor xenograft model. [00731 Figure 32 depicts effect of KPU-02 in combination with CPT- 11 on the excised tumor weight in the HT-29 human colon tumor xenograft model. [0074] Figure 33 depicts rapid tubulin depolymerization in HuVEC cells induced by KPU-02 and KPU-35. [00751 Figure 34 depicts effect of KPU-02 on monolayer permeability in HuVEC cells. [0076] Figure 35 depicts the effect of KPU-02 on tumor blood flow in the P22 rat sarcoma model using the 1251-IAP technique. -11- WO 2005/077940 PCT/US2005/003636 [00771 Figure 36 depicts the effect of KPU-02 15 mg/kg IP (expressed as % vehicle control) on blood flow in different tissues 1 and 24 hours post-dose. [0078] Figure 37 depicts the tumor necrosis induced by KPU-02 7.5 and 15.0 mg/kg IP in the P22 rat sarcoma model [00791 Figure 38 lists the activity of various tBu-dehydro-PLH derivatives at HT 29 cells. [0080] Figure 39 depicts 3D QSAR (CoMFA) analysis of tBu-dehydro-PLH derivatives. [0081] Figure 40 depicts X-ray crystallographic analysis of tBu-dehydro-PLH derivatives. [00821 Figure 41 depicts the biologically activity of various phenylahistin derivatives compared to colchicine. [0083] Figure 42 depicts the effect on cell cycle progression of HeLa cells by tBu dehydro-PLH (KPU-2) and KPU-35. [0084] Figure 43 depicts the effect of dehydro-PLH and tBu-dehydro-PLH (KPU 2) on drug-sensitive and drug-resistant tumor cell lines as compared to paclitaxel. [0085] Figure 44A depicts turbidity spectra of microtubule protein polymerization in the presence of DMSO drug vehicle (0), 1.25 AM (o), 2.5 pM (-), and 5 pM (o) KPU-02. [0086] Figure 44B depicts turbidity spectra of microtubule protein polymerization in the presence of DMSO drug vehicle (0), 1.25 pM (o), 2.5 AM (-),-and 5 AM (o) CA4. [0087] Figure 44C depicts turbidity spectra of microtubule protein polymerization in the presence of DMSO drug vehicle (0), 1.25 pM (o), 2.5 pM (-), and 5 pM (o) CLC. [0088] Figure 45 depicts inhibition of MT in the absence or presence of a range of KPU-02 (o),CA4 (o), and colchicine (0) concentrations. [0089] Figure 46A depicts frequency histograms of mean microtubule lengths in vitro at steady state in the presence of KPU-02. [0090] Figure 46B depicts frequency histograms of mean microtubule lengths in vitro at steady state in the presence of CA4. [0091] Figure 46C depicts frequency histograms of mean microtubule lengths in vitro at steady state in the presence of CLC. -12- WO 2005/077940 PCT/US2005/003636 [00921 Figure 47A depicts electron micrographs of MAP-rich microtubules formed in vitro at steady state in the presence of KPU-02. [0093] Figure 47B depicts electron micrographs of MAP-rich microtubules formed in vitro at steady state in the presence of CA4. [0094] Figure 47C depicts electron micrographs of MAP-rich microtubules formed in vitro at steady state in the presence of CLC. [0095] Figure 48 depicts a graphical summary of MT length decrease at steady state in the presence of KPU-02, CA4, and colchicine. [0096] Figure 49A depicts fluorescence emission spectra of tubulin in the presence of increasing KPU-02. [0097] Figure 49B depicts a fit to fluorescence emission maxima at 487 nm to obtain the Kd of tubulin for KPU-02. The inset depicts residuals. [0098] Figure 49C depicts double reciprocal transformation of the binding data. [0099] Figure 50 depicts the graphical results of a competitive inhibition assay of colchicine binding to tubulin with various concentrations of [ 3 H]CLC in the absence (0), or presence of 10 gM KPU-02 (o) or 10 pM CA4 (o). [0100] Figure 51 depicts log [compound] response curves for mitotic progression inhibition by KPU-02, CA4, and CLC in MCF7 cells cultured in the presence of KPU-02 (o), CA4 (o), and colchicine (0). [0101] Figure 52 depicts immunofluorescence microscopy images of MCF7 cells. a-d: Tubulin in control-(a) Tubulin in control, (b) KPU-02, (c) CA4, and-(d) CLC treated cells; e-h: DNA in control-(e) DNA in control, (f) KPU-02, (g) CA4, and (h) CLC treated cells. [0102] Figure 53A depicts immunofluorescence microscopy images of MCF7 cells treated with KPU-02 [01031 Figure 53B depicts immunofluorescence microscopy images of MCF7 cells treated with CA4. [0104] Figure 53C depicts immunofluorescence microscopy images of MCF7 cells treated with CLC. -13- WO 2005/077940 PCT/US2005/003636 [01051 Figure 54A depicts immunofluorescence microscopy images of MCF7 cells treated with KPU-02 [0106] Figure 54B depicts immunofluorescence microscopy images of MCF7 cells treated with CA4. 101071 Figure 54C depicts immunofluorescence microscopy images of MCF7 cells treated with CLC. [0108] In certain Figures, compounds are identified using an alternative designation. A complete chart to convert these alternative designations is as follows: Alternative designation Designation used herein NPI-2350 (-)-phenylahistin NPI-2352 KPU-01 NPI-2353 KPU-03 NPI-2354 KPU-04 NPI-2355 KPU-05 NPI-2356 KPU-06 NPI-2357 KPU-07 NPI-2358 KPU-02 NPI-2359 KPU-08 NPI-2360 KPU-09 NPI-2361 KPU-10 NPI-2362 KPU- l NPI-2363 KPU-12 NPI-2364 KPU-13 NPI-2365 KPU-14 NPI-2366 KPU-15 NPI-2367 KPU-16 NPI-2368 KPU-17 NPI-2369 KPU-18 NPI-2370 KPU-19 NPI-2371 KPU-21 NPI-2372 KPU-22 NPI-2373 KPU-23 NPI-2374 KPU-24 NPI-2375 KPU-25 NPI-2376 KPU-28 NPI-2377 KPU-26 NPI-2378 KPU-27 NPI-2379 KPU-29 NPI-2380 KPU-20 NPI-2381 KPU-30 NPI-2382 KPU-31 NPI-2383 KPU-32 NPI-2384 KPU-33 NPI-2385 KPU-34 14- WO 2005/077940 PCT/US2005/003636 Alternative designation Designation used herein NPI-2386 KPU-35 NPI-2387 KPU-36 NPI-2388 KPU-37 NPI-2389 KPU-38 NPI-2390 KPU-39 NPI-2391 KPU-40 NPI-2392 KPU-41 NPI-2393 KPU-42 NPI-2394 KPU-43 NPI-2395 KPU-44 NPI-2396 KPU-45 NPI-2397 KPU-46 NPI-2398 KPU-47 NPI-2399 KPU48 NPI-2400 KPU-49 NPI-2401 KPU-50 NPI-2402 KPU-51 NPI-2403 KPU-52 NPI-2404 KPU-53 NPI-2405 KPU-54 NPI-2406 KPU-55 NPI-2407 KPU-56 NPI-2408 KPU-57 NPI-2409 KPU-58 NPI-2410 KPU-59 NPI-2411 KPU-60 NPI-2412 KPU-61 NPI-2413 KPU-62 NPI-2414 KPU-63 NPI-2415 KPU-64 NPI-2416 KPU-65 NPI-2417 KPU-66 NPI-2418 KPU-67 NPI-2419 KPU-68 NPI-2420 KPU-69 NPI-2421 KPU-70 NPI-2422 KPU-71 NPI-2423 KPU-72 NPI-2424 KPU-73 NPI-2425 KPU-74 NPI-2426 KPU-75 NPI-2427 KPU-76 NPI-2428 KPU-77 NPI-2429 KPU-79 NPI-2430 KPU-80 NPI-2431 KPU-81 NPI-2432 KPU-82 -15- WO 2005/077940 PCT/US2005/003636 Alternative designation Designation used herein NPI-2433 KPU-83 NPI-2434 KPU-84 NPI-2435 KPU-86 NPI-2436 KPU-87 NPI-2437 KPU-88 NPI-2438 KPU-89 NPI-2439 KPU-90 NPI-2440 KPU-91 NPI-2441 KPU-92 NPI-2442 KPU-80 NPI-2455 KPU-94 NPI-2456 KPU-95 NPI-2457 KPU-96 NPI-2458 KPU-97 NPI-2459 KPU-98 NPI-2460 t-butyl phenylahistin Detailed Description of the Preferred Embodiment [0109] Each reference cited herein, including the U.S. patents cited herein, is to be considered incorporated by reference in its entirety into this specification, to the full extent permissible by law. U.S. Patent Application No. 10/632,531, and PCT Application No. PCTUS03/24232, both filed on August 1, 2003, and both entitled, "DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF AND THE SYNTHESIS OF DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF," are incorporated herein by reference in their entireties. [0110] The disclosure provides methods for the synthetic preparation of compounds, including novel compounds, including dehydrophenylahistin and dehydrophenylahistin analogs, and provides methods for producing pharmaceutically acceptable cell cycle inhibitors, antitumor agents and antifungal agents in relatively high yield, wherein said compounds and/or their derivatives are among the active ingredients in these cell cycle inhibitors, antitumor agents and antifungal agents. Other objects include providing novel compounds not obtainable by currently available, non-synthetic methods. It is also an object to provide a method of treating cancer, particularly human cancer, comprising the step of administering an effective tumor-growth inhibiting amount of a member of a class of new anti-tumor compounds. This invention also provides a method for preventing or treating a pathogenic fungus in a subject which involves administering to the -16- WO 2005/077940 PCT/US2005/003636 subject an effective anti-fungal amount of a member of a class of new anti-fungal compounds, e.g., administering a dehydrophenylahistin or its analog in an amount and manner which provides the intended antifungal effect. In the preferred embodiment of the compounds and methods of making and using such compounds disclosed herein, but not necessarily in all embodiments of the present invention, these objectives are met. [01111 Disclosed herein, also, are compounds, and methods of producing a class of compounds, wherein the compounds are represented by Formula (I): R1' \,zR1", X, R4 Z R 2 N 1 Z -N NR R1 Z 4 X \ 3 (I) [01121 wherein: [0113] R 1 , R 4 , and R 6 , are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1

-C

24 alkyl, unsaturated C 1

-C

24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, -CO-0-R 7 , cyano, alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl -CCO-R 7 , wherein R 7 is selected from a hydrogen atom, a halogen atom, and saturated C 1

-C

24 alkyl, unsaturated C 1

-C

24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups; [01141 R 1 ' and R 1 " are independently selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1

-C

24 alkyl, unsaturated C 1

-C

2 4 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, -CO-0-R 7 , cyano, alkylthio, halogenated alkyl including -17- WO 2005/077940 PCT/US2005/003636 polyhalogenated alkyl, halogenated carbonyl, and carbonyl -CCO-R 7 , wherein R 7 is selected from a hydrogen atom, a halogen atom, and saturated Ci-C 24 alkyl, unsaturated C 1

-C

24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups; [0115] R, R 1 ' and R 1 " are either covalently bound to one another or are not covalently bound to one another; [01161 R 2 , R 3 , and R 5 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1

-C

1 2 alkyl, unsaturated C 1

-C

1 2 alkenyl, acyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups, sulfonyl and substituted sulfonyl groups; [0117] X 1 and X 2 are separately selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom, each either unsubstituted or substituted with a R 5 group, as defined above; [01181 Y is selected from the group consisting of a nitrogen atom, a substituted nitrogen atom with a R 5 group from above, an oxygen atom, a sulfur atom, a oxidized sulfur atom, a methylene group and a substituted methylene group; [0119] n is an integer equal to zero, one or two; [01201 Z, for each separate n, if non-zero, and Zi, Z 2 , Z 3 and Z 4 are each separately selected from a carbon atom, a sulfur atom, a nitrogen atom or an oxygen atom; and [01211 the dashed bonds may be either single or double bonds. [0122] The method comprises a method of producing compounds of Formula (I) by the steps of: [01231 reacting a diacyldiketopiperazine with a first aldehyde to produce an intermediate compound; and [0124] reacting said intermediate compound with a second aldehyde to produce said class of compounds with said generic structure, wherein -18- WO 2005/077940 PCT/US2005/003636 [01251 said first aldehyde and said second aldehydes are selected from the group consisting of an oxazolecarboxaldeyhyde, imidazolecarboxaldehyde, a benzaldehyde, imidazolecarboxaldehyde derivatives, and benzaldehyde derivatives, thereby forming a compound of Formula (I) wherein [0126] R 1 , R 4 , and R 6 , are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1

-C

24 alkyl, unsaturated CI-C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, -CO-0-R 7 , cyano, alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl -CCO-R 7 , wherein R 7 is selected from a hydrogen atom, a halogen atom, and saturated C 1

-C

24 alkyl, unsaturated C1-C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups; [0127] R 1 ' and R 1 " are independently is selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1

-C

24 alkyl, unsaturated C 1

-C

24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, -CO-0-R 7 , cyano, alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl -CCO-R 7 , wherein R 7 is selected from a hydrogen atom, a halogen atom, and saturated C 1

-C

24 alkyl, unsaturated C 1

-C

24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups; [0128] R 2 , R 3 , and R 5 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1

-C

12 alkyl, unsaturated C 1

-C

12 alkenyl, acyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups, sulfonyl and substituted sulfonyl groups; -19- WO 2005/077940 PCT/US2005/003636 [01291 X 1 and X 2 are separately selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur. atom, and [0130] Y is selected from the group consisting of a nitrogen atom, a substituted nitrogen atom with a R 5 group from above, an oxygen atom, a sulfur atom, a oxidized sulfur atom, a methylene group and a substituted methylene group; [01311 Z, for each separate n, if non-zero, and Z 1 , Z 2 , Z 3 and Z 4 are each separately selected from a carbon atom, a sulfur atom, a nitrogen atom or an oxygen atom; and [0132] the dashed bonds may be either single or double bonds. [0133] Also provided are pharmaceutically acceptable salts and pro-drug esters of the compound of Formulae (I) and (II) and provides methods of synthesizing such compounds by the methods disclosed herein. [01341 The term "pro-drug ester," especially when referring to a pro-drug ester of the compound of Formula (I) synthesized by the methods disclosed herein, refers to a chemical derivative of the compound that is rapidly transformed in vivo to yield the compound, for example, by- hydrolysis in blood or inside tissues. The term "pro-drug ester" refers to derivatives of the compounds disclosed herein formed by the addition of any of several ester-forming groups that are hydrolyzed under physiological conditions. Examples of pro-drug ester groups include pivoyloxymethyl, acetoxymethyl, phthalidyl, indanyl and methoxymethyl, as well as other such groups known in the art, including a (5-R-2-oxo-1,3 dioxolen-4-yl)methyl group. Other examples of pro-drug ester groups can be found in, for example, T. Higuchi and V. Stella, in "Pro-drugs as Novel Delivery Systems", Vol. 14, A.C.S. Symposium Series, American Chemical Society (1975),; and "Bioreversible Carriers in Drug Design: Theory and Application", edited by E. B. Roche, Pergamon Press: New York, 14-21 (1987) (providing examples of esters useful as prodrugs for compounds containing carboxyl groups). [0135] The term "pro-drug ester," as used herein, also refers to a chemical derivative of the compound that is rapidly transformed in vivo to yield the compound, for example, by hydrolysis in blood. The term "pro-drug ester" refers to derivatives of the compounds disclosed herein formed by the addition of any of several ester-forming groups -20- WO 2005/077940 PCT/US2005/003636 that are hydrolyzed under physiological conditions. Examples of pro-drug ester groups include pivoyloxymethyl, acetoxymethyl, phthalidyl, indanyl and methoxymethyl, as well as other such groups known in the art, including a (5-R-2-oxo-1,3-dioxolen-4-y)methyl group. Other examples of pro-drug ester groups can be found in, for example, T. Higuchi and V. Stella, in "Pro-drugs as Novel Delivery Systems", Vol. 14, A.C.S. Symposium Series, American Chemical Society (1975); and "Bioreversible Carriers in Drug Design: Theory and Application", edited by E. B. Roche, Pergamon Press: New York, 14-21 (1987) (providing examples of esters useful as prodrugs for compounds containing carboxyl groups). [0136] The term "pharmaceutically acceptable salt," especially when referring to a pharmaceutically acceptable salt of the compound of Formula (I) synthesized by the methods disclosed herein, refers to any pharmaceutically acceptable salts of a compound, and preferably refers to an acid addition salt of a compound. Preferred examples of pharmaceutically acceptable salt are the alkali metal salts (sodium or potassium), the alkaline earth metal salts (calcium or magnesium), or ammonium salts derived from ammonia or from pharmaceutically acceptable organic amines, for example C-C 7 alkylamine, cyclohexylamine, triethanolamine, ethylenediamine or tris-(hydroxymethyl)-aminomethane. With respect to compounds synthesized by the method that are basic amines, the preferred examples of pharmaceutically acceptable salts are acid addition salts of pharmaceutically acceptable inorganic or organic acids, for example, hydrohalic, sulfuric, phosphoric acid or aliphatic or aromatic carboxylic or sulfonic acid, for example acetic, succinic, lactic, malic, tartaric, citric, ascorbic, nicotinic, methanesulfonic, p-toluensulfonic or naphthalenesulfonic acid. [0137] The term "pharmaceutically acceptable salt," as used herein, also refers to any pharmaceutically acceptable salts of a compound, and preferably refers to an acid addition salt of a compound. Preferred examples of pharmaceutically acceptable salt are the alkali metal salts (sodium or potassium), the alkaline earth metal salts (calcium or magnesium), or ammonium salts derived from ammonia or from pharmaceutically acceptable organic amines, for example C-C 7 alkylamine, cyclohexylamine, triethanolamine, ethylenediamine or tris-(hydroxymethyl)-aminomethane. With respect to compounds that are basic amines, the preferred examples of pharmaceutically acceptable salts are acid addition -21- WO 2005/077940 PCT/US2005/003636 salts of pharmaceutically acceptable inorganic or organic acids, for example, hydrohalic, sulfuric, phosphoric acid or aliphatic or aromatic carboxylic or sulfonic acid, for example acetic, succinic, lactic, malic, tartaric, citric, ascorbic, nicotinic, methanesulfonic, p toluensulfonic or naphthalenesulfonic acid. 101381 Preferred pharmaceutical compositions disclosed herein include pharmaceutically acceptable salts and pro-drug esters of the compound of Formula (1) synthesized by the method disclosed herein. Accordingly, if the manufacture of pharmaceutical formulations involves intimate mixing of the pharmaceutical excipients and the active ingredient in its salt form, then it is preferred to use pharmaceutical excipients which are non-basic, that is, either acidic or neutral excipients. [01391 In preferred embodiments of the methods of the compounds disclosed herein, a relatively rigid, planar pseudo three-ring structure may be formed. To stabilize such a relatively rigid, planar pseudo three-ring structure, R 3 may preferably be chosen to be hydrogen. [0140] In other preferable embodiments of the compounds and methods described herein, n is equal to zero or one, more preferable one, and Z 2 , Z 3 , and Z 4 , and each separately selected from an oxygen atom, a nitrogen atom, and a carbon atom, more preferable at one least one of Z 2 , Z 3 , and Z 4 being a carbon atom, and most preferable at least two of Z 2 , Z 3 , and Z 4 being a carbon atom. All Z's may simultaneous be carbon atoms. [01411 Still other preferred embodiments of the methods and compositions disclosed herein involve compounds having the structures of Formulae (Ia) and (lb), below: S' XI N RR - - R .5 - N N X2 3 6 (Ia)

R

1 ' R 2 X1 4 / I7 N y-R 5

Z

2 , N N =

R

1

Z

3 3 6 (lb) -22- WO 2005/077940 PCT/US2005/003636 [0142] wherein the variable groups are as defined herein. [0143] The term "halogen atom," as used herein, means any one of the radio stable atoms of column 7 of the Periodic Table of the Elements, i.e., fluorine, chlorine, bromine, or iodine, with fluorine and chlorine being preferred. [0144] The term "alkyl," as used herein, means any unbranched or branched, substituted or unsubstituted, saturated hydrocarbon, with C 1

-C

6 unbranched, saturated, unsubstituted hydrocarbons being preferred, with methyl, ethyl, iosbutyl, and tert-butyl being most preferred. Among the substituted, saturated hydrocarbons, C 1

-C

6 mono- and di- and per-halogen substituted saturated hydrocarbons and amino-substituted hydrocarbons are preferred, with perfluromethyl, perchloromethy, perfluoro-tert-butyl, and perchloro-tert-butyl being the most preferred. The term "substituted" has its ordinary meaning, as found in numerous contemporary patents from the related art. See, for example, U.S. Patent Nos. 6,583,143, 6,509,331; 6,506,787; 6,500,825; 5,922,683; 5,886,210; 5,874,443; and 6,350,759. Specifically, the definition of substituted is as broad as that provided in U.S. Patent No. 6,583,143, which defines the term substituted as any groups such as alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle and heterocyclealkyl, wherein at least one hydrogen atom is replaced with a substituent. The term "substituted" is also as broad as the definition provided in U.S. Patent No. 6,509,331, which defines the term "substituted alkyl" such that it refers to an alkyl group, preferably of from 1 to 10 carbon atoms, having from 1 to 5 substituents, and preferably 1 to 3 substituents, selected from the group consisting of alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyacylamino, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, keto, thioketo, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, --SO-alkyl, --SO-substituted alkyl, --SO aryl, --SO-heteroaryl, --S0 2 -alkyl, -- S0 2 -substituted alkyl, --S02-aryl and -S02-heteroaryl. The other above-listed patents also provide standard definitions for the term "substituted" that are well-understood by those of skill in the art. The term "cycloalkyl" refers to any non aromatic hydrocarbon ring, preferably having five to twelve atoms comprising the ring. The -23- WO 2005/077940 PCT/US2005/003636 term "acyl" refers to alkyl or aryl groups derived from an oxoacid, with an acetyl group being preferred. [0145] The term "alkenyl," as used herein, means any unbranched or branched, substituted or unsubstituted, unsaturated hydrocarbon including polyunsaturated hydrocarbons, with C 1

-C

6 unbranched, mono-unsaturated and di-unsaturated, unsubstituted hydrocarbons being preferred, and mono-unsaturated, di-halogen substituted hydrocarbons being most preferred. In the R 1 and R 4 positions, of the compound of structure (1) a z isoprenyl moiety is particularly preferred. The term "cycloalkenyl" refers to any non aromatic hydrocarbon ring, preferably having five to twelve atoms comprising the ring. 101461 The terms "aryl," "substituted aryl," "heteroaryl," and "substituted heteroaryl," as used herein, refer to aromatic hydrocarbon rings, preferably having five, six, or seven atoms, and most preferably having six atoms comprising the ring. "Heteroaryl" and "substituted heteroaryl," refer to aromatic hydrocarbon rings in which at least one heteroatom, e.g., oxygen, sulfur, or nitrogen atom, is in the ring along with at least one carbon atom. [01471 The term "alkoxy" refers to any unbranched, or branched, substituted or unsubstituted, saturated or unsaturated ether, with C-C 6 unbranched, saturated, unsubstituted ethers being preferred, with methoxy being preferred, and also with dimethyl, diethyl, methyl-isobutyl, and methyl-tert-butyl ethers also being preferred. The term "cycloalkoxy" refers to any non-aromatic hydrocarbon ring, preferably having five to twelve atoms comprising the ring. [01481 The terms "purified," "substantially purified," and "isolated" as used herein refer to the compound being free of other, dissimilar compounds with which the compound is normally associated in its natural state, so that the compound of the invention comprises at least 0.5%, 1%, 5%, 10%, or 20%, and most preferably at least 50% or 75% of the mass, by weight, of a given sample. [01491 The compound of Formula (I) may be chemically synthesized or produced from reagents known and available in the art. For example, modifications of diacyldiketopiperazine (diacetyldiketopiperazine) have been described, for example, by Loughlin et al., 2000 Bioorg Med Chen Lett 10:91 or by Brocchini et al. in WO 95/21832. -24- WO 2005/077940 PCT/US2005/003636 The diacyldiketopiperazine (diacetyldiketopiperazine) may be prepared, for example, by diacetylation of inexpensive 2,5-piperazinedione (TCI Cat. No. G0100, 25 g) with sodium acetate and sodium anhydride. The diacetyl structure of the activated deketopiperazine can be replaced with other acyl groups, to include carbamates such as Boc (t-butoxycarbonyl), Z (benzoyloxycarbonyl). [01501 The imidazolecarboxaldehyde may be prepared, for example, according the procedure disclosed in Hayashi et al., 2000 JOrganic Chen 65: 8402 as depicted below: LDA CH3CHO _ Tos-CI DBU o THF -70 "C OH 0 pridine, rt. OTs 0 reflux(140 OC) 6B% E8% 26% 4N NaOH CoC1 2 EtOCOCH 2 COOH H BuLi 0 EtOHrt. 0 CH2CIIt 0 THF,-7Dto-1O"C 99% 66% 92% HnNCHO. O0 2 co 2 ,..I Et H20 OOEt DIBALH o o CHCI, re1ux 0 0 reflu,140"C N. NH Toluene, -S"C 77% 46% 59% OH Mno2 N NH acetone, rt NH 95% 2 t2 0NCHOM DIBALH 0 0 CHCb, Mfux a 0 reflux, 145"C N NH Tolueng -50"C 18 21% (2 step) 66% ( LiAIH4 THF, rt OH NnO2 04% N NH acetone, rt N NH 25% 15 - 25 - WO 2005/077940 PCT/US2005/003636 [01521 The synthetic method disclosed herein may be preferably performed in the presence of cesium carbonate as a base in DMF and in a deoxygenated atmosphere. The inert atmosphere circumvents the probable oxidation of activated a-carbon atoms of the diketopiperazine ring during the treatment with cesium carbonate (see below) as reported, for example, by Watanabe et al., 1 8 1h International Congress of Heterocyclic Chemistry in Yokohama, Japan (30 July 2001), Abstract, page 225. Cs salt RH DMF ROH Air-oxidation of Activated Carbonyl Compounds with Cesium Salts [01531 Other embodiments of the synthetic method involve modifications to the compounds used in or otherwise involved in the synthesis of compounds represented by Formula (I). Such derivatives may include modifications to the phenyl ring, introduction of other aromatic ring systems, position of the aromatic ring, alterations to the imidazole ring system and/or further modifications to the 5-position on the imidazole ring. Examples of such modifications are discussed, for example, in Example 4. The result of such modifications includes increased nitrogen content of the phenyl ring and/or the compound which may increase compound solubility. Other modifications may incorporate derivatives of known tubulin inhibitors, thereby mimicking the activity of the tubulin inhibitors. Other modifications may simplify the synthesis of the p-ketoester involved in the production of the imidazolecarboxaldehyde used in the methods disclosed herein. Pharmaceutical Compositions [01541 The present invention also encompasses the compounds disclosed herein, optionally and preferably produced by the methods disclosed herein, in pharmaceutical compositions comprising a pharmaceutically acceptable carrier prepared for storage and subsequent administration, which have a pharmaceutically effective amount of the products disclosed above in a pharmaceutically acceptable carrier or diluent. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A.R. Gennaro edit. 1985). Preservatives, stabilizers, dyes and even flavoring agents may be provided in the -26- WO 2005/077940 PCT/US2005/003636 pharmaceutical composition. For example, sodium benzoate, ascorbic acid and esters of p hydroxybenzoic acid may be added as preservatives. In addition, antioxidants and suspending agents may be used. [01551 The dehydrophenylahistin or dehydrophenylahistin analog compositions may be formulated and used as tablets, capsules, or elixirs for oral administration; suppositories for rectal administration; sterile solutions, suspensions for injectable administration; patches for transdermal administration, and sub-dermal deposits and the like. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection or infusion, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride, human serum albumin and the like. In addition, if desired, the injectable pharmaceutical compositions may contain minor amounts of nontoxic auxiliary substances, such as wetting agents, pH buffering agents, and the like. If desired, absorption enhancing preparations (for example, liposomes), may be utilized. [01561 Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or other organic oils such as soybean, grapefruit or almond oils, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. [0157] Pharmaceutical preparations for oral use may be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize -27- WO 2005/077940 PCT/US2005/003636 starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses. Such formulations can be made using methods known in the art (see, for example, U.S. Patent Nos. 5,733,888 (injectable compositions); 5,726,181 (poorly water soluble compounds); 5,707,641 (therapeutically active proteins or peptides); 5,667,809 (lipophilic agents); 5,576,012 (solubilizing polymeric agents); 5,707,615 (anti-viral formulations); 5,683,676 (particulate medicaments); 5,654,286 (topical formulations); 5,688,529 (oral suspensions); 5,445,829 (extended release formulations); 5,653,987 (liquid formulations); 5,641,515 (controlled release formulations) and 5,601,845 (spheroid formulations). [01581 Further disclosed herein are various pharmaceutical compositions well known in the pharmaceutical art for uses that include intraocular, intranasal, and intraauricular delivery. Pharmaceutical formulations include aqueous ophthalmic solutions of the active compounds in water-soluble form, such as eyedrops, or in gellan gum (Shedden et al., 2001 Clin Ther 23(3):440-50) or hydrogels (Mayer et al., 1996 Ophthalmologica 210:101-3); ophthalmic ointments; ophthalmic suspensions, such as microparticulates, drug containing small polymeric particles that are suspended in a liquid carrier medium (Joshi, A., 1994 J Ocul Pharmacol 10:29-45), lipid-soluble formulations (Alm et al., 1989 Prog Clin Biol Res 312:447-58), and microspheres (Mordenti, 1999 Toxicol Sci 52:101-6); and ocular -28- WO 2005/077940 PCT/US2005/003636 inserts. Such suitable pharmaceutical formulations are most often and preferably formulated to be sterile, isotonic and buffered for stability and comfort. Pharmaceutical compositions may also include drops and sprays often prepared to simulate in many respects nasal secretions to ensure maintenance of normal ciliary action. As disclosed in Remington's Pharmaceutical Sciences (Mack Publishing, 18 t" Edition), and well-known to those skilled in the art, suitable formulations are most often and preferably isotonic, slightly buffered to maintain a pH of 5.5 to 6.5, and most often and preferably include antimicrobial preservatives and appropriate drug stabilizers. Pharmaceutical formulations for intraauricular delivery include suspensions and ointments for topical application in the ear. Common solvents for such aural formulations include glycerin and water. 10159] When used as a cell cycle inhibitor, a tumor-growth-inhibiting, or a fungus-growth-inhibiting compound, the compound of Formula (I) can be administered by either oral or a non-oral pathways. When administered orally, it can be administered in capsule, tablet, granule, spray, syrup, or other such form. When administered non-orally, it can be administered as an aqueous suspension, an oily preparation or the like or as a drip, suppository, salve, ointment or the like, when administered via injection or infusion, subcutaneously, intreperitoneally, intravenously, intramuscularly, or the like. Similarly, it may be administered topically, rectally, or vaginally, as deemed appropriate by those of skill in the art for bringing the compound into optimal contact with a tumor, thus inhibiting the growth of the tumor. Local administration at the site of the tumor is also contemplated, either before or after tumor resection, as are controlled release formulations, depot formulations, and infusion pump delivery. Methods of Administration [0160] The present invention also encompasses methods for making and for administering the disclosed chemical compounds and the disclosed pharmaceutical compositions. Such disclosed methods include, among others, (a) administration though oral pathways, which administration includes administration in capsule, tablet, granule, spray, syrup, or other such forms; (b) administration through non-oral pathways, which administration includes administration as an aqueous suspension, an oily preparation or the like or as a drip, suppository, salve, ointment or the like; administration via injection or -29- WO 2005/077940 PCT/US2005/003636 infusion, subcutaneously, intraperitoneally, intravenously, intramuscularly, intradermally, or the like; as well as (c) administration topically, (d) administration rectally, or (e) administration vaginally, as deemed appropriate by those of skill in the art for bringing the compound into contact with living tissue; and (f) administration via controlled released formulations, depot formulations, and infusion pump delivery. As further examples of such modes of administration and as further disclosure of modes of administration, disclosed herein are various methods for administration of the disclosed chemical compounds and pharmaceutical compositions including modes of administration through intraocular, intranasal, and intraauricular pathways. [01611 The pharmaceutically effective amount of the dehydrophenylahistin or dehydrophenylahistin analog composition required as a dose will depend on the route of administration, the type of animal, including human, being treated, and the physical characteristics of the specific animal under consideration. The dose can be tailored to achieve a desired effect, but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize. [0162] In practicing the methods, the products or compositions can be used alone or in combination with one another, or in combination with other therapeutic or diagnostic agents. For example, as disclosed herein, the compounds disclosed herein are effective in the treatment of cancer when used in combination with other actives, specifically other chemotherapeutics, for example biologics and the specific chemotherapeutics CPT-11, Taxotene (docataxel) and paclitaxel. The compounds disclosed herein are also effective in the treatment of cancer when used in combination with other actives, including anti-vascular agents, anti-angiogenenic agents, such as Erbuitux (hnclone/bristol-Myers) and Iressa (AstraZeneca), other VEGF inhibitors and biologics, more specifically, at least one anti VEGF antibodies, especially monoclonal antibodies to the VEGF receptor, including DC101, a rat monoclonal antibody, which blocks the mouse VEGF receptor 2 (fik-1). Such combinations may be utilized in vivo, ordinarily in a mammal, preferably in a human, or in vitro. In employing them in vivo, the disclosed compounds, alone or in combination with other chemotherapeutics or other biologic products, may be administered to the mammal in a variety of ways, including parenterally, intravenously, via infusion or injection, -30- WO 2005/077940 PCT/US2005/003636 subcutaneously, intramuscularly, colonically, rectally, vaginally, nasally or intraperitoneally, employing a variety of dosage forms. Such methods may also be applied to testing chemical activity in vivo. [0163] As will be readily apparent to one skilled in the art, the useful in vivo dosage to be administered and the particular mode of administration will vary depending upon the age, weight and mammalian species treated, the particular compounds employed, and the specific use for which these compounds are employed. The determination of effective dosage levels, that is the dosage levels necessary to achieve the desired result, can be accomplished by one skilled in the art using routine pharmacological methods. Typically, human clinical applications of products are commenced at lower dosage levels, with dosage level being increased until the desired effect is achieved. Alternatively, acceptable in vitro studies can be used to establish useful doses and routes of administration of the compositions identified by the present methods using established pharmacological methods. [0164] In non-human animal studies, applications of potential products are commenced at higher dosage levels, with dosage being decreased until the desired effect is no longer achieved or adverse side effects disappear. The dosage may range broadly, depending upon the desired affects and the therapeutic indication. Typically, dosages may be between about 10 microgram/kg and 100 mg/kg body weight, preferably between about 100 microgram/kg and 10 mg/kg body weight. Alternatively dosages may be based and calculated upon the surface area of the patient, as understood by those of skill in the art. Administration may be oral on an every third day, every other day, daily, twice daily, or thrice daily basis. [01651 The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. See for example, Fingl et al., in The Pharmacological Basis of Therapeutics, 1975. It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity, or to organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administrated dose in the management of the disorder of interest will vary with the severity of the condition to be treated and to the route of -31- WO 2005/077940 PCT/US2005/003636 administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine. [01661 Depending on the specific conditions being treated, such agents may be formulated and administered systemically or locally. A variety of techniques for formulation and administration may be found in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, PA (1990). Suitable administration routes may include oral, rectal, transdermal, vaginal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, via infusion, intraperitoneal, intranasal, or intraocular injections. [0167] For injection or infusion, the agents may be formulated in aqueous solutions, for example, in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. For such transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. Use of pharmaceutically acceptable carriers to formulate the compounds herein disclosed for the practice of the invention into dosages suitable for systemic administration is within the scope of the invention. With proper choice of carrier and suitable manufacturing practice, the compositions disclosed herein, in particular, those formulated as solutions, may be administered parenterally, such as by intravenous injection or infusion. The compounds can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration. Such carriers enable the compounds to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. [0168] Agents intended to be administered intracellularly may be administered using techniques well known to those of ordinary skill in the art. For example, such agents may be encapsulated into liposomes, then administered as described above. All molecules present in an aqueous solution at the time of liposome fonnation are incorporated into the -32- WO 2005/077940 PCT/US2005/003636 aqueous interior. The liposomal contents are both protected from the external micro environment and, because liposomes fuse with cell membranes, are efficiently delivered into the cell cytoplasm. Additionally, due to their hydrophobicity, small organic molecules may be directly administered intracellularly. [0169] Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. The preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions. The pharmaceutical compositions may be manufactured in a manner that is itself known, for example, by means of conventional mixing, dissolving, granulating, dragee-making, levitating, emulsifying, encapsulating, entrapping, or lyophilizing processes. [0170] Compounds disclosed herein can be evaluated for efficacy and toxicity using known methods. For example, the toxicology of a particular compound, or of a subset of the compounds, sharing certain chemical moieties, may be established by determining in vitro toxicity towards a cell line, such as a mammalian, and preferably human, cell line. The results of such studies are often predictive of toxicity in animals, such as mammals, or more specifically, humans. Alternatively, the toxicity of particular compounds in an animal model, such as mice, rats, rabbits, or monkeys, may be determined using known methods. The efficacy of a particular compound may be established using several art recognized methods, such as in vitro methods, animal models, or human clinical trials. Art-recognized in vitro models exist for nearly every class of condition, including the conditions abated by the compounds disclosed herein, including cancer, cardiovascular disease and various fungal infections. Similarly, acceptable animal models may be used to establish efficacy of chemicals to treat such conditions. When selecting a model to determine efficacy, the skilled artisan can be guided by the state of the art to choose an appropriate model, dose, and route of administration, and regime. Of course, human clinical trials can also be used to determine the efficacy of a compound in humans. -33- WO 2005/077940 PCT/US2005/003636 [01711 When used as an anti-cancer agent, or a tumor-growth-inhibiting compound, the compounds disclosed herein may be administered by either oral or a non-oral pathways. When administered orally, it can be administered in capsule, tablet, granule, spray, syrup, or other such form. When administered non-orally, it can be administered as an aqueous suspension, an oily preparation or the like or as a drip, suppository, salve, ointment or the like, when administered via injection or infusion, subcutaneously, intreperitoneally, intravenously, intramuscularly, intradermally, or the like. Similarly, it may be administered topically, rectally, or vaginally, as deemed appropriate by those of skill in the art for bringing the compound into optimal contact with a tumor, thus inhibiting the growth of the tumor. Local administration at the site of the tumor or other disease condition is also contemplated, either before or after tumor resection, or as part of an art-recognized treatment of the disease condition. Controlled release formulations, depot formulations, and infusion pump delivery are similarly contemplated. [0172] When used as an anti-cancer agent or an anti-tumor agent, may be orally or non-orally administered to a human patient in the amount of about .0007 mg/day to about 7,000 mg/day of the active ingredient, and more preferably about 0.07 mg/day to about 70 mg/day of the active ingredient at, preferably, one time per day or, less preferably, over two to about ten times per day. Alternatively and also preferably, the compound may preferably be administered in the stated amounts continuously by, for example, an intravenous drip. Thus, for a patient weighing 70 kilograms, the preferred daily dose of the active anti-tumor ingredient would be about 0.0007 mg/kg/day to about 35 mg/kg/day including 1.0 mg/kg/day and 0.5 mg/kg/day, and more preferable, from 0.007 mg/kg/day to about 0.050 mg/kg/day, including 0.035 mg/kg/day. Nonetheless, as will be understood by those of skill in the art, in certain situations it may be necessary to administer the anti-tumor compound in amounts that excess, or even far exceed, the above-stated, preferred dosage range to effectively and aggressively treat particularly advanced or lethal tumors. [01731 When used as an antifungal agent the preferable amount of the dehydrophenylahistin or its analog effective in the treatment or prevention of a particular fungal pathogen will depend in part on the characteristics of the fungus and the extent of infection, and can be determined by standard clinical techniques. In vitro or in vivo assays -34- WO 2005/077940 PCT/US2005/003636 may optionally be employed to help identify optimal dosage ranges. Effective doses may be extrapolated from dose-response curves derived from in vitro analysis or preferably from animal models. The precise dosage level should be determined by the attending physician or other health care provider and will depend upon well known factors, including route of administration, and the age, body weight, sex and general health of the individual; the nature, severity and clinical stage of the infection; the use (or not) of concomitant therapies. [01741 The effective dose of the dehydrophenylahistin or its analog will typically be in the range of about 0.01 to about 50 mg/kgs, preferably about 0.1 to about 10 mg/kg of mammalian body weight per day, administered in single or multiple doses. Generally, the compound may be administered to patients in need of such treatment in a daily dose range of about 1 to about 2000 mg per patient. [0175] To formulate the dosage including the compounds disclosed herein as a tumor-growth-inhibiting compound, known surface active agents, excipients, smoothing agents, suspension agents and pharmaceutically acceptable film-forming substances and coating assistants, and the like may be used. Preferably alcohols, esters, sulfated aliphatic alcohols, and the like may be used as surface active agents; sucrose, glucose, lactose, starch, crystallized cellulose, mannitol, light anhydrous silicate, magnesium aluminate, magnesium methasilicate aluminate, synthetic aluminum silicate, calcium carbonate, sodium acid carbonate, calcium hydrogen phosphate, calcium carboxymethyl cellulose, and the like may be used as excipients; magnesium stearate, talc, hardened oil and the like may be used as smoothing agents; coconut oil, olive oil, sesame oil, peanut oil, soya may be used as suspension agents or lubricants; cellulose acetate phthalate as a derivative of a carbohydrate such as cellulose or sugar, or methyiacetate-methacrylate copolymer as a derivative of polyvinyl may be used as suspension agents; and plasticizers such as ester phthalates and the like may be used as suspension agents. In addition to the foregoing preferred ingredients, sweeteners, fragrances, colorants, preservatives and the like may be added to the administered formulation of the compound, particularly when the compound is to be administered orally. [0176] The compositions disclosed herein in a pharmaceutical compositions may also comprise a pharmaceutically acceptable carrier. Such compositions may be prepared for storage and for subsequent administration. Acceptable carriers or diluents for therapeutic use -35- WO 2005/077940 PCT/US2005/003636 are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A.R. Gennaro edit. 1985). For example, such compositions may be formulated and used as tablets, capsules or solutions for oral administration; suppositories for rectal or vaginal administration; sterile solutions or suspensions for injectable administration. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection or infusion, or as emulsions. Suitable excipients include, but are not limited to, saline, dextrose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride, and the like. In addition, if desired, the injectable pharmaceutical compositions may contain minor amounts of nontoxic auxiliary substances, such as wetting agents, pH buffering agents, and the like. If desired, absorption enhancing preparations (for example, liposomes), may be utilized. [0177] The pharmaceutically effective amount of the composition required as a dose will depend on the route of administration, the type of animal being treated, and the physical characteristics of the specific animal under consideration. The dose can be tailored to achieve a desired effect, but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize. [0178] The products or compositions, as described above, may be used alone or in combination with one another, or in combination with other therapeutic or diagnostic agents. Specifically, the disclosed compounds products may be used alone or in combination with other chemotherapeutics or biologics, including antibodies, for the treatment of cancer, or in combination with other anti-infective for the treatment of fungal infection. These products or compositions can be utilized in vivo or in vitro. The useful dosages and the most useful modes of administration will vary depending upon the age, weight and animal treated, the particular compounds employed, and the specific use for which these composition or compositions are employed. The magnitude of a dose in the management or treatment for a particular disorder will vary with the severity of the condition to be treated and to the route of administration, and depending on the disease conditions and their severity, the compositions may be formulated and administered either systemically or locally. A variety of techniques -36- WO 2005/077940 PCT/US2005/003636 for formulation and administration may be found in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co., Easton, PA (1990). [0179] To formulate the compounds of Formula (I), preferably synthetically produced according to the methods disclosed herein, as a cell cycle inhibitor, a tumor growth-inhibiting, or an antifungal compound, known surface active agents, excipients, smoothing agents, suspension agents and pharmaceutically acceptable film-forming substances and coating assistants, and the like may be used. Preferably alcohols, esters, sulfated aliphatic alcohols, and the like may be used as surface active agents; sucrose, glucose, lactose, starch, crystallized cellulose, mannitol, light anhydrous silicate, magnesium aluminate, magnesium methasilicate aluminate, synthetic aluminum silicate, calcium carbonate, sodium acid carbonate, calcium hydrogen phosphate, calcium carboxymethyl cellulose, and the like may be used as excipients; magnesium stearate, talc, hardened oil and the like may be used as smoothing agents; coconut oil, olive oil, sesame oil, peanut oil, soya may be used as suspension agents or lubricants; cellulose acetate phthalate as a derivative of a carbohydrate such as cellulose or sugar, or methyiacetate-methacrylate copolymer as a derivative of polyvinyl may be used as suspension agents; and plasticizers such as ester phthalates and the like may be used as suspension agents. In addition to the foregoing preferred ingredients, sweeteners, fragrances, colorants, preservatives and the like may be added to the administered formulation of the compound produced by the method, particularly when the compound is to be administered orally. [0180] The cell cycle inhibitors, the antitumor agents, and the antifungal agents that may be produced by the method may be orally or non-orally administered to a human patient in the amount of about 0.001 mg/kg/day to about 10,000 mg/kg/day of the active ingredient, and more preferably about 0.1 mg/kg/day to about 100 mg/kg/day of the active ingredient at, preferably, once every three days on a cyclic basis, once every other day, one time per day, twice per day, or less preferably, over two to about ten times per day. Alternatively and also preferably, the compound produced by the method may preferably be administered in the stated amounts continuously by, for example, an intravenous drip. Thus, for the example of a patient weighing 70 kilograms, the preferred daily dose of the active anti-tumor ingredient would be about 0.07 mg/day to about 700 grams/day, and more -37- WO 2005/077940 PCT/US2005/003636 preferable, 7 mg/day to about 7 grams/day. Nonetheless, as will be understood by those of skill in the art, in certain situations it may be necessary to administer the anti-tumor compound produced by the method in amounts that excess, or even far exceed, the above stated, preferred dosage range to effectively and aggressively treat particularly advanced or lethal tumors. [0181] In the case of using the cell cycle inhibitor produced by methods as a biochemical test reagent, the compound produced by methods of the invention inhibits the progression of the cell cycle when it is dissolved in an organic solvent or hydrous organic solvent and it is directly applied to any of various cultured cell systems. Usable organic solvents include, for example, methanol, methylsulfoxide, and the like. The formulation can, for example, be a powder, granular or other solid inhibitor, or a liquid inhibitor prepared using an organic solvent or a hydrous organic solvent. While a preferred concentration of the compound produced by the method of the invention for use as a cell cycle inhibitor is generally in the range of about 1 to about 100 gg/ml, the most appropriate use amount varies depending on the type of cultured cell system and the purpose of use, as will be appreciated by persons of ordinary skill in the art. Also, in certain applications it may be necessary or preferred to persons of ordinary skill in the art to use an amount outside the foregoing range. [0182] From a pharmaceutical perspective, certain embodiments provide methods for preventing or treating fungal infections and/or a pathogenic fungus in a subject, involve administering to the subject a composition including a dehydrophenylahistin or its analog, for example, administering the dehydrophenylahistin or its analog in an amount and manner which provides the intended antifungal effect. [01831 Other embodiments include the treatment or prevention of infection in a patient by a pathogenic fungus such as those listed above or referred to below. [0184] Another embodiment relates to the treatment or prevention of infection in a patient by a pathogenic fungus which is resistant to one or more other antifungal agents, especially an agent other than dehydrophenylahistin or its analog, including e.g. amphotericin B or analogs or derivatives thereof (including 14(s)-hydroxyamphotericin B methyl ester, the hydrazide of amphotericin B with I-amino-4-methylpiperazine, and other derivatives) or other polyene macrolide antibiotics, including, e.g., nystatin, candicidin, pimaricin and -38- WO 2005/077940 PCT/US2005/003636 natamycin; flucytosine; griseofulvin; echinocandins or aureobasidins, including naturally occurring and semi-synthetic analogs; dihydrobenzo[a]napthacenequinones; nucleoside peptide antiflungals including the polyoxins and nikkomycins; allylamines such as naftifine and other squalene epoxidase inhibitors; and azoles, imidazoles and triazoles such as, e.g., clotrimazole, miconazole, ketoconazole, econazole, butoconazole, oxiconazole, terconazole, itraconazole or fluconazole and the like. For additional conventional antifungal agents and new agents under development, see e.g. Turner and Rodriguez, 1996 Current Pharmaceutical Design, 2:209-224. Another embodiment involves the treatment or prevention of infection in a patient by a pathogenic fungus in cases in which the patient is allergic to, otherwise intolerant of, or nonresponsive to one or more other antifungal agents or in whom the use of other antifungal agents is otherwise contra-indicated. Those other antifungal agents include, among others, those antifungal agents disclosed above and elsewhere herein. [0185] In the foregoing methods for treatment or prevention, a dehydrophenylahistin or its analog, is administered to the subject in an effective antifungal amount. [0186] Other embodiments relate to the treatment or prevention of infection by a pathogenic fungus in a patient by administration of a dehydrophenylahistin or its analog, in conjunction with the administration of one or more other antifungal agents, including for example, any of the previously mentioned agents or types of agents (e.g. in combination with treatment with amphotericin B, preferably in a lipid or liposome formulation; an azole or triazole such as fluconazole, for example; an aureobasidin; dihydrobenzo[alnapthacenequinone; or an echinocardin) as well as with a different dehydrophenylahistin or its analog. [0187] The dehydrophenylahistin or its analog may be administered before, after or at the same time the other antifungal agent is administered. In certain embodiments, the combination therapy will permit the use of reduced amounts of one or both antifungal components, relative to the amount used if used alone. [0188] Still other embodiments relate to administration of a dehydrophenylahistin or its analog to a subject for the treatment or prevention of infection by a pathogenic fungus, where the subject is immunosuppressed or immunocompromised, e.g. as the result of genetic -39- WO 2005/077940 PCT/US2005/003636 disorder, disease such as diabetes or HIV or other infection, chemotherapy or radiation treatment for cancer or other disease, or drug- or otherwise induced immunosuppression in connection with tissue or organ transplantation or the treatment of an autoimmune disorder. Where the patient is being or will be treated with an immunosuppressive agent, e.g., in connection with a tissue or organ transplantation, a dehydrophenylahistin or its analog may be co-administered with the immunosuppressive agent(s) to treat or prevent a pathogenic fungal infection. [0189] Another aspect of this invention is the treatment or prevention of infection by a pathogenic fungus in a patient infected, or suspected of being infected, with HIV, by administration of an antifungal dehydrophenylahistin or its analog, in conjunction with the administration of one or more anti-HIV therapeutics (including e.g. HIV protease inhibitors, reverse transcriptase inhibitors or anti-viral agents). The dehydrophenylahistin or its analog may be administered before, after or at the same time as administration of the anti-HIV agent(s). [0190] Another aspect of this invention is the treatment or prevention of infection by a pathogenic fungus in a patient by administration of an antifungal dehydrophenylahistin or its analog, in conjunction with the administration of one or more other antibiotic compounds, especially one or more antibacterial agents, preferably in an effective amount and regiment to treat or prevent bacterial infection. Again, the dehydrophenylahistin or its analog may be administered before, after or at the same time as administration of the other agent(s). [0191] Pathogenic fungal infections which may be treated or prevented by the disclosed methods include, among others, Aspergillosis, including invasive pulmonary aspergillosis; Blastomycosis, including profound or rapidly progressive infections and blastomycosis in the central nervous system; Candidiasis, including retrograde candidiasis of the urinary tract, e.g. in patients with kidney stones, urinary tract obstruction, renal transplantation or poorly controlled diabetes mellitus; Coccidioidomycosis, including chronic disease which does not respond well to other chemotherapy; Cryptococcosis; Histopolasmosis; Mucormycosis, including e.g. craniofacial mucormycosis and pulmonary mucormycosis; Paracoccidioidomycosis; and Sporotrichosis. It should be noted that -40- WO 2005/077940 PCT/US2005/003636 administration of a composition comprising an antifungal amount of one or more dehydrophenylahistin or its analogs may be particularly useful for treating or preventing a pathogenic fungal infection in a mammalian subject where the fungus is resistant to one or more other antifungal therapies, or where the use of one or more other antifungal therapies is contraindicated, e.g., as mentioned above. [0192] Antifungal pharmaceutical compositions containing at least one antifungal dehydrophenylahistin or its analog, are also provided for use in practicing the disclosed methods. Those pharmaceutical compositions may be packaged together with an appropriate package insert containing, inter alia, directions and information relating to their antifungal use. Pharmaceutical compositions are also provided which contain one or more dehydrophenylahistin or its analog together with a second antifungal agent. Methods of Treating Fungal Infections [01931 Certain embodiments disclosed herein relate to methods for treating or preventing a pathogenic fungal infection, including for example Aspergillosis, including invasive pulmonary aspergillosis; Blastomycosis, including profound or rapidly progressive infections and blastomycosis in the central nervous system; Candidiasis, including retrograde candidiasis of the urinary tract, e.g. in patients with kidney stones, urinary tract obstruction, renal transplantaion or poorly controlled diabetes mellitus; Coccidioidomycosis, including chronic disease which does not respond well to other chemotherapy; Cryptococcosis; Histopolasmosis; Mucormycosis, including e.g. craniofacial mucormycosis and pulmonary mucormycosis; Paracoccidioidomycosis; and Sporotrichosis. The methods may involve administering at least one antifungal dehydrophenylahistin or its analog, as described above, to a human subject such that the fungal infection is treated or prevented. In certain embodiments the dehydrophenylahistin or its analog may be administered in conjunction with administration of one or more non-dehydrophenylahistin or its analog antifungal agents such as amphotericin B, or an imidazole or triazole agent such as those mentioned previously. [01941 The pathogenic fungal infection may be topical, e.g., caused by, among other organisms, species of Candida, Trichophyton, Microsporum or Epiderinophyton or mucosal, e.g., caused by Candida albicans (e.g. thrush and vaginal candidiasis). The infection may be systemic, e.g., caused by Candida albicans, Cryptococcus neoformans, -41- WO 2005/077940 PCT/US2005/003636 Aspergillusfumigatus, Coccidiodes, Paracocciciodes, Histoplasma or Blastomyces spp. The infection may also involve eumycotic mycetoma, chromoblastomycosis, cryptococcal meningitits or phycomycosis. [01951 Further embodiments relate to methods for treating or preventing a pathogenic fungal infection selected from the group consisting of Candida spp. including C. albicans, C. tropicalis, C. kefyr, C. krusei and C. galbrata; Aspergillus spp. including A. fumigatus and A. flavus; Cryptococcus neoibrnans; Blastoinyces spp. including Blastomyces dermatitidis; Pneumocvstis carinii; Coccidioides iminitis; Basidiobolus ranarum; Conidiobolus spp.; Histoplasma capsulatum; Rhizopus spp. including R. oryzae and R. microsporus; Cunninghamella spp.; Rhizoniucor spp.; Paracoccidioides brasiliensis; Pseudallescheria boydii; Rhinosporidium seeberi; and Sporothrix schenckii. Again, the method may involve administering a non-immunosuppressive antifungal dehydrophenylahistin or its analog to a patient in need thereof such that the fungal infection is treated or prevented without inducing an untoward immunosuppressive effect. [0196] Further embodiments relate to methods for treating or preventing a pathogenic fungal infection which is resistant to other antifungal therapy, including pathogenic fungal infections which are resistant to one or more antifungal agents mentioned elsewhere herein such as amphotericin B, flucytosine, one of the imidazoles or triazoles (including e.g. fluconazole, ketoconazole, itraconazole and the other previously mentioned examples). The methods may involve administering to the patient one or more antifungal dehydrophenylahistin or its analog, in an amount and dosing regimen such that a fungal infection resistant to another antifungal therapy in the subject is treated or prevented. [01971 Further embodiments relate to methods for treating or preventing a pathogenic fungal infection in a patient who is allergic to, intolerant of or not responsive to another antifungal therapy or in whom the use of other antifungal agents is otherwise contra indicated, including one or more other antifungal agents mentioned elsewhere herein such as amphotericin B, flucytosine, one of the imidazoles or triazoles (including e.g. fluconazole, ketoconazole, itraconazole and the other previously mentioned examples). The methods may involve administering to such patient one or more antifungal dehydrophenylahistin or its analog, in an amount such that a fungal infection is treated or prevented. -42- WO 2005/077940 PCT/US2005/003636 Packaged Dehydrophenylahistin or its analogs 10198] Certain embodiments relate to packaged dehydrophenylahistin or its analogs, preferably packaged nonimmunosuppressive antifungal dehydrophenylahistin or its analogs, which term is intended to include at least one dehydrophenylahistin or its analog, as described above, packaged with instructions for administering the dehydrophenylahistin or its analog(s) as an antifungal agent without causing a untoward immunosuppressive effects within a human subject. In some embodiments, the non-immunosuppressive antifungal dehydrophenylahistin or its analog is a member of one of the preferred subsets of compounds described above. The dehydrophenylahistin or its analog can be packaged alone with the instructions or can be packaged with another dehydrophenylahistin or its analog, raparnycin or another ingredient or additive, e.g., one or more of the ingredients of the pharmaceutical compositions. The package can contain one or more containers filled with one or more of the ingredients of the phan-naceutical compositions. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceutical or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. [01991 The following non-limiting examples are meant to describe the preferred methods using certain preferred embodiments. Variations in the details of the particular methods employed and in the precise chemical compositions obtained will undoubtedly be appreciated by those of skill in the art. EXAMPLE 1 A. Synthesis of Dehydrophenylahistin [0200] Dehydrophenylahistin was synthesized by condensation according to the following basic reaction scheme, as shown in Figure 1: O 2c A4 NH I NH\ A A c NH N H A NHN4 Cs 2

CO

3 /DMF 0 Cs 2

CO

3 /DMF 0 3 DehydroPLH -43- WO 2005/077940 PCT/US2005/003636 N,N'-diacetvL-2,5-piperazinedione [0201] 25.0 g of global 2,5-piperazinedione 1 [2,5-piperazinedione (Aldrich G640-6), 25.0 g, 0.218 mol] in 100 mL of acetic anhydride (Ac 2 O) was mixed with sodium acetate (NaOAc) (17.96 g, .0218 mol). The mixture was heated at 110'C for 8 h using a double -coiled condenser under an Ar atmosphere. After Ac 2 O was removed by evaporation, the residue was dissolved in AcOEt, washed with 10% citric acid, 10% NaHCO 3 and saturated NaCl (three times each), dried over Na 2

SO

4 , and concentrated in vacuo. The residue was triturated with ether to form a solid. This solid was recrystallized from EtOAc with ether-hexane to afford 26.4 g (61%) of NN'-diacetyl-2,5-piperazinedione 1. 1-Acetyl-3- {(Z-1 -[5-(1, 1-dimethyl-2-propenvl)-lH-4-imidazolvllmethylidenell-2,5 piperazinedione 2 [02021 To a solution of 5-(1,1-dimethyl-2-propenyl)imidazole-4-carboxaldehyde (100 mg, 0.609 mmol) in DMF (2 mL) was added compound 1 (241 mg, 1.22 mmol) and the solution was repeatedly evacuated in a short time to remove oxygen and flushed with Ar, followed by the addition of Cs 2

CO

3 (198 mg, 0.609 mmol) and the evacuation-flushing process was repeated again. The resultant mixture was stirred for 5 h at room temperature. After the solvent was removed by evaporation, the residue was dissolved in the mixture of EtOAc and 10% Na 2

CO

3 , and the organic phase was washed with 10% Na 2

CO

3 again and saturated NaCl for three times, dried over Na 2

SO

4 and concentrated in vacuo. The residual oil was purified by column chromatography on silica using CHC1 3 -MeOH (100:0 to 50:1) as an eluant to give 60 mg (33 %) of a pale yellow solid 2. Dehydrophenylahistin [02031 To a solution of 2 (30 mg, 0.099 mmol) in DMF (0.8 mL) was added benzaldehyde (51 tL, 0.496 mmol, 5 eq) and the solution was repeatedly evacuated in a short time to remove oxygen and flushed with Ar, followed by the addition of Cs 2

CO

3 (53 mg, 0.149 mmol, 1.5 eq) and the evacuation-flushing process was repeated again. The resultant mixture was heated for 2.5 h at 80'C. (The temperature must be increased slowly. Rapid heating increases the production of E-isomer at the benzylidene moiety.) After the solvent was removed by evaporation, the residue was dissolved in EtOAc, washed with water for two -44- WO 2005/077940 PCT/US2005/003636 times and saturated NaC1 for three times, dried over Na 2 SO4 and concentrated in vacuo. On TLC using CHC1 3 -MeOH (10:1), you can observe a spot with bright green-yellow luminescence at 365 nm UV. The purity of this crude product was more than 75% from HPLC analysis. The resulting residue was dissolved in 90% MeOH aq and applied to reverse-phase HPLC column (YMC-Pack, ODS-AM, 20 x 250 mm) and eluted using a linear gradient from 70 to 74% MeOH in water over 16 min at a flow rate of 12 mL/min, and the desired fraction was collected and concentrated by evaporation to give a 19.7 mg (60%) of yellow colored dehydrophenylahistin. The HPLC profile of the synthetic crude dehydrophenylahistin is depicted in Figure 2. 102041 In the purification of dehydrophenylahistin, as shown in Figure 4, a major peak was the desired Z- form compound of dehydrophenylahistin. The formation of an E isomer was observed as a minor component (about 10%), which was eluted as a more polar peak than Z-isomer. As other minor peaks, the reduced Z- and E-compounds, in which the dimethylallyl part of dehydrophenylahistin was reduced, was also observed. The formation of these reduced compounds was due to the aldehyde 2 with a reduced impurity, which was generated during the reduction of with DIBAL-H and was not separated in the subsequent process. [02051 These minor compounds could be removed by preparative HPLC purification, afforded dehydrophenylahistin with the Z-configuration at the benzylidene part in a 60% yield (20% yield in two steps) with more than 95% purity. The compounds with E configuration at the imidazole side of the diketopiperazine -ring were not observed in this HPLC chart, suggesting that the first reaction from compound 1 to 3 in Figure 1 is Z selective. B. Chemical Characteristics: [02061 The above dehydrophenylahistin compound is a pale yellow solid. Its structure is confirmed by standard NMR analyses. -45- WO 2005/077940 PCT/US2005/003636 EXAMPLE 2 Synthesis and Physical Characterization of tBu-dehydrophenylahistin Derivatives [02071 Structural derivatives of dehydrophenylahistin were synthesized according to the following reaction schemes to produce tBu-dehydrophenylahistin. Synthesis by Route A (see Figure 1) is similar in certain respects to the synthesis of the dehydrophenylahistin synthesized as in Example 1. Route A O HO 0 0 CAC Ac NAc N T-- ___4 - HNY -s- NH NH I NH A NAc Cs2C DMF A Cs 2

CO

3 /DMF 1 33% (1st) 16 50% tBu-.dehydroPLH Route B N-4 0 HN~ 15 )__HN N ~ NH A 'Ac Cs 2 C %/DMF 'Ac Cs 2 CO IDMF 0 0 0 1 17 1.2 % tBu-dehydroPLH -46- WO 2005/077940 PCT/US2005/003636 Route A: [0208] NN'-diacethyl-2,5-piperazinedione 1 was prepared as in Example 1. 1) 1-Acetyl-3-{(Z)-1-[5-tert-butyl-1H-4-imidazolyllmethylidene ]-2, 5-iperazinedione (16) 0 AcsN KNH N__/ 0 .[0209] To a solution of 5-tert-butylimidazole-4-carboxaldehyde 15 (3.02 g, 19.8. mmol) in DMF (30 mL) was added compound 1 (5.89 g, 29.72 mmol) and the solution was repeatedly evacuated in a short time to remove oxygen and flushed with Ar, followed by the addition of Cs 2

CO

3 (9.7 g, 29.72 mmol) and the evacuation-flushing process was repeated again. The resultant mixture was stirred for 5 h at room temperature. After the solvent was removed by evaporation, the residue was dissolved in the mixture of EtOAc and 10% Na 2

CO

3 , and the organic phase was washed with 10% Na 2

CO

3 again and saturated NaC1 for three times, dried over Na 2

SO

4 and concentrated in vacuo. The residual oil was purified by column chromatography on silica using CHC1 3 -MeOH (100:0 to 50:1) as an eluant to give 1.90 g (33 %) of a pale yellow solid 16. 'H NMR (270 MHz, CDCl 3 ) 8 12.14 (d, br-s, 1H), 9.22 (br-s, 1H), 7.57 (s, 1H), 7.18, (s, 1H), 4.47 (s, 2H), 2.65 (s, 3H), 1.47 (s, 9H). 2) t-Bu-dehydrophenylahistin 0 HN I , - NH .- NH N__/N 0 [02101 To a solution of 1-Acetyl-3-{(Z)-l-[5-tert-butyl-lH-4 imidazolyl]methylidene}]-2,5-piperazinedione (16) (11 mg, 0.038 mmol) in DMF (1.0 mL) was added benzaldehyde (19 tL, 0.19 mmol, 5 eq) and the solution was repeatedly evacuated in a short time to remove oxygen and flushed with Ar, followed by the addition of Cs 2

CO

3 (43 mg, 0.132 mmol, 3.5 eq) and the evacuation-flushing process was repeated again. The resultant mixture was heated for 2.5 h at 80*C. After the solvent was removed by -47- WO 2005/077940 PCT/US2005/003636 evaporation, the residue was dissolved in EtOAc, washed with water for two times and saturated NaCI for three times, dried over Na 2

SO

4 and concentrated in vacuo. The resulting residue was dissolved in 90% MeOH aq and applied to reverse-phase HPLC column (YMC Pack, ODS-AM, 20 x 250 mm) and eluted using a linear gradient from 70 to 74% MeOH in water over 16 min at a flow rate of 12 mL/min, and the desired fraction was collected and concentrated by evaporation to give a 6.4 mg (50%) of yellow colored tert-butyl dehydrophenylahistin. 'H NMR (270 MHz, CDCl 3 ) 8 12.34 br-s, 1H), 9.18 (br-s, 1H), 8.09 (s, 1H), 7.59 (s, 1H), 7.31 - 7.49 (m, 5H), 7.01 s, 2H), 1.46 (s, 9H). [0211] The dehydrophenylahistin reaction to produce tBu-dehydrophenylahistin is identical to Example 1. [0212] The total yield of the tBu-dehydrophenylahistin recovered was 16.5%. Route B: [0213] N,N'-diacethyl-2,5-piperazinedione 1 was prepared as in Example 1. 1) 1-Acetyl-3-[(Z)-benzylidenell-2,5-piperazinedione (17) 0 Acs z 0 [0214] To a solution of benzaldehyde 4 (0.54 g, 5.05. mmol) in DMF (5 mL) was added compound 1 (2.0 g, 10.1 mmol) and the solution was repeatedly evacuated in a short time to remove oxygen and flushed with Ar, followed by the addition of Cs 2

CO

3 (1.65 g, 5.05 mmol) and the evacuation-flushing process was repeated again. The resultant mixture was stirred for 3.5 h at room temperature. After the solvent was removed by evaporation, the residue was dissolved in the mixture of EtOAc and 10% Na 2

CO

3 , and the organic phase was washed with 10% Na 2

CO

3 again and saturated NaCl for three times, dried over Na 2

SO

4 and concentrated in vacuo. The residual solid was recrystalized from MeOH-ether to obtain a off-white solid of 17; yield 1.95 g (79%). -48- WO 2005/077940 PCT/US2005/003636 2) t-Bu-dehydrophenylahistin 0 0- HN*

-

NH - NH N,-/H 0 [0215] To a solution of 1-Acetyl-3-[(Z)-benzylidenel]-2,5-piperazinedione (17) (48 mg, 0.197 mmol) in DMF (1.0 mL) was added 5-tert-butylimidazole-4-carboxaldehyde 15 (30 mg, 0.197 mmol) and the solution was repeatedly evacuated in a short time to remove oxygen and flushed with Ar, followed by the addition of Cs 2

CO

3 (96 mg, 0.296 mmol) and the evacuation-flushing process was repeated again. The resultant mixture was heated for 14 h at 80*C. After the solvent was removed by evaporation, the residue was dissolved in EtOAc, washed with water for two times and saturated NaCl for three times, dried over Na 2

SO

4 and concentrated in vacuo. The resulting residue was dissolved in 90% MeOH aq and applied to reverse-phase HPLC column (YMC-Pack, ODS-AM, 20 x 250 mm) and eluted using a linear gradient from 70 to 74% MeOH in water over 16 min at a flow rate of 12 mL/min, and the desired fraction was collected and concentrated by evaporation to give a 0.8 mg (1.2%) of yellow colored tert-butyl-dehydrophenylahistin. [0216] The total yield of the tBu-dehydrophenylahistin recovered was 0.9%. [0217] The HPLC profile of the crude synthetic tBu-dehyrophenylahistin from Route A and from Route B is depicted in Figure 4. [0218] Two other tBu-dehydrophenylahistin derivatives were synthesized according to the method of Route A. In the synthesis of the additional tBu dehydrophenylahistin derivatives, modifications to the benzaldehyde compound 4 were made. [0219] Figure 4 illustrates the similarities of the HPLC profiles (Column: YMC Pack ODS-AM (20 x 250mm); Gradient: 65% to 75% in a methanol-water system for 20 min, then 10 min in a 100% methanol system; Flow rate: 12mL/min; O.D. 230 nm) from the synthesized dehydrophenylahistin of Example 1 (Fig 2) and the above exemplified tBu dehydrophenylahistin compound produced by Route A. [0220] The sequence of introduction of the aldehydes is a relevant to the yield and is therefore aspect of the synthesis. An analogue of dehydrophenylahistin was synthesized, as -49- WO 2005/077940 PCT/US2005/003636 a control or model, wherein the dimethylallyl group was changed to the tert-butyl group with a similar steric hindrance at the 5-position of the imidazole ring. [0221] The synthesis of this "tert-butyl (tBu)-dehydrophenylahistin" using "Route A" was as shown above: Particularly, the sequence of introduction of the aldehyde exactly follows the dehydrophenylahistin synthesis, and exhibited a total yield of 16.5% tBu dehydrophenylahistin. This yield was similar to that of dehydrophenylahistin (20%). Using "Route B", where the sequence of introduction of the aldehydes is opposite that of Route "A" for the dehydrophenylahistin synthesis, only a trace amount of the desired tBu-dehydroPLH was obtained with a total yield of 0.9%, although in the introduction of first benzaldehyde 4 gave a 76% yield of the intermediate compound 17. This result indicated that it may be difficult to introduce the highly bulky imidazole-4-carboxaldehydes 15 with a substituting group having a quaternary-carbon on the adjacent 5-position at the imidazole ring into the intermediate compound 17, suggesting that the sequence for introduction of aldehydes is an important aspect for obtaining a high yield of dehydrophenylahistin or an analog of dehydrophenylahistin employing the synthesis disclosed herein; [0222] From the HPLC analysis of the final crude products, as shown in Figure 4, a very high content of tBu-dehydrophenylahistin and small amount of by-product formations were observed in the crude sample of Route A (left). However, a relatively smaller amount of the desired tBu-dehydrophenylahistin and several other by-products were observed in the sample obtained using Route B (right). -50- WO 2005/077940 PCT/US2005/003636 EXAMPLE 3 Alternative. Larger-Scale Synthesis of Dehydrophenylahistin and Analogs Synthesis of 3-Z-Benzyiidenze-6-f5 "-(7, 1-diinethylailyl)-1H-imiidazol-4 "-Z--yimethyleneJ piperazine-2, 5-dione fDehydrophenylahistinj (1) 0 OK 0 0 e, f ltV, OHd 00 0 0 cl 0 OH - ~NH - N NH 0 0 N -JN 00 0 N. Ni N=\ (NH N=N H N N~ NH y N NH NH -51- WO 2005/077940 PCT/US2005/003636 [0223] Reagents: a) LDA, CH 3 CHO; b) Tos-C1, pyridine; c) DBU; d) NaOH; e)

C

2 C1 2 0 2 ; f) KOOCCH 2 COOEt, BuLi; g) S0 2 C1 2 ; h) H 2 NCHO, H 2 0; i) LiAlH 4 ; j) MnO2; k) 1,4-diacetyl-piperazine-2,5-dione, Cs 2

CO

3 ; 1) benzaldehyde, Cs 2

CO

3 3-Hydroxy-2,2-dimethyl-butyric acid methyl ester Q 0 LDA OH O [0224] A solution of LDA in heptane/THF/ethylbenzene (2 M, 196 ml, 0.39 mol) was added under argon to a solution of methyl isobutyrate (45 ml, 0.39 mol) in THF (270 ml) at -60* and the resultant mixture was stirred for 30 min. A solution of acetaldehyde (27 ml, 0.48 mol) in THF (45 ml), precooled to ~60', was added slowly and the resulting solution stirred for a further 30 min. Saturated ammonium chloride (50 ml) was added and the solution was allowed to warm to room temperature. The reaction mixture was extracted with ethyl acetate, and the extracts were washed with HCI (2 M), sodium bicarbonate, then brine. The organic layer was dried over magnesium sulfate, filtered, then evaporated to give a clear oil (52.6 g). Distillation 76-82*/30 mmHg gave pure 3-hydroxy-2,2-dimethyl-butyric acid methyl ester (42.3 g, 74%). (Burk et al., J. Am. Chem. Soc., 117:4423-4424 (1995)). [0225 1 H NMR (400 MHz, CDCl 3 ) 5 1.15 (d, J= 6.2 Hz, 3H); 1.17 (s, 6H); 2.66 (d, J= 6.2 Hz, 1H, -OH); 3.71 (s, 3H, -OMe); 3.87 (app quintet, J= 6.4 Hz, 1H, H3). 2,2-Dimethyl-3-(toluene-4-sulfonyloxy)-butyric acid methyl ester 0 TsCI O& OH 0 Pyridine 0 0 O=s=O -52- WO 2005/077940 PCT/US2005/003636 [0226] To a cooled (00) solution of 3-hydroxy-2,2-dimethyl-butyric acid methyl ester (52.0 g, 0.36 mol) in pyridine (100 ml) was added gradually, p-toluene sulfonyl chloride (69.0 g, 0.36 mol). The mixture was allowed to warm to room temperature and was stirred for 60 h. The reaction was again cooled in ice and was acidified by addition of HC1 (2 M). The resultant solution was extracted with ethyl acetate, the extracts were washed with HC1, then brine, dried and evaporated to give an oil which formed a white precipitate upon standing. This mixture was dissolved in the minimum amount of ethyl acetate and then light petroleum was added to afford a white precipitate which was collected and washed with more light petroleum. The filtrate was partially evaporated and a second crop of crystals was collected and added to the first to afford 2,2-dimethyl-3-(toluene-4-sulfonyloxy)-butyric acid methyl ester (81.2 g, 76%). [0227] 'H NMR (400 NMz, CDC1 3 ) 8 1.12 (s, 3H); 1.13 (s, 3H); 1.24 (d, J= 6.4 Hz, 311); 2.45 (s, 3H, -PhMe) 3.58 (s, 3H, -OMe); 4.94 (quartet, J= 6.4 Hz, 1H, H3), 7.33 (d, J= 8.0 Hz, 2H), 7.78 (d, J= 8.0 Hz, 2H). [0228] Evaporation of the final filtrate afforded additional crude 2,2-dimethyl-3 (toluene-4-sulfonyloxy)-butyric acid methyl ester (19.0 g, 18%). 2,2-Dimethyl-but-3-enoic acid methyl ester 0 0 O= O0 DBU 0 [0229] A solution of 2,2-dimethyl-3-(toluene-4-sulfonyloxy)-butyric acid methyl ester (18.06 g, 0.06 mol) in DBU (15 ml) was heated at 140-160* for 3.5 h. The mixture was allowed to cool to room temperature and was then diluted with ether. The mixture was washed with HC1 (1 M), sodium bicarbonate, then brine. The ethereal layer was dried and partially evaporated to give a concentrated solution of 2,2-dimethyl-but-3-enoic acid methyl ester (10 g). (Savu and Katzenellenbogen, J. Org. Chem, 46:239-250 (1981)). Further -53- WO 2005/077940 PCT/US2005/003636 evaporation was avoided due to the volatility of the product (bp 102*). (Tsaconas et al., Aust. J. Chem., 53:435-437 (2000)). 102301 H NMR (400 NMz, CDC1 3 ) 6 1.31 (s, 6H); 3.68 (s, 3H); 5.06 (d, J= 17.1 Hz, 1H, -CH=CH 2 ); 5.11 (d, J= 10.7 Hz, 1H, -CH=CH 2 ); 6.03 (dd, J= 17.1, 10.7 Hz, 1H, CH=CH 2 ). 2,2-Dimethyl-but-3-enoic acid OH 0 0 [02311 The above ethereal solution of 2,2-dimethyl-but-3-enoic acid methyl ester (10 g) was diluted with ethanol (25 ml), sodium hydroxide (4 M, 22 ml) was added and the mixture was stirred overnight. The solution was partially evaporated to remove the ethanol and the resultant mixture was added to HCl (1M, 100 ml). The product was extracted with ethyl acetate and the extracts were dried and evaporated to give 2,2-dimethyl-but-3-enoic acid (6.01 g, 88% 2 steps). (Hayashi et al., J. Org. Chem., 65:8402-8405 (2000). 102321 1H NMR (400 MHz, CDC1 3 ) 6 1.33 (s, 6H); 5.11 (d, J= 10.8 Hz, 1H, CH=CH 2 ); 5.15 (d, J = 17.2 Hz, 1H, -CH=CH 2 ); 6.05 (dd, J = 17.2, 10.8 Hz, 1H, CH=CH 2 ). [02331 Monoethyl hydrogen malonate (Wierenga and Skulnick, "Aliphatic and Aromatic p-keto Esters from Monoethyl Malonate: Ethyl 2-Butyrylacetate," Organic Syntheses Collective Volume 7, 213). OO~ K+ -O IA HO A [02341 Ethyl potassium malonate (25.0 g, 0.15 mol) was suspended in water (15.6 ml) and cooled in an ice bath. Concentrated HCl (12.5 ml) was added dropwise over 30 min, -54- WO 2005/077940 PCT/US2005/003636 then the mixture was stirred for a further 10 min. The precipitate was filtered, then washed twice with ether. The filtrate was separated and the aqueous phase was extracted with ether. The combined ethereal solutions were dried (MgS04) and evaporated to afford, as an oil, monoethyl hydrogen malonate (19.2 g, 99%) which was dried under vacuum overnight (or 50*/1 mm for 1 h) prior to use. 4,4-Dimethyl-3-oxo-hex-5-enoic acid ethyl ester OH i) C 2 0 2

C

2 / DMF O i) 0 0 B 00 HO 5-. Bl [0235] Oxalyl chloride (3.83 ml, 43.9 mmol) was added dropwise to a cooled (00) solution of 2,2-dimethyl-but-3-enoic acid (5.0 g, 43.9 mmol) and DMF (1 drop) in anhydrous dichloromethane (25 ml). The mixture was stirred for 1 h at 00, then for 16 h at room temperature. Fractional distillation (1210/760 mmHg) afforded 2,2-dimethyl-but-3-enoyl chloride (4.1 g, 71%). [0236] Monoethyl hydrogen malonate (7.2 g, 0.05 mol) and bipyridyl (few milligrams) were dissolved in THF (90 ml) and the system was flushed with nitrogen. The solution was cooled to -70*, then BuLi (2.5 M in hexanes, 37 ml, 0.09 mol) was added. After the addition of only ~10 ml of BuLi the solution turned pink and additional THF (15 ml) was required to enable magnetic stirring. The cooling bath was removed and the remaining BuLi was added, the temperature was allowed to reach -100, upon which the solution turned colorless. The mixture was again cooled to -60' and a solution of 2,2-dimethyl-but-3-enoyl chloride (4.1 g, 0.03 mol) in THF (12 ml) was added dropwise. After addition was complete the mixture was allowed to warm to 00 and stir for 3 h, then it was added to a 1:1 mixture of ether/1M HC1 (260 ml) at 00 and stirred for a further 1.5 h. The organic layer was removed, .washed with HCI (1 M), sodium bicarbonate solution, brine then dried and evaporated to give 4,4-dimethyl-3-oxo-hex-5-enoic acid ethyl ester (5.6 g, 98%). (Hayashi et al., J. Org. Chen., 65:8402-8405 (2000). Distillation with a Kugelrohr oven (1600/1 mmHg) afforded pure material. -55- WO 2005/077940 PCT/US2005/003636 [02371 'H NMR (400 MHz, CDC1 3 ) 5 1.26 (s, 6H); 1.27 (t, J = 6.9 Hz, 3H, CH 2

CH

3 ); 3.51 (s, 2H); 4.18 (q, J = 6.9 Hz, 2H, -CH 2

CH

3 ); 5.20 (d, J = 17.7 Hz, 1H, CH=CH 2 ); 5.21 (d, J= 9.6 Hz, 1H, -CH=CH 2 ); 5.89 (dd, J= 17.7, 9.6 Hz, 1H, -CH=CH 2 ). 2-Chloro-4,4-dinethyl-3-oxo-hex-5-enoic acid ethyl ester S0 2 C O 0 0 0 0 [0238] Sulfuryl chloride (0.84 ml, 10.4 mmol) was added to a cooled (00) solution of 4,4-dimethyl-3-oxo-hex-5-enoic acid ethyl ester (1.83 g, 9.93 mmol) in chloroform (7 ml). The resulting mixture was allowed to warm to room temperature and stir for 30 min, after which it was heated under reflux for 2 h. After cooling to room temperature the reaction mixture was diluted with chloroform, then was washed with sodium bicarbonate, water then brine. The organic phase was dried and evaporated to afford, as a brown oil, 2-chloro-4,4 dimethyl-3-oxo-hex-5-enoic acid ethyl ester (2.01 g, 93%). (Hayashi et al., J. Org. Chem., 65:8402-8405 (2000). [02391 1H NMR (400 MHz, CDC1 3 ) 8 1.28 (t, J= 7.0 Hz, 3H, -CH 2

CH

3 ); 1.33 (s, 3H); 1.34 (s, 3H); 4.24 (q, J= 7.0 Hz, 2H, -CH 2

CH

3 ); 5.19 (s, 1H; 5.28 (d, J= 16.9 Hz, 1H, CH=CH 2 ); 5.29 (d, J = 10.9 Hz, 1H, -CH=CH 2 ); 5.96 (dd, J 16.9, 10.9 Hz, 1H, CH=CH 2 ). 10240] LC/MS tR = 8.45 (219.3 [M(Cl 37 )+H]+ min. [0241] This material was reacted without further purification. 5-(1,1-Dimethyl-allyl)-3H-inidazole-4-carboxylic acid ethyl ester 0 O OOH o 0 C 1 k N H 2 O NNH + NH N 0 N-/N' [02421 A suspension of 2-chloro-4,4-dimethyl-3-oxo-hex-5-enoic acid ethyl ester (19.4 g, 0.09 mol) and water (1.94 ml, 0.11 mol) in formamide (36.8 ml) was shaken briefly, then dispensed into 15 x 18 ml vials. The vials were sealed and heated at 150' for 5 h. After -56- WO 2005/077940 PCT/US2005/003636 cooling to room temperature, the vials' contents were combined and extracted exhaustively with chloroform. The extracts were dried and evaporated to afford a concentrated formamide solution (14.7 g). This was added to a silica column (7 cm diameter, 11 cm height) packed in 1% MeOH/1% Et 3 N in chloroform. Elution of the column with 2 L of this mixture followed by 2 L of 2% MeOH/1% Et 3 N in chloroform afforded, in the early fractions, a compound suspected of being 5-(1, 1-dimethyl-allyl)-oxazole-4-carboxylic acid ethyl ester (1.23 g. 7%). [0243] HPLC (214nm) tR = 8.68 (50.4%) min. [02441 1H NMR (400 MHz, CDC1 3 ) 8 1.40 (t, J= 7.2 Hz, 3H, -CH 2

CH

3 ); 1.54 (s, 6H); 4.38 (t, J= 7.2 Hz, 2H, -CH 2 CH); 5.03 (d, J= 17.4 Hz, 1H, -CH=CH 2 ); 5.02 (d, J= 10.4 Hz, 1H, -CH=CH 2 ); 6.26 (dd, J= 17.4, 10.4 Hz, 1H, -CH=CH 2 ); 7.83 (s, 1H). [0245] LCMS tR 8.00 (210.1 [M+H]+, 361.1 [2M+H]) min. 10246] Recovered from later fractions was the desired 5-(1,1-dimethyl-allyl)-3H imidazole-4-carboxylic acid ethyl ester (3.13 g, 17%). (Hayashi et al., J. Org. Chem., 65:8402-8405 (2000)). [0247] HPLC (214nm) tR = 5.52 (96.0%) min. [02481 1H NMR (400 MHz, CDC1 3 ) 6 1.38 (t, J= 7.0 Hz, 3H); 1.57 (s, 6H); 4.35 (q, J = 7.0 Hz, 2H); 5.04-5.14 (in, 2H, -CH=CH 2 ); 6.28 (dd, J = 18.0, 10.4 Hz, 1H, CH=CH 2 ); 7.52 (s, 1H). [0249] LC/MS tR = 5.30 (209.1 [M+H]*, 417.2 [2M+H]*) min. [0250] Additional 5-(1,1-dimethyl-allyl)-3H-imidazole-4-carboxylic acid ethyl ester was also recovered from the column (3.59 g, 19%) which was of lower purity but still sufficient for further reaction. [0251] Another byproduct isolated from a similar reaction (smaller scale) by further elution of the column with 5% MeOH/1% Et 3 N in chloroform was a compound suspected of being 5-(1, 1-dimethyl-allyl)-3H-imidazole-4-carboxylic acid (0.27 g, 9%). [0252] HPLC (245nm) tR = 5.14 (68.9%) min. [02531 'H NMR (400 MHz, CD 3 0D) 5 1.45 (s, 6H); 4.97 (d, J= 10.6 Hz, 1H, CH=CH 2 ); 5.01 (d, J = 17.7 Hz, 1H, -CH=CH 2 ); 6.28 (dd, J = 17.7, 10.6 Hz, 1H, CH=CH 2 ); 7.68 (s, 1H). [0254] LCMS tR = 4.72 (181.0 [M+H]+, 361.1 [2M+H]+) min. -57- WO 2005/077940 PCT/US2005/003636 [5-(1,1-Dimethyl-allyl)-3H-inidazol-4-ylJ-methanol o O'- OH

UALIH

4 NH NH N= N [0255] A solution of 5-(1,1-dimethyl-allyl)-3H-imidazole-4-carboxylic acid ethyl ester (3.13 g, 15.0 mmol) in THF (60 ml) was added dropwise to a suspension of lithium aluminium hydride (95% suspension, 1.00 g, 25.0 mmol) in THF (40 ml) and the mixture was stirred at room temperature for 4 h. Water was added until the evolution of gas ceased, the mixture was stirred for 10 min, then was filtered through a sintered funnel. The precipitate was washed with THF, then with methanol, the filtrate and washings were combined, evaporated, then freeze-dried to afford [5-(1,1-dimethyl-allyl)-3H-imidazol-4-yl] methanol (2.56 g, 102%). Residual water was removed by azeotroping with chloroform prior to further reaction. (See Hayashi et al., J. Org. Chem., 65:8402-8405 (2000)). [02561 HPLC (240nm) tR = 3.94 (56.8%) min. [02571 'H NMR (400 MHz, CD 3 OD) 6 1.43 (s, 6H); 4.57 (s, 2H); 5.01 (d, J= 10.5 Hz, 1H, -CH=CH 2 ); 5.03 (d, J= 17.7 Hz, 1H, -CH=CH 2 ); 6.10 (dd, J= 17.7, 10.5 Hz, 1H, -CH=CH 2 ); 7.46 (s, 1H). [0258] LC/MS tR = 3.77 (167.3 [M+H]*) min. 5-(1,1-Dimethyl-allyl)-3H-imidazole-4-carbaldehyde OH 0 Mn0 2 NH MNH [02591 Manganese dioxide (20 g, 0.23 mol) was added to a solution of [5-(1,1 dimethyl-allyl)-3H-imidazol-4-yl]-methanol (2.56 g, 0.02 mol) in acetone (300 ml) and the resulting mixture was stirred at room temperature for 5 h. The mixture was filtered through filter paper and the residue was washed with acetone. The filtrate and washings were combined and evaporated to afford 5-(1,1-dimethy-allyl)-3H-imidazole-4-carbaldehyde (1.82 g, 5 1%). (Hayashi et al., J. Org. Chem., 65:8402-8405 (2000)). [02601 HPLC (240nm) tR = 4.08 (91.5%) min. -58- WO 2005/077940 PCT/US2005/003636 102611 'H NMR (400 MHz, CDCl 3 ) 8 1.56 (s, 6H); 5.16 (d, J= 10.6 Hz, 1H, CH=CH 2 ); 5.19 (d, J= 17.3 Hz, 1H, CH=CH 2 ); 6.22 (dd, J= 17.3, 10.6 Hz, 1H, -CH=CH 2 ); 7.75 (s, 1H), 10.02 (s, 1H, HCO). [0262] LC/MS tR = 3.75 (165.2 [M+H]+) min. 1-Acetyl-3-[5'-(1,1-dimethyl-allyl)-1H-imidazol-4'-Z-ylinethylene]-piperazine-2,5-dione + I~~K ~NH N=\ NH N N N_ 102631 To a solution of 5-(1,1-dimethyl-allyl)-3H-imidazole-4-carbaldehyde (1.78 g, 0.01 mol) in DMF (35 ml) was added 1,4-diacetyl-piperazine-2,5-dione (8.59 g, 0.04 mol) and the mixture was evacuated, then flushed with argon. The evacuation-flushing process was repeated a further two times, then cesium carbonate (3.53 g, 0.01 mol) was added. The evacuation-flushing process was repeated a further three times, then the resultant mixture was heated at 450 for 5 h. The reaction mixture was partially evaporated (heating under high vacuum) until a small volume remained and the resultant solution was added dropwise to ice water (50 ml). The yellow precipitate was collected, washed with water, then freeze-dried to afford 1-acetyl-3-[5'-(1,1-dimethyl-allyl)-1H-imidazol-4'-ylmethylene]-piperazine-2,5-dione (1.18 g, 36%). (Hayashi, Personal Communication (2001)). [0264] HPLC (214nm) tR = 6.01 (72.6%) min. 102651 1H NMR (400 MHz, CDCl 3 ) 5 1.53 (s, 6H); 2.64 (s, 3H); 4.47 (s, 2H); 5.19 (d, J= 17.3 Hz, 1H, -CH=CH 2 ); 5.23 (d, J= 10.7 Hz, 1H, -CH=CH 2 ); 6.06 (dd, J= 17.3, 10.7 Hz, 1H, -CH=CH 2 ); 7.16 (s, 1H), 7.59 (s, 1H), 9.47 (bs, 1H); 12.11 (bs, 1H) [observed ~2% 1,4-diacetyl-piperazine-2,5-dione contamination 6 2.59 (s, 6H); 4.60 (s, 4H).] [02661 LC/MS tR = 6.65 (303.3 [M+H]+, 605.5 [2M+H]*) min. (n.b. different system used). -59- WO 2005/077940 PCT/US2005/003636 3-Z-Benzylidene-6-[5 "-(I, 1-dimethylallyl)-IH-iindazol-4 "-Z-ylinethylene]-piperazine- 2 ,5 dione 0 0 0 NH N\ NH N=\ N HN NH_ H NH 00- 0 0~ [02671 To a solution of 1-acetyl-3-[5'-(1,1-dimethyl-allyl)-1H-imidazol-4' ylmethylene]-piperazine-2,5-dione (2.91 g, 9.62 mmol) in DMF (70 ml) was added benzaldehyde (4.89 ml, 48.1 mmol) and the solution was evacuated, then flushed with Argon. The evacuation-flushing process was repeated a further two times, then cesium carbonate (4.70 g, 14.4 mmol) was added. The evacuation-flushing process was repeated a further three times, then the resultant mixture was heated under the temperature gradient ad shown below. [0268] After a total time of 5 h the reaction was allowed to cool to room temperature and the mixture was added to ice-cold water (500 ml). The precipitate was collected, washed with water (300 ml), then freeze-dried to afford a yellow solid (2.80 g). This material was dissolved in chloroform (250 ml) filtered through filter paper and evaporated to azeotrope remaining water. The residual yellow precipitate (2.70 g, HPLC (214nm) tR = 7.26 (93.6%) min.) was partially dissolved in chloroform (20 ml), the suspension was sonicated for 5 min, then the solid was collected and air dried to afford 3-Z benzylidene-6-[5"-(1, 1 -dimethylallyl)- IH-imidazol-4"-Z-ylmethylene]-piperazine-2,5-dione (1.82 g, 54%) (Hayashi, Personal Communication (2001)), m.p. 239-240' (dec.). [0269] HPLC (214nm) tR = 6.80 (1.92) min, 7.33 (95.01%). 10270] 'H NMR (400 MHz, CDC1 3 ) 5 1.53 (s, 6H); 5.18 (d, J= 17.6 Hz, 1H, CH=CH 2 ); 5.21 (d, J = 11.0 Hz, 1H, -CH=CH 2 ); 6.06 (dd, J = 17.6, 11.0 Hz, 1H, CH=CH 2 ); 6.99 (s, 1H, -C-C=CH); 7.00 (s, 1H, -C-C=CH); 7.30-7.50 (in, 5 x ArH); 7.60 (s, H2"); 8.07 (bs, NH); 9.31 (bs, NH); 12.30 (bs, NH). [02711 LC/MS tR = 6.22 (349.3 [M+H]*, E isomer), 6.73 (349.5 [M+H]*, 697.4 [2M+H]+, Z isomer) min. [0272] ESMS n/z 349.5 [M+H]+, 390.3 [M+CH 4 CN]*. -60- WO 2005/077940 PCT/US2005/003636 [02731 Evaporation of the chloroform solution gave additional 3-Z-benzylidene-6 [5"-(1,1-dimethylallyl)-1H-imidazol-4"-Z-ylmethylene]-piperazine-2,5-dione (0.76 g, 29%). [02741 HPLC (214nm) tR = 7.29 (84.5%) min. 3-E-Benzylidene-6-[5"-(1,1-dimethylallyl)-1H-imidazol-4"-Z-ylmethylene]-piperazine-2,5 dione 00 0 NH N\ NH N=\ NNHN NH 0 00 [0275] Preparative HPLC purification of a crude sample of material synthesized as above afforded the geometric isomer 3-E-Benzylidene-6-[5"-(1,1-dimethylallyl)-1H imidazol-4"-Z-ylmethylene]-piperazine-2,5-dione (1.7 mg). [02761 HPLC (214nm) tR 6.75 (87.79) min. 10277] 'H NMR (400 MHz, CDC1 3 ) 6 1.52 (s, 6H); 5.19 (d, J = 20.8 Hz, 1H,

CH=CH

2 ); 5.22 (d, J= 14.0 Hz, 1H, CH=CH 2 ); 6.05 (dd, J= 18.0, 10.4 Hz, 1H, CH=CH 2 ); 6.33 (s, 1H, C-C=CH); 6.90-7.65 (m, 7H). [02781 ESMS m/z 349.5 [M+H]*, 390.4 [M+CH 4 CN]+. -61- WO 2005/077940 PCT/US2005/003636 Synthesis of 3-Z-Benzylidene-6-(5"-tert-butyl-IH-imidazol-4"-Z-ylnethylene)-piperazine 2,5-dione (2) 0 0 - O OOH h NH 0 0 /0 H N k -~HN *-. NH ---- y-.N H. 4VNH 0 0 J H 2 [0279] Reagents: g) S0 2

C

2 ; h) H 2 NCHO, H 2 0; I)LiAH 4 ; j) MnO 2 ; k) 1,4 diacetyl-piperazine-2,5-dione, Cs 2

CO

3 ; 1) benzaldehyde, Cs 2

CO

3 2-Chloro-4,4-dimethyl-3-oxo-pentanoic acid ethyl ester C1 O s0 2 C1 2 00 0 [0280] Sulfuryl chloride (14.0 ml, 0.17 mol) was added to a cooled (00) solution of ethyl pivaloylacetate (27.17 g, 0.16 mol) in chloroform (100 ml). The resulting mixture was allowed to warm to room temperature and was stirred for 30 min, after which it was heated under reflux for 2.5 h. After cooling to room temperature, the reaction mixture was diluted with chloroform, then washed with sodium bicarbonate, water then brine. -62- WO 2005/077940 PCT/US2005/003636 [02811 The organic phase was dried and evaporated to afford, as a clear oil, 2 chloro-4,4-dimethyl-3-oxo-pentanoic acid ethyl ester (33.1 g, 102%). (Durant et al., "Aminoalkylimidazoles and Process for their Production." Patent No. GB1341375 (Great Britain, 1973)). [02821 HPLC (214nm) tR = 8.80 (92.9%) min. [02831 1 H NMR (400 MHz, CDC1 3 ) 8 1.27 (s, 9H); 1.29 (t, J= 7.2 Hz, 3H); 4.27 (q, J= 7.2 Hz, 2H); 5.22 (s, 1H). 102841 1 3 C NMR (100 MHz, CDC1 3 ) 5 13.8, 26.3, 45.1, 54.5, 62.9, 165.1, 203.6. 5-tert-Butyl-3H-inidazole-4-carboxylic acid ethyl ester NHo o0 0,,, OH 0 og-, 1NNH + H, + N [0285] A solution of 2-chloro-4,4-dimethyl-3-oxo-pentanoic acid ethyl ester (25.0 g, 0.12 mol) in formamide (47.5 ml) and water (2.5 ml) was shaken, then dispensed into 15 x 8 ml vials. All vials were sealed and then heated at 150* for 3.5 h. The vials were allowed to cool to room temperature, then water (20 ml) was added and the mixture was exhaustively extracted with chloroform. The chloroform was removed to give a concentrated formamide solution (22.2 g) which was added to a flash silica column (6 cm diameter, 12 cm height) packed in 1% MeOH/1% Et 3 N in chloroform. Elution of the column with 2.5 L of this mixture followed by 1 L of 2% MeOH/1% Et 3 N in chloroform gave, in the early fractions, a product suspected of being 5-tert-butyl-oxazole-4-carboxylic acid ethyl ester (6.3 g, 26%). [0286] HPLC (214nm) tR = 8.77 min. [0287] 'H NMR (400 MHz, CDC1 3 ) 6 1.41 (t, J= 7.2 Hz, 3H); 1.43 (s, 9H); 4.40 (q, J= 7.2 Hz, 2H); 7.81 (s, IH). 102881 1 3 C NMR (100 MHz, CDC1 3 ) 6 14.1, 28.8, 32.5, 61.3, 136.9, 149.9, 156.4, 158.3. [02891 ESMS n/z 198.3 [M+H]+, 239.3 [M+CH 4 CN]+. [0290] LC/MS tR = 7.97 (198.1 [M+H]*) min. -63- WO 2005/077940 PCT/US2005/003636 [02911 Recovered from later fractions was 5-tert-butyl-3H-imidazole-4-carboxylic acid ethyl ester (6.20 g, 26%). (Durant et al., "Aminoalkylimidazoles and Process for their Production." Patent No. GB 1341375 (Great Britain, 1973)). [02921 HPLC (214nm) tR = 5.41 (93.7%) min. 102931 'H NMR (400 MHz, CDC1 3 ) 8 1.38 (t, J= 7.0 Hz, 3H); 1.47 (s, 9H); 4.36 (q, J= 7.2 Hz, 2H); 7.54 (s, 1H). [02941 1 3 C NMR (100 MHz, CDC1 3 ) 8 13.7, 28.8, 32.0, 59.8, 124.2, 133.3, 149.2, 162.6. [0295] ESMS m/z 197.3 [M+H]+, 238.3 [M+CH 4 CN]*. [0296] Further elution of the column with 1L of 5% MeOh/1% Et 3 N gave a compound suspected of being 5-tert-butyl-3H-imidazole-4-carboxylic acid (0.50 g, 2%). [02971 HPLC (245nm) tR = 4.68 (83.1%) min. [02981 'H NMR (400 MHz, CD 3 OD) S 1.36 (s, 9H); 7.69 (s, 1H). [0299] 'H NMR (400 MHz, CDCl 3 ) S 1.37 (s, 9H); 7.74 (s, 1H). [0300] 'H NMR (400 MHz, CD 3 SO) 8 1.28 (s, 9H); 7.68 (s, 1H). [03011 ESMS m/z 169.2 [M+H]+, 210.4 [M+CH 4 CN]*. (5-tert-Butyl-3H-imidazol-4-yl)-methanol O OOH LiAIH 4 H NH N-H [0302] A solution of 5-tert-butyl-3-imidazole-4-carboxylic acid ethyl ester (3.30 g, 16.8 mmol) in THF (60 ml) was added dropwise to a suspension of lithium aluminium hydride (95% suspension, 0.89 g, 22.2 mmol) in THF (40 ml) and the mixture was stirred at room temperature for 3 h. Water was added until the evolution of gas ceased, the mixture was stirred for 10 min, then was filtered through a sintered funnel. The precipitate was washed with THF, then with methanol, the filtrate and washings were combined and evaporated. The residue was freeze-dried overnight to afford, as a white solid (5-tert-butyl -64- WO 2005/077940 PCT/US2005/003636 3H-imidazol-4-yl)-methanol (2.71 g, 105%). (Durant et al., "Aminoalkylimidazoles and Process for their Production." Patent No. GB1341375 (Great Britain, 1973)). [0303] HPLC (240nm) tR = 3.70 (67.4%) min. [03041 'H NMR (400 MHz, CD 3 0D) 6 1.36 (s, 9H); 4.62 (s, 2H); 7.43 (s, 1H). 103051 13 C NMR (100 MHz, CD 3 0D) 8 31.1, 33.0, 57.9, 131.4, 133.9, 140.8. 103061 LC/MS tR = 3.41 (155.2 [M+H]*) min. [0307] This material was used without further purification. 5-tert-Butyl-3H-imidazole-4-carbaldehyde OH 0 MnO 2 -4 NH M-nNH [0308] Manganese dioxide (30 g, 0.35 mol) was added to a heterogeneous solution of (5-tert-butyl-3H-imidazol-4-yl)-methanol (4.97 g, 0.03 mol) in acetone (700 ml) and the resulting mixture was stirred at room temperature for 4 h. The mixture was filtered through a pad of Celite and the pad was washed with acetone. The filtrate and washings were combined and evaporated. The residue was triturated with ether to afford, as a colorless solid, 5-tert-butyl-3H-imidazole-4-carbaldehyde (2.50 g, 51%). (Hayashi, Personal Communication (2000)). [0309] HPLC (240nm) tR = 3.71 (89.3%) min. [03101 'H NMR (400 MHz, CDC1 3 ) 6 1.48 (s, 9H); 7.67 (s, 1H); 10.06 (s, 1H). [03111 LC/MS tR = 3.38 (153.2 [M+H]*) min. [0312] Evaporation of the filtrate from the trituration gave additional 5-tert-butyl 3H-imidazole-4-carbaldehyde (1.88 g, 38%). -65- WO 2005/077940 PCT/US2005/003636 I-Acetyl-3-(5'-tert-butyl-JH-imdazol-4'-Z-ylnethylene)-piperazine-2,5-dione .0 0 0 O N NH = ) NH +Y NNY [0313] To a solution of 5-tert-butyl-3H-imidazole-4-carbaldehyde (2.50 g, 164.4 mmol) in DMF (50 ml) was added 1,4-diacetyl-piperazine-2,5-dione (6.50 g, 32.8 mmol) and the solution was evacuated; then flushed with argon. The evacuation-flushing process was repeated a further two times, then cesium carbonate (5.35 g, 16.4 mmol) was added. The evacuation-flushing process was repeated a further three times, then the resultant mixture was stirred at room temperature for 5 h. The reaction mixture was partially evaporated (heat and high vacuum) until a small volume remained and the resultant solution was added dropwise to water (100 ml). The yellow precipitate was collected, then freeze-dried to afford 1-acetyl 3-(5'-tert-butyl-1H-imidazol-4'-Z-ylmethylene)-piperazine-2,5-dione (2.24 g, 47%). (Hayashi, Personal Communication (2000)). [0314] HPLC (214nm) tR = 5.54 (94.4%) min. [03151 'H NMR (400 MHz, CDC1 3 ) 8 1.47 (s, 9H); 2.65 (s, 3H), 4.47 (s, 2H); 7.19 (s, 1H); 7.57 (s, 1H), 9.26 (s, 1H), 12.14 (s, 1H). [03161 1 3 C NMR (100 MHz, CDC1 3

+CD

3 0D) 8 27.3, 30.8, 32.1, 46.5, 110.0, 123.2, 131.4, 133.2, 141.7, 160.7, 162.8, 173.0 [0317] LC/MS tR = 5.16 (291.2 [M+H]+, 581.6 [2M+H]) min. 3-Z-Benzylidene-6-(5 "-tert-butyl-JH-imidazol-4 "-Z-ylinethylene)-piperazine-2,5-dione 0 -;Z'4 .,0 0 NH N NH N N HHN H 0 0 0 [0318] To a solution of 1-acetyl-3-(5'-tert-butyl-1H-imidazol-4'-Z-ylmethylene) piperazine-2,5-dione (2.43 g, 8.37 mmol) in DMF (55 ml) was added benzaldehyde (4.26 ml, 41.9 mmol) and the solution was evacuated, then flushed with nitrogen. The evacuation -66- WO 2005/077940 PCT/US2005/003636 flushing process was repeated a further two times, then cesium carbonate (4.09 g, 12.6 mmol) was added. The evacuation-flushing process was repeated a further three times, then the resultant mixture was heated under the temperature gradient as shown below. After a total time of 5 h the reaction was allowed to cool to room temperature and the mixture was added to ice-cold water (400 ml). The precipitate was collected, washed with water, then freeze dried to afford a yellow solid (2.57 g, HPLC (214nm) tR = 6.83 (83.1%) min.). This material was dissolved in chloroform (100 ml) and evaporated to azeotrope remaining water, resulting in a brown oil. This was dissolved in chloroform (20 ml) and cooled in ice. After 90 min the yellow precipitate was collected and air-dried to afford 3-Z-benzylidene-6-(5"-tert-butyl-lH imidazol-4"-Z-ylmethylene)-piperazine-2,5-dione (1.59 g, 56%). (Hayashi, Personal Communication (2000)). [03191 HPLC (214nm) tR = 6.38 (2.1%), 6.80 (95.2) min. 10320] 'H NMR (400 MHz, CDC 3 ) 5 1.46 (s, 9H); 7.01 (s, 1H, -C-C=CH); 7.03 (s, 1H, -C-C=CH); 7.30-7.50 (in, 5H, Ar); 7.60 (s, 1H); 8.09 (bs, NH); 9.51 (bs, NH); 12.40 (bs, NH). [0321] LC/MS tR = 5.84 (337.4 [M+H]+, E isomer), 6.25 (337.4 [M+H]+, 673.4 [2M+H]*, Z isomer) min. [0322] ESMS m/z 337.3 [M+H]*, 378.1 [M+CH 4 CN]*. [0323] Evaporation of the chloroform solution gave additional 3-Z-benzylidene-6 (5"-tert-butyl-1H-imidazol-4"-Z-ylmethylene)-piperazine-2,5-dione (0.82 g, 29%). HPLC (214nm) tR 6.82 (70.6%) min. General Experimental [03241 Sodium bicarbonate refers to a 5% solution. (0325] Organic solvents were dried over sodium sulfate unless otherwise stated. Analytical Conditions NMR Conditions [0326] 1H NMR (400 MHz) analysis was performed on a Varian Inova Unity 400 MHz NMR machine. Samples were run in deuterated chloroform containing 0.1% TMS (unless otherwise specified). Chemical shifts (ppm) are referenced relative to TMS (0.00 -67- WO 2005/077940 PCT/US2005/003636 ppm) or CH 3 0H at 3.30 ppm for samples run CD 3 0D. Coupling constants are expressed in hertz (Hz). Analytical HPLC Conditions [0327] System 6 conditions: [03281 RP-HPLC was done on a Rainin Microsorb-MV C18 (5 pm, 100A) 50 x 4.6 mm column. [03291 Buffer A: 0.1% aqueous TFA [0330] Buffer B: 0.1% TFA in 90% aqueous MeCN [0331] Gradient: 0 - 100% Buffer B over 11 min [03321 Flow rate: 1.5 mL/min LCMS Conditions [03331 LCMS were run on a Perkin-Elmer Sciex API-100 instrument. [0334] LC conditions: [0335] Reverse Phase HPLC analysis [0336] Column: Monitor 5 pm C18 50x4.6 mm [0337] Solvent A: 0.1% TFA in water [0338] Solvent B: 0.085% TFA in 90% aqueous MeCN [0339] Gradient: 0-100% B over 11.0 min [0340] Flow rate: 1.5 mL/min [03411 Wavelength: 214 nm [03421 MS conditions: [0343] Ion Source: Ionspray [0344] Detection: Ion counting [0345] Flow rate to the mass spectrometer: 300 pL/min after split from column (1.5 mL/min). ESMS Conditions [0346] ESMS was done on a Perkin Elmer/Sciex-API III LC/MS/MS using an electro spray inlet. [0347] S6lvent: 0.1% AcOH in 60% aqueous MeCN [0348] Flow rate: 25 pL/min -68- WO 2005/077940 PCT/US2005/003636 [03491 Ionspray: 5000 V 103501 Orifice plate: 55 V 103511 Acquisition time: 2.30 min [0352] Scan range: 100-1000 amu/z [03531 Scan step size: 0.2 amu/z Preparative RP-HPLC Purification Conditions [0354] Reverse phase HPLC purification was carried out using Nebula with the Waters XterraMS column (19x50 mm, 5 pm, C18) using the following conditions: [03551 Solvent A: 0.1% aqueous TFA [0356] Solvent B: 0.1% TFA in 90% aqueous MeCN [0357] Gradient: 5-95% B over 4 min [0358] Flow rate: 20 mL/min [03591 Wavelength: 214 nm [03601 Abbreviations are as follows: br s: broad singlet; BuLi : n-butyl lithium; d: doublet; DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene; ESMS: electrospray mass spectrometry; HCl: hydrochloric acid; HPLC: high performance liquid chromatography; LCMS: liquid chromatography mass spectrometry; LD: lithium diisopropylamide; M+: molecular ion; m: multiplet; MeCN: acetonitrile; M: mass spectrometry; MW: molecular weight; NMR: nuclear magnetic resonance; q: quartet; s: singlet; : triplet; tR: retention time; TFA: trifluoroacetic acid; THF: tetrahydrofuran Detailed Procedure for the Synthesis of Dehydrophenylahistin Ac-N N NH Ac-, N /-HN- -. YNH I NH N'AcNNH vN1!/ NH N-1/ o Cs2CO3 /IDMF 0 Cs2CO3 1DMF 0 1 2 -69- WO 2005/077940 PCT/US2005/003636 1-Acetyl-3-{(Z)-1-[5-(1,1-dimethyl-2-propenyl)-1H-4-imidazolyl]methylidene}]-2,5 piperazinedione (2) NH N /N [0361] To a solution of 5-(1,1-dimethyl-2-propenyl)imidazole-4-carboxaldehyde (100 mg, 0.609 mmol) in DMF (2 mL) was added compound 1 (241 mg, 1.22 mmol) and the solution was repeatedly evacuated in a short time to remove oxygen and flushed with Ar, followed by the addition of Cs 2

CO

3 (198 mg. 0.609 mmol) and the evacuation-flushing process was repeated again. The removal of oxygen is preferred because such removal is believed to decrease oxidation of alpha-carbon at the position 6 of the diketopiperazine ring. The resultant mixture was stirred for 5 h at room temperature. After the solvent was removed by evaporation, the residue was dissolved in the mixture of EtOAc and 10% Na 2

CO

3 , and the organic phase was washed with 10% Na 2

CO

3 again and saturated NaCI for three times, dried over Na 2

CO

3 and concentrated in vacuo. The residual oil was purified by column chromatography on silica using CHC1 3 -MeOH (100:0 to 50:1) as an eluant to give 60 mg (33%) of a pale yellow solid 2. Dehydrophenylahistin [0362] To a solution of 2 (30 mg, 0.099 mmol) in DMF (0.8 mL) was added benzaldehyde (51 jiL, 0.496 mmol, 5 eq) and the solution was repeatedly evacuated in a short time to remove oxygen and flushed with Ar, followed by the addition of Cs 2

CO

3 (53 mg, 0.149 mmol, 1.5 eq) and the evacuation-flushing process was repeated again. The resultant mixture was heated for 2.5 h at 80*C. (The temperature must be increased slowly. Rapid heating increases the production of E-isomer at the benzylidene moiety.) After the solvent was removed by evaporation, the residue was dissolved in EtOAc, washed with water for two times and saturated NaC1 for three times, dried over Na 2

SO

4 and concentrated in vacuo. On TLC using CHC1 3 -MeOH (10:1), you can observe a spot with bright green-yellow luminescence at 365 nm UV. The purity of this crude product was more than 75% from -70- WO 2005/077940 PCT/US2005/003636 HPLC analysis. The resulting residue was dissolved in 90% MeOH aq and applied to reverse-phase HPLC column (YMC-Pack, ODS-AM, 20 x 250 mm) and eluted using a linear gradient from 70 to 74% MeOH in water over 16 min at a flow rate of 12 mL/min, and the desired fraction was collected and concentrated by evaporation to give a 19.7 mg (60%), although the yields are not optimized for each step,. of yellow colored dehydrophenylahistin. EXAMPLE 4 Biological Characteristics of Dehydrophenvlahistin and Dehydrophenvlahistin Analogs A. Biological Evaluation [03631 The biological characteristics of synthesized tBu-dehydrophenylahistin and dehydrophenylahistin were evaluated in both HT29 human colon cells, and PC-3 prostatic adenocarcinoma cells. [0364] HT-29 (ATCC HTB-38) a human colorectal adenocarcinoma was maintained in McCoy's complete medium -(McCoy's 5A medium with L-glutamine and 25mM HEPES supplemented with 10% FBS, 1mM Na pyruvate, IX NEAA, 2mM L glutamine, and Pen/Strep at 100IU/ml and 100pg/ml, respectively). PC-3 _(ATCC CRL 1435), a human prostate adenocarcinoma, was maintained in F12K complete medium (F12K medium supplemented with 10% FBS; 2mM Glutamine; 1% HEPES; and Pen/Strep at 100IU/ml and 100pg/ml, respectively). Cell lines were cultured at 37 'C, 5% CO 2 in a 95% humidified incubator. [0365] For tumor cytotoxicity assays HT-29 or PC-3 cells were seeded at 5,000 cells/well in 90 pl complete media into a Coming 3904 black-walled, clear-bottom tissue culture plate and the plate were incubated overnight to allow cells to establish and enter log phase growth. 20 mM stock solutions of dehydrophenylahistin and tBu-dehydrophenylahistin were prepared in 100% DMSO and stored at -20 'C. 1OX concentrated serial dilutions of the two compounds were prepared in appropriate culture medium for final concentrations ranging from 2.0 x 10_ M to 2.0 x 10-" M. Ten pl volumes of the lOX serial dilutions were added to the test wells in triplicate and the plates returned to the incubator for 48 hours. The final concentration of DMSO was 0.25% in all samples. [03661 Following 48 hours of drug exposure 10 pil of 0.2 mg/ml resazurin (obtained from Sigma-Aldrich Chemical Co.) in Mg 2 +, Ca2+ free PBS was added to each well -71- WO 2005/077940 PCT/US2005/003636 and the plates were returned to the incubator for 3-4 hours. The plates were removed and resazurin fluorescence was measured using 530 nm excitation and 590 nm emission filters in a Fusion fluorimeter (Packard Instruments). Resazurin dye without cells was used to determine the background, which was subtracted from the data for all experimental wells. The data were analyzed using Prism software (GraphPad Software). The data were normalized to the average of the cells treated with media only (100% cell growth) and EC 5 o values were determined using a standard sigmoidal dose response curve fitting algorithm. [03671 As indicated in Table 1 below, tBu-dehydrophenylahistin demonstrates about a 4-times greater cytotoxic activity in comparison with dehydrophenylahistin. Table 1. Cytotoxic Effect of dehydrophenylahistin and derivative. 0 0 HN 01 H H~- N N NH H- NHil& NH NNH Dehydrophenylahistin tBu-dehydrophenylahstin

EC

5 0 (nM) cell APLH tBu-APLH HT29 48 13 PC-3 5.4 1.0 [03681 See also Figure 41 for additional data at HT-29, PC-3, and P-388 cells. B. Structure and Activity Study of Dehydrophenylahistin Derivatives 103691 The cytotoxic effects of phenylahistin, dehydrophenylahistin and various derivatives of dehydrophenylahistin were examined in P388 murine leukemia cells, HT-29 human colon cells, and PC-3 prostatic adenocarcinoma cells. 103701 As explained above, HT-29 a human colorectal adenocarcinoma was maintained in McCoy's complete medium (McCoy's 5A medium with L-glutamine and 25mM HEPES supplemented with 10% FBS, 1mM Na pyruvate, 1X NEAA, 2mM L glutamine, and Pen/Strep at 100IU/ml and 100ptg/ml, respectively). PC-3, a human prostate -72- WO 2005/077940 PCT/US2005/003636 adenocarcinoma, was maintained in F12K complete medium (F12K medium supplemented with 10% FBS; 2mM Glutamine; 1% HEPES; and Pen/Strep at 1001U/ml and 100pg/ml, respectively). Cell lines were cultured at 37 'C, 5% CO 2 in a 95% humidified incubator. [03711 For tumor cytotoxicity assays HT-29 or PC-3 cells were seeded at 5,000 cells/well in 90 pl complete media into a Corning 3904 black-walled, clear-bottom tissue culture plates and the plates were incubated overnight to allow cells to establish and enter log phase growth. 20 mM stock solutions of dehydrophenylahistin and tBu-dehydrophenylahistin were prepared in 100% DMSO and stored at -20 'C. 1OX concentrated serial dilutions of the two compounds were prepared in appropriate culture medium for final concentrations ranging from 2.0 x 105 M to 2.0 x 1010 M. Ten pl volumes of the 1OX serial dilutions were added to the test wells in triplicate and the plates returned to the incubator for 48 hours. The final concentration of DMSO was 0.25% in all samples. [0372] Following 48 hours of drug exposure 10pl1 of 0.2 mg/ml resazurin (obtained from Sigma-Aldrich Chemical Co.) in Mg 2 +, Ca 2 + free PBS was added to each well and the plates were returned to the incubator for 3-4 hours. The plates were removed and resazurin fluorescence was measured using 530 nm excitation and 590 nm emission filters in a Fusion fluorimeter (Packard Instruments). Resazurin dye without cells was used to determine the background, which was subtracted from the data for all experimental wells. The data were analyzed using Prism software (GraphPad Software). The data were normalized to the average of the cells treated with media only (100% cell growth) and EC 50 values were determined using a standard sigmoidal dose response curve fitting algorithm. [03731 EC 5 o and IC 5 0 values of phenylahistin, dehydrophenylahistin and dehydrophenylahistin derivatives are summarized in Table 2 below. -73- WO 2005/077940 PCT/US2005/003636 Table 2. SAR study of phenlIahistin or dehydrophenylahistin and of dehydrophenylahistin derivatives

EC

5 o (nM) ICso (nM) COMPOUNDS STRUCTURE HT-29 PC-3 P-388 (-)-Phenylahistin N /--N NH '- 833+15 NH ,1600 n.t. 83_5 APLH NH N NH48 4. 6 x1. (n=5) KPU-2 APLH N/--N NH 48 4.7 36+ 12.8 NH. NH _ (n=5) KPU-2 tBu-APLH NH/-N NH 13 1 31.85.0 (n=5) 0 KPU-6 0 tBu-APLH-p-OMe /.N NH >2000 n.t. 9333 + CociieNH 28Me 5457 0 ~(n3) KPU-8 0 W~e tBu-APLH-o-OMe NH/--N NH NH 89 315+ 137 (n=4) KPU-9 0 tBu-APLH-M-OMe /---N NH 0 M e 31 20.8 +68 N H CH(n=4) 0 Colchicine -- 208+68 (n=4) -74- WO 2005/077940 PCT/US2005/003636 [0374] Modifications to the phenyl ring have a significant effect of the cytotoxic activities. In comparison with the activity of tBu-dehydrophenylahistin (#6), the activity of the methoxy group at the meta-position (KPU-9) exhibited the highest activity than the other derivatives with an IC 50 of 20.8±3.3 nM in P388 cells. The KPU-9 derivative also exhibited cytotoxicity in HT-29 cells (EC 5 0 31 nM). Dehydrophenylahistin, tBu-dehydrophenylahistin (KPU-2) and the KPU-9 derivative all exhibited cytotoxicity in P388 cells. C. Structure and Activity Study of Additional Dehydrophenvlahistin Derivatives [0375] The cytotoxic effects of phenylahistin, dehydrophenylahistin and various additional derivatives of dehydrophenylahistin were examined in HT-29 human colon cells and PC-3 prostatic adenocarcinoma cells using the methodology described above. Table 3. SAR study of phenylahistin, dehydrophenylahistin and of additional dehydrophenylahistin derivatives COMPOUNDS STRUCTURE SALT M.W. EC 50 N FORM HT-29 PC-3 0 (-)-Phenylahistin --- N NH 350.41 1600 n.t. NH j 7 N Hx 0 0 KPU-1 /-N NH - 348.40 48 4.7 APLH NH 0 0 KPU-2 NH/MN NH - 336.39 13 1 tBu-APLH N NH 0 KPU-6 NH/-N NH - 366.41 >2000 n.t. tBu-APLH-p-OMe NH OMe -75- WO 2005/077940 PCT/US2005/003636 COMPOUNDS STRUCTURE SALT M.W. EC 50 FORM HT-29 PC-3 o OMe KPU-8 NH/-N NH .- 1 - 366.41 89 tBu-APLH-o-OMe -" NH 0 0 KPU-9 NH/-N NH OMe - 366.41 31 tBu-APLH-m-OMe N H 0 o OMe KPU-14 /-N NH OMe TFA 396.44 610 96% tBu-APLH-2,3- NH / NH / 510.46 diOMe 0 (+TFA) o OMe KPU-12 /=:N NH - 396.44 4980 tBu-APLH-2,4- NH NH / diOMe We 0 o OMe KPU-10 /===N NH - 396.44 1350 tBu-APLH-2,5- NH NH diOMe o OMe KPU-15 N/- NH / . TFA 396.44 4430 96% tBu-APLH-2,6- NH / NH / 510.46 diOMe r MeO (+TFA) 0 KPU-13 /==N NH / OMe - 396.44 2130 tBu-APLH-3,4- NH / / NH / diOMe Of -76- WO 2005/077940 PCT/US2005/003636 COMPOUNDS STRUCTURE SALT M.W. EC 5 FORM HT-29 PC-3 0 KPU-16 /==:N NH / OMe - 396.44 42 82% tBu-APLH-3,5- NH / NH / diOMe o Oe 0 KPU-11 /=N NH / OMe - 426.47 >20 tBu-APLH-3,4,5- NH / / NH / gm triOMe O OMe KPU-17 /=N NH OMe TFA 426.47 4060 94% t~u-APLH-2,3,4- N NH OMe540.49 triOMe (+TFA) 0 o ci KPU-18 /==N NH TFA 370.83 42 100 tBu-APLH-o-Cl NH NH 484.86 % (+TFA) 0 KPU-19 /===N NH CI TFA 370.83 20 98% tBu-APLH-m-Cl NH NH 484.86 (+TFA) 0 0 KPU-20 /:N NH I TFA 370.83 545 tBu-APLH-p-C1 N NH 484.86 (+TFA) 0 0 Cl KPU-21 /=:N NH TFA 415.83 51 100 tBu-APLH-2CI-5- NH NH 529.85 %

NO

2 0 NO 2 (+TFA) -77- WO 2005/077940 PCT/US2005/003636 COMPOUNDS STRUCTURE SALT T EC 50 FORM HT-29 PC-3 0 KPU-22 /-N NH 0 TFA 380.40 82 95% tBu-APLH-3,4- N NH 494.42 methylene-dioxy 0 (+TFA) O OH KPU-23 /--N NH OMe TFA 382.41 5870 86% tBu-APLH-2-OH- NH NH 496.44 3-OMe (TFA) (o-vanillin) 0 0 KPU-24 H/N NH TFA 364.40 7040 100 tBu-APLH- N N 487.42 % cyclized-3-MeO 0 OMe (+TFA) 0 KPU-25 /-N NH TFA 337.38 544 98% tBu-APLH-4- NH NH N 565.42 pyridyl (+2TFA 0) 0 KPU-28 /-N NH TFA 337.38 >20 99% tBu-APLH-2- N NH N 565.42 iM pyridyl (+2TFA 0) 0 KPU-26 -- N NH / TFA 326.35 600 88% tBu-APLH-2-furyl NH NH 440.37 (+TFA) 0 KPU-27 /SN NH / S Me TFA 356.44 80 97% tBu-APLH-5-Me- NH NH 470.47 2-thienyl (+TFA) -78- WO 2005/077940 PCT/US2005/003636 COMPOUNDS STRUCTURE SALT M.W. EC 50 (M FORM HT-29 PC-3 0 KPU-29 /--N NH S TFA 356.44 44 81% tBu-APLH-3-Me- N NH 470.47 2-thienyl Me (+TFA) [0376] Additional cytotoxicity assays were performed as described above under this example, using Resazurin fluorescence as an indicator of cell viability. The results are shown below in Table 3.1. Table 3.1. Study of phenylahistin, dehydrophenvlahistin and of additional dehydrophenylahistin derivatives EC6 (M) % cytotox NPI Structure Chemical name Mean SD Mean SD n 0 HY NH (-)-(S)-HaIlmide, () H H2 (S)-Phenylahistin, (-) 2350 (S)-PLH 3.94E-07 9.49E-08 87 2 5 NH N\ o HC 2 Dehydrophenylahistin, 2352 delta-PLH, KPU-1 4.26E-08 1.08E-08 86 2 5 OCHH N- N~ NH OC ,CH KPU-4, D,L-bislactim 2354 YV PLH >2E-05 NA 4 NA 2 0 NH N

CHH

3 C 2 KPU-5, D,L 2355 monolactim-PLH >2E-05 NA 13 NA 2 0 N N H NH HC0JY HH 2 Hoco CH 2356 KPU-6 6.57E-06 NA 63 NA 2 H 2357 KPU-7 8.25E-06 NA 63 NA 2 0 N H N H o t-butyl-delta-PLH, 2358 H acg KPU-2 1.49E-08 3.77E-09 86 2 5 -79- WO 2005/077940 PCT/US2005/003636 OCHa 0 N H 2359 HAc' KPU-8 7.55E-08 2.47E-08 87 3 3 0 HNcoN NH 0 2360 c c 93H KPU-9 2.61E-08 8.54E-09 87 3 3 OCHa 0 NH N=\ - y HNN H 2361 0 PCU KPU-10 9.70E-07 NA 86 NA 2 0

H

3 c0 N N NH H 2362 a s KPU-11 8.19E-06 NA 78 NA 2 OCH 0 H3Co N NH 2363 0 3 CcRH3 KPU-12 5.08E-06 NA 79 NA 2 0

N

3 CO N NH H

H

3 00 ~ H Nl Nl 2364

H

3 C c 1 9H 3 KPU-13 2.02E-06 NA 76 NA 2 0 OMe HNN H N OMe o KPU-14, tBu-delta 2365 H 3

H

3 PLH-2,3-diOMe 8.68E-07 NA 84 NA 2 o QMe HNN HN r H - A N o KPU-15, tBu-delta 2366 N3" N 3 PLH-2,6-diOMe 5.17E-06 NA 81 NA 2 0 HN N HN oMe o OMe KPU-16, tBu-delta 2367 HaC Ha 3,5-diOMe 4.54E-08 1.21E-08 87 2 3 o oMe H-NHN A OMe HO 0 ""* KPU-17, tBu-delta 2368 Ca" PLH-2,3,4-triOMe 4.80E-06 NA 78 NA 2 o ci H A HN o3 KPU-18, tBu-delta 2369 C a PLH-o-CI 4.63E-08 1.35E-08 86 3 3 0 /H N HN C' 0 KPU-19, tBu-delta 2370 3H PLH-m-CI 2.45E-08 8.73E-09 85 3 3 -80- WO 2005/077940 PCT/US2005/003636 0 ci /--N N HH 231 C 0~3 N02 KPU-21, tBu-delta 231T, PLH-2-CI-5-N02 5.34E-08 4.85E-09 86 3 3 0 HN NH -0> KPU-22, tBu-deita 0PC H PLH-3,4-methylene 2372 'Y3 3iH dioxy 8.73E-08 1.1OE-08 84 4 3 o OH -~NHN -I HN - H - KPU-23, tBu-delta H,0 0PLH-2-OH-3-OMe 2373 H bH, (o-vanillin) 5.36E-06 NA 79 NA 2 0 2374 HPGcH ~ KPU-24, tBu-delta 2374__ PLH-cyclized-3-MeO 6.92E-06 NA 58 NA 2 0 /--N HN- N HN ~-N 235HC I~H 0l- KPU-25, tBu-delta 2375_____ PLH-4-pyridyl 5.48E-07 NA 82 NA 2 0 A-N HN'r HN 2376 CI~PH, 0KPU-28, tBu-delta- N 9 N H376Co PLH-2-pyridyl >2E-05 NA___ 39___ NA__ 2 0 ~H N H 237 H, 0 ~, 0KPU-26, tBu-delta 2377__O_ PLH-2-furyl 7.12E-07 NA 80 NA 2 0 1--NHN -I- Me HN f NH S/ H Cq30 KPU-27, tBu-delta 2378 '~c ~~PLH-5-Me-2-thienyl 8.52E-08 1 .35E-08 85 3 3 0

/HN

HNI- NH "YMe KPU-29, tBu-delta 2379 HCCp, 0PLH-3-Me-2-thienyl 4.70E-08 1 .30E-08 86 3 3 KPU-20; t-butyl-delta PLH-p-CI + TFA salt 2380 -TF (MW: 484) 7.09E-07 NA 81 NA 2 0'NN 0\ KPU-30, tBu-delta HN /- N NH F LH-2,3 231 ~ c 0 ~,N0 methylendioxy; TEA 231salt (MW:494.42) 5.20E-07 NA 82 NA 2 0 N 1H - N H KPU-31, tBu-delta _ NH PLH-3-pyridyl; 2TFA 2382 H3C 0 H salt (MW 565.42) 1.03E-07 ,1.16E-08 86 3 3 -81- WO 2005/077940 PCT/US2005/003636 0 CH H H KPU-32, tBu-delta PLH-o-Me; TFA salt 2383 HaC a (MW: 464.44) 4.58E-08 1.15E-08 86 3 3 HN 0 N KPU-33, tBu-delta HNN - NH PLH-3-Me-2-pyridyl; o cH 2TFA salt (MW: 2384 'jH3 579.45) >2E-05 NA 37 NA 2 N/--N HN H KPU-34, tBu-delta F PLH-4-F; TFA salt 2385 (MW:468.40) 5.01E-07 8.48E-08 81 5 3 0 F NH N - NH KPU-35, tBu-delta PLH-m-F; TFA salt 2386 HC H3 (MW:468.40) 1.31E-08 5.32E-09 85 2 5 o 0 CH KPU-36, tBu-delta H NH N- NH PLH-5-Me-4-im; Hc 0 1 Hz 2TFA salt 2387 H3C H3 (MW:584.47) 2.35E-06 NA 84 NA 2 0 F HN H KPU-37, tBu-delta 1 HPLH-o-F, TFA salt 2388 H (MW: 468.40) 3.OE-08 1.65E-08 86 3 3 0 -~NHN . NCH HN N- H - KPU-38, tBu-delta PLH-m-Me; TFA salt 2389 (MW: 464.44) 4.67E-08 9.64E-09 86 3 3 0 HN H-NH KPU-39, tBu-delta

CH

3 PLH-p-Me; TFA Salt 2390 C cH 3 (MW: 464.44) 4.83E-07 6.15E-08 84 4 3 0 HN HN KPU-40, tBu-delta Br PLH-p-Br; TFA Salt 2391 HaC "H (MW: 529.31) 7.14E-07 NA 82 NA 2 0 -~NHN Br HNAN H Br KPU-41, tBu-delta 2392 H~CPLH-m-Br; TFA Salt 2392 _______ -(MW: 529.31) 3.11E-08 7.29E-09 87 3 3 0 N NH s KPU-42, tBu-delta 3' PLH-3-thienyl; TFA 2393 cf a Salt MW: 456.44) 5.58E-08 6.23E-09 86 3 3 0 1H NH KPU-43, tBu-delta O N PLH-p-CN; TFA Salt 2394 HCM 3 (MW: 475.42) >2E-05 NA 14 NA 2 -82- WO 2005/077940 PCT/US2005/003636 0 H N HN 0,CHa KPU-44, tBu-delta PLH-m-EtO; TFA Salt 2395 (MW: 494.46) 4.59E-08 1.02E-08 85 4 3 o O'H KPU-45, tBu-delta H AN H N "N PLH-2,4,6-TriOMe; A* TFA Salt (MW: 2396 H3* 540.49) >2E-05 NA 2 NA 2 o 'N HN N H A KPU-46, tBu-delta PLH-o-N02; TFA 2397 "Ha" Salt (MW: 495.41) 5.03E-08 1.24E-08 86 4 3 0 0* HNN NH O- KPU-47, tBu-delta o PLH-m-N02; TFA 2398 HC 0 Salt (MW: 495.41) 4.47E-08 1.19E-08 86 3 3 0 H N HN N KPU-48, tBu-delta o 6 PLH-p-N02; TFA 2399 HaC H Salt (MW: 495.41) >2E-05 NA 23 NA 2 0 AN /N HN ' N HNA NH N KPU-49, tBu-delta c c 0PLH-m-CN; TFA Salt 2400 3" (MW: 475.42) 3.56E-08 1.40E-08 85 3 3 o Br H KPU-50, tBu-delta 240 PLH-o-Br; TFA Salt 2401 (MW: 529.31) 4.05E-08 1.09E-08 86 3 3 0 NN HN - KOP-51, tBu-delta N HA KPU51 o 0PLH-m-OH; TFA Salt 2402 pC C Ha (MW: 466.41) 3.64E-07 1,86E-07 86 2 4 o ONf KPU-52, tBu-delta H INN N A N PLH-2-NO2-5-Cl; H TFA salt (MW: 2403 "a" "a 529.85) 9.97E-08 2.63E-08 86 2 5 o NH HNN - H NN KPU-53, tBu-delta PLH-o-OH; TFA Salt 2404 ceN (MW: 466.41) 6.1OE-06 1.23E-06 66 10 3 0 OH KPU-54, tBu-delta N N NH PLH-2-OH-5-OMe; _ o TFA Salt (MW: 2405 3a" N 0 496.44) >2E-05 NA 25 12 4 0 HN . KPU-55, tBu-delta N PLH-3-furanyl; TFA 2406 , 4Na Salt (MW: 440.37) 3.59E-08 1.03E-08 86 2 5 -83- WO 2005/077940 PCT/US2005/003636 0 OH H N NH KPU-56, tBu-delta O Br PLH-2-OH-5-Br; TFA 2407 """ Salt (MW: 545.31) >2E-05 NA 13 6 3 0 NOH KPU-57, tBu-delta H - N- PLH-3-OH-4-OMe; H3 o H, TFA Salt (MW; 2408 C 496.44) 7.48E-06 8.62E-07 66 4 3 oH OH KPU-58, tBu-delta HN H N PLH-2-OH-4-OMe; H 0 H, TFA Salt (MW: 2409 "" H 496.44) >2E-05 NA 8 10 4 O OH _ NNH H N H N KPU-59, tBu-delta o H c PLH-2-OH-5-Cl; TFA 2410 H'' cH Salt (MW: 500.86) >2E-05 NA 37 17 3 1--N N 0KPU-60, tBu-delta H H NH cH PLH-5-Me-2-furanyl; NC TFA Salt (MW: 2411 Hac 454.40) 5.72E-08 2.OOE-08 85 2 5 KPU-61, tBu-delta /N N HNH NH PLH-5-Cl-2-thionyl; H 0TFA Salt (MW: 2412 "'" o~N 490.88) 1.65E-07 3.32E-08 85 3 3 0 !/'-N HN S H N H KPU-62, tBu-delta H3O PLH-2-thionyl; TFA 2413 Hc H Salt (MW: 456.44) 2.74E-08 6.29E-09 88 2 3 o CH KPU-63, tBu-delta N HN N HNN H NH PLH-N-Me-2-pyrrole; o TFA Salt 2414 H'C H (MW:453.42) 1.17E-07 3.14E-08 88 3 3 0 /--NHN

-

l NH NH KPU-64, tBu-delta N3C 0 PLH-3,5-diCl; TFA 2415 - NoH Salt (MW 519.30) 9.49E-08 5.05E-09 87 3 3 O F H-- HN F KPU-65, tBu-delta PLH-m-CF3; TFA Salt 2416 R"" H (MW 518.41) 4.40E-08 7.40E-09 87 2 3 o ~ KPU-66, tBu-delta NH NH .- PLH-1-napthalene; TFA Salt (MW 500.47 2417 H3' Z" 0 1.49E-08 2.12E-09 88 2 3 0 NKPU-67, tBu-delta H -NH PLH-2-napthalene; 0 TFA Salt (MW 2418 | 3 c | 500.47) 1.73E-06 NA 83 NA 2 -84- WO 2005/077940 PCT/US2005/003636 0 cl ,HNHN - N.

0 deta HN N CN KPU-68, tBu-delta PLH-2,3-diCl; TFA 2419 "a c fH 0 Salt (MW 519.30) 2.99E-08 4.46E-09 88 2 3 0 H1-N N - CH 2 KPU-69, tBu-delta HcilHa PLH-m-Vinyl; TFA 2420 Salt (MW 476.45) 1.70E-08 1.52E-09 88 2 3 0 ,'-N HN 00N H KPU-70, tBu-delta PLH-oxazole; TFA 2421 Ha" H Salt (MW 451.40) 2.22E-08 3.28E-09 88 2 3 0 KPU-71, tBu-delta H PLH-2-Hydroxybenzyl; H, 0 TFA Salt (MW 2422 495.91) >2E-05 NA 14 NA 2 s KPU-72, tBu-delta HN NH \ PLH-4-Br-2-thionyl; Br TFA Salt (MW 2423 HC H 0 484.49) 1.71E-07 1.86E-08 86 3 3 0 HKPU-73, tBu-delta HNAN H CH, PLH-5-Et-2-thionyl; TFA Salt (MW 2424 HaC H 535.34) 1.32E-07 2.56E-08 87 3 3 0 1--N NH . 0 B NH 7Br KPU-74, tBu-delta HOg 0 PLH-5-Br-2-furyl; TFA 2425 ci" Salt (MW 519.27) 3.05E-08 8.71 E-09 87 3 3 0 N - H CH KPU-75, tBu-delta H3,C ,OH, 0 PLH-5-Et-2-furyl; TFA 2426 H-3 H _ Salt (MW 468.43) 2.42E-07 NA 86 NA 2 0 /--NHN)-00 HN NH I KPU-76, tBu-delta 0 PLH-5-CI-2-furyl; TFA 2427 "aC "RH3 Salt (MW 474.82) 3.82E-08 8.88E-09 87 2 3 0 F - ON FN H N NH KPU-77, tBu-delta 0 , PLH-2-F-5-1; TFA Salt 2428 Hac H (MW 594.30) 4.17E-08 7.78E-09 87 2 3 0 S,CH KPU-79, tBu-delta HN N HN 6 PLH-2-(Methylthio); TFA Salt (MW 2429 H3C caH3 496.50) 2.86E-08 3.59E-09 87 2 3 0 HN NH F HC ZHKPU-80, tBu-delta PLH-m-OCF3; TFA 2430 Salt (MW ) 1.43E-08 4.93E-09 87 2 3 -85- WO 2005/077940 PCT/US2005/003636 O F HNN H KPU-81, tBu-delta PLH-2-F5-OMe; TFA 2431 N3" H " Salt (MW) 2.03E-08 2.12E-09 88 2 3 1--NHN-~ 0 . H N KPU-82, tBu-delta NC PLH-4-F-3-OMe; TFA 2432 H_ Salt (MW) 4.93E-07 NA 85 NA 2 o CH, /HN1-NHN H HN N o KPU-83, tBu-delta HcH PLH-2-OH-5-tBU; 2433 TFA Salt (MW) 8.53E-06 NA 80 NA 2 0 NH N H KPU-84, tBu-delta 2434 0 PLH-cyclohexane; 2434 H" _ _ __ TFA Salt (MW) 7.89E-08 1.41 E-08 87 3 3 o CH, HNN HNH - KPU-86, tBu-delta 0 PLH-2-Me-3-F; TFA 2435 ""H Salt (MW 3.34E-08 6.66E-09 86 3 3 o F H N- N HN KPU-87, tBu-delta 2C 0 kH3 0 CH3 PLH-2-F-5-Me; TFA 2436 Salt (MW) 2.50E-08 3.52E-10 86 3 3 o F HN N N ' N H N . KPU-88, tBu-delta 2N PLH-2-CI-6-F; TFA 2437 H tc Salt (MW) 2.49E-08 1.31E-09 86 2 3 O F N HN H NH KPU-89, tBu-delta H3C O F PLH-2,5-di-F; TFA 2438 H Salt (MW) 3.07E-08 2.14E-09 87 3 3 o CH, /--N HN ~CH3 H N H KPU-90, tBu-delta PLH-2,3-di-Me; TFA 2439 *0 i cH Salt (MW) 2.96E-09 2.27E-10 87 3 3 o CN3 .1P-N HN N H NH KPU-91, tBu-delta 0 O NPLH-2,6-di-Me; TFA 2440 "C" 0 Salt (MW) 4.30E-07 NA 85 NA 2 o No 2 /H-N HN O Ha HN NH KPU-92, tBu-delta Hac H PLH-2-NO2-3-OMe; 2441 TFA Salt (MW) 6.63E-07 NA 83 NA 2 H N H KPU-93, tBu-delta 42 3 o NHO 3 PLH-2,5-diMe; TFA 2442 Salt (MW) 8.82E-08 1.40E-08 87 3 3 -86- WO 2005/077940 PCT/US2005/003636 0 NH, N HNN 'CHa HN rI

H

2 C 0KPU-94, tBu-delta PLH-2-NH2-3-OMe; 2455 TFA Salt 3.49E-07 NA 87 NA 2 0 HN /- HN KPU-95, tBu-delta H 0 CH PLH-3-OMe-2-furyl; 2456 "" TFA Salt 1.25E-07 3.68E-08 88 2 3 o NH 2 1HNN H HNI- .- NH i 2 C KPU-96, tBu-delta 2457 PLH-2-NH2; TFA Salt 4.32E-07 NA 86 NA 2 0 N HN NH2 Nc KPU-97, tBu-delta 2458 2 e PLH-m-NH2; TFA Salt 3.10E-08 1.71E-09 87 3 3 0 H/--N HN NN H KPU-98, tBu-delta O HOOH PLH-3-B(OH)2-2 2459 NaC HN thienyl; TFA Salt 2.53E-08 4.31E-09 88 3 3 0 NHN 2460 0 (-)-tBu-PLH 2.55E-07 1.24E-07 87 2 5 EXAMPLE 5 Other Dehydrophenylahistin Analogs A. Modifications for the synthesis of dehydrophenyIahistin derivatives [0377] Other derivatives of dehydrophenylahistin are synthesized using the foregoing techniques alone or in conjunction with other well known organic synthesis techniques. [03781 Modifications to the diacyldiketopiperazine and the first and second aldehydes involved in the synthesis method vary according to the desired derivative to produce. Derivatives are synthesized that: A) modify the phenyl ring and/or introduce other aromatic ring systems, B) alter the position of the aromatic ring, C) alter the imidazole aromatic ring system, and/or D) modify the 5-position on the imidazole ring. [0379] The figure below depicts regions of the dehydrophenylahistin compound modified to produce derivatives of dehydrophenylahistin. Non-limiting examples of -87- WO 2005/077940 PCT/US2005/003636 modifications are disclosed, and based on this disclosure would be understood by those of skill in the art. C B ;""N HN I-11 HN 1NH A D A 1) Modification of the phenyl ring besed on the structure of known anti-tubulin compounds Alkyl, Halogen, Alkoxy, Acetyl, Sulfonamide, Amino, Hydroxyl, Nitro, etc.

H

3 CO Y ~ CH 3 HC NI 'NH

H

3 00 ' OH

HN

2

H

3 CO / HC H2No2S C H 0 0 C H 3 O0 H 3 M oI. W t 3 8 5 8 5 c E7070

OCH

3 combretastain A-4 0.15 ug/mL Colchicine P-388 Phase 11 2) Introduction of other aromatic ring systems etc B Position of the aromatic ring C Change to the other ring systems 1

/-

etc D Further modification of the 5-positin on the imidazole ring HN/N H HN/N HN ' etc -88- WO 2005/077940 PCT/US2005/003636 [02971 Expanding on the above modifications to the dehydrophenylahistin compound, derivatives of the compound may include the following substitutions at the phenyl ring (A): -CF 3 , -SO 2

NH

2

(-SO

2

NR

1

R

2 ), -S03H, -CONH 2

(-CONRR

2 ), -COOH, etc. Other ring systems (C) may also include the following: 0-~ - oJ- Se~ N'-N\ N\I B. Examples of synthesized dehydro-phenvahistin derivatives [03801 Additional examples of synthesized dehydrophenylahistin derivatives are disclosed in the Table 4. Table 4. Additional synthesized derivatives of dehydrophenylahistin COMPOUNDS STRUCTURE FORM M.W. 0 KPU-20 /===N NH TFA 370.83 tBu-APLH-p-C1 NH al r NH C 484.86 (+TFA) 7r 0 o 0 KPU-30 /=:=N NH 0 TFA 380.40 NH t -NH -6 tBu-APLH-2,3-methylendioxy 494.42 o (+TFA) 0 KPU-31 /-:=N NH 2TFA 337.38 NHH I; tBu-APLH-3-pyridyl N NH N 565.42 0 (+2TFA) 0 Me KPU-32 H/=N NH - N TFA 350.41 tBu-APLH-o-Me NH NH 4 464.44 (+TFA) -89- WO 2005/077940 PCT/US2005/003636 COMPOUNDS STRUCTURE SALT M.W. FORM 0 KPU-33 /1=N NH / ' 2TFA 351.40 tBu-APLH-3-Me-2-pyridyl NH / / NH N / 579.45 o Me (+2TFA) 0 KPU-34 /--N NH TFA 354.38 tBu-APLH-4-F N / NH F 468.40 o (+TFA) 0 KPU-35 /==N NH F TFA 354.38 tBu-APLH-m-F N NH 468.40 0 (+TFA) o Me KPU-36 NH/-N NH -NH 2TFA 356.42 tBu-APLH-5-Me-4-im H / NH N/ 584.47 0 (+2TFA) 0 F KPU-37 /-:N NH / - TFA 354.38 tBu-APLH-o-F NNH 468.40 o (+TFA) 0 KPU-38 /==N NH Me TFA 350.41 tBu-APLH-m-Me NH / / NH / 464.44 0 (+TFA) 0 KPU-39 /--N NH / TFA 350.41 tBu-APLH-p-Me NH NH / Me 464.44 0 (+TFA) -90- WO 2005/077940 PCT/US2005/003636 COMPOUNDS STRUCTURE SALT M.W. FORM 0 KPU-40 /==N NH TFA 415.28 NH ~ t.- NH 529Br tBu-APLH-p-Br NHr529.31 o (+TFA) O KPU-41 /==-N NH Br TFA 415.28 tBu-APLH-m-Br 529.31 o (+TFA) a 0 KPU-42 NH/=N NH s TFA 342.42 tBu-APLH-3-thienyl N / NH 456.44 0o (+TFA) 0 KPU-43 /-=N NH TFA 361.40 tBu-APLH-p-CN NH / / NH CN 475.42 o (+TFA) 0 KPU-44 /==N NH OE TFA 380.44 tBu-APLH-m-EtO NH / NH 494.46 o (+TFA) o OMe KPU-45 / =N NH TFA 426.47 tBu-APLH-2,4,6-TriOMe Nt Ne O: e 54049 Meo (±TFA) 0

NO

2 KPU-46 /-N NH N TFA 381.39 tBu-APLH-o-N0 2 495.41 0 (+TFA) -91- WO 2005/077940 PCT/US2005/003636 COMPOUNDS STRUCTURE SALT M.W. FORM 0 KPU-47 /MN NH NO 2 TFA 381.39 tBu-APLH-m-N0 2 N NH 495.41 O (+TFA) 0 KPU-48 /=:N NH TFA 381.39 tBu-APLH-p-N0 2 NH / NH NO 2 495.41 O (+TFA) 0 KPU-49 /-:N NH CN TFA 361.40 tBu-APLH-m-CN NH / / NH 475.42 o (+TFA) O Br LPU-50 /--N NH TFA 415.28 tBu-APLH-o-Br NH 529.31 O (+TFA) 0 KPU-51 /--N NH OH TFA 352.39 tBu-APLH-m-OH NH / NH 466.41 O (+TFA) O

NO

2 KPU-52 /-=N NH /H TFA 415.83 tBu-APLH-2-NO 2 -5-C1 NH / / NH / 529.85 O CI (+TFA) O OH KPU-53 /-=N NH /- " TFA 352.39 tBu-APLH-o-OH NH NH466.41 O (+TFA) -92- WO 2005/077940 PCT/US2005/003636 COMPOUNDS STRUCTURE SALT M.W. FORM O OH KPU-54 /=:N NH / TFA 382.41 tBu-APLH-2-OH-5-OMe NH NH 496.44 O OMe (+TFA) 0 KPU-55 NH/=::N NH TFA 326.35 tBu-APLH-3-furanyl NNH 440.37 O (+TFA) O OH KPU-56 NH/=N NH NH TFA 431.28 tBu-APLH-2-OH-5-Br 545.31 O Br (+TFA) 0 OO KPU-57 / =N NH OH TFA 382.41 tBu-APLH-2-OH-4-OMe NHC NH /OMe 496.44 O (+TFA) O OH KPU-58 /=:N NH r I TFA 382.41 tBu-APLH-2-OH-4-OMe NH / NH /OMe 496.44 0 (+TFA) O OH KPU-59 /=:N NH TFA 386.83 tBu-APLH-2-OH-5-Cl NH / / NH (+TFA) O cl 500.86 0 KPU-60 /-=N NH 0 CH 2 TFA 340.38 NH tBu-APLH-5-Me-2-furanyl NH 454.40 (+TFA) -93- WO 2005/077940 PCT/US2005/003636 COMPOUNDS STRUCTURE FORM M.W. FOR 0 KPU-61 /MN NH / ci TFA 376.86 NH 11ft NH tBu-APLH-5-Cl-2-thionyl 490.88 o (+TFA) 0 KPU-62 N/=N NH s TFA 342.42 NH S/ N tBu-APLH-2-thionyl 456.44 o (+TFA) o CH 3 KPU-63 /-=N NH N TFA 339.39 tBu-APLH-N-Me-2-pyrrole 453.42 o (+TFA) 0 KPU-64 /--N NH Cl TFA 405.27 tBu-APLH-3,5-diCl NH / NH o ci 0 KPU-65 / -N NH -CF 3 TFA 404.39 tBu-APLH-m-CF 3 NH / NH KPU-66 NH-:TFA 386.44 0 KPU-67 /--N NH TFA 386.44 tBu-APLH-2-Naphthalene NH / NH -94- WO 2005/077940 PCT/US2005/003636 COMPOUNDS STRUJCTUJRE SALT M.W. FORM 0 ci KP-8/ N NH -c N TEA 405.27 TBu-APLLI-2,3-d~ NH -r NH 0 0 K-9/--N NH - TEA 362.42 TBu-APLH-m-Vinyl NHN ~ H . 0 F KU7NH/--zN NH -~'~ TEA 480.28 TBu-APLII-2-F-5-I N - NH 0 1 KPU-7 NH TEA 368.45 tBu-APLH-2-(M4ethylthio) NH / - NH 5 -z 0 KPU-80 NH/--N NH OCF 3 TEA 420.38 TBu-APLTI-m-OCF 3 NH - NH 0 F KU8NH/--N NH ~ . TEA 384.38 TBu-APLH[-2-F-5-OMe NH N 0 ome KPU-82 11-N NH W .Oe TEA 384.38 TBu-APLH-4-F-3-OMe HN~ H I F 0 -95- WO 2005/077940 PCT/US2005/003636 COMPOUNDS STRUCTURE SALT M.W. FORM 0 KPU-83 / N NH HI TFA 408.39 TBu-APLH-2-OH-5-tBu H NH OH 0 0 KPU-84 /zN NH TFA 341.39 TBu-APLH-cyclohexane NH 0 0 KPU-86 HN/:N NH F TFA 368.39 TBu-APLH-2-Me-3-F NH 0 o F KPU-87 /-N NH TFA 368.39 TBu-APLH-2-F-5-Me HN NH 0 O F KPU-88 HN/-N N TFA 388.83 TBu-APLH-2-C-6-F NH OCI 0 o F KPU-89 /MzN NH - ~" TFA 372.38 TBu-APLH-2,5-di-F HN O NH 3 8 KPU-9 HN? F 343 O F 0 KPU-90 HN/-N NH TFA 364.38 TBu-APLH-2,3-di-Me NH 0 0 "PU-91 N/--N NH - ~ TEA 364.38 TBu-APLJI-2,6-di-Me H NH 0 -96- WO 2005/077940 PCT/US2005/003636 COMPOUNDS STRUCTURE SALT M.W. ________________FORM O

NO

2 KPU-92 HN/-N NOMe TFA 411.39 tBu-APLH-2-NO 2 -3-OMe NH 0 0 KPU-93 /-N NH TFA 364.38 TBu-APLH-2,5-diMe HN NH 0 O

NH

2 KPU-94 /-N NH OMe TFA 381.399 tBu-APLH-2-NH 2 -3-OMe NH 0 O

NH

2 KPU-96 /:N NH TFA 351.41 TBu-APLH-2-NH 2 H NH 0 0 KPU-97 /-N NH

NH

2 TFA 351.41 TBu-APLH-m-NH 2 H NH 0 C. Evaluation of dehydrophenylahistin derivatives [0381] Evaluation of derivatives described above is assessed according to the methods described in Example 3. Additional evaluation of the derivatives are extended to specific activities such as determining the inhibiting effect on cell proliferation, the effects on a specific cellular mechanism (i.e. microtuble function), effects on cell cycle progression, evaluating in vitro anti-tumor activity against cancer cell lines, etc. Some evaluation method protocols are given below. -97- WO 2005/077940 PCT/US2005/003636 1) Cell Proliferation Inhibiting Effect of Dehydrophenylahistin And Its Analogs [03821 Into each well of a 96-well microtiter plate, 100pl of A-549 cells derived from human lung cancer prepared to 105 cells/ml in a culture medium obtained by adding 10% bovine fetus serum to EMEM culture medium (Nissui Seiyaku Co., Ltd.) having antitumor effect against A-549 cells derived from human lung cancer are placed. Methanol solution of the derivative obtained by the above-listed examples are added to the wells of the uppermost row, specimens are diluted by the half-log dilution method and added, and the plate is incubated in a carbon dioxide gas incubator at 37 0 C for 48 hours. The result is added in lots of 10p1 with MTT reagent (3-(4,5-dimethyl-2-thiazole)-2,5-diphenyl-2H-tetra bromide)(lmg/ml - PBS), followed by incubation in a carbon dioxide gas incubator at 37 "C for 6 hours. The culture medium is discarded and the crystal of produced in the cells are dissolved in 100pl/well of dimethylsulfoxide. Absorption of 595 nm light is then measured with a microplate reader. By comparing the light absorptions of the untreated cells to that of cells treated with a specimen of a known concentration, the specimen concentration that inhibited cell proliferation 50% (IC 50 ) is calculated. 2) Cell Cycle Inhibiting Activity of Dehydrophenvlahistin And Its Analogs [0383] Cell strain A431 is derived from human lung cancer. EMEM culture medium containing 10% bovine fetal serum and 1% MEM nonessential amino acid solution (SIGMA M2025) is used to incubate A431 cells at 37 *C in an incubator saturated with 5% carbon dioxide gas and water vapor. The refined specimen of dehydrophenylahistin obtained by the methods above is added to the cells in the log-growth phase and progression of the cell cycle is analyzed by flow cytometer and microscopic observation. [03841 The effect on cell cycle progression of HeLa cells is depicted in Figure 42. EXAMPLE 6 Structure-Activity Relationship Of Synthesized Dehydrophenvlahistin (DehydroPLH) Derivatives 1) Overview in derivative syntheses [03851 Many, but not all, of the derivatives of dehydroPLH disclosed herein include one, two, or three modifications at the phenyl ring (Figure 5 below). The derivatives were synthesized by the methods described above. As shown in Table 5, certain compounds -98- WO 2005/077940 PCT/US2005/003636 showed more potent cytotoxic activity than dehydroPLH and tBu-dehydroPLH. The most potent compound exhibiting an EC50 value of 3 nM was KPU-90. This value was 16-times and 4-times higher than that of dehydroPLH and tBu-dehydroPLH, respectively. These derivatives have mono-substitution at the o- or m-position of the phenyl ring with the halogen atoms such as fluorine and chlorine atoms or the methyl, vinyl or methoxy group. Derivatives with substitutions to heteroaryl structures such as the npahthalene, thiophene and furan rings also elicited a potent activity.. KPU-35, 42, 69, 80 and 81 also showed higher activity than tBu-dehydroPLH. Table 5. Synthetic potent dehydroPLH derivatives Compound Structure EC 50 (nM) 0 KPU-9 N/-N NH OM 31 5 NH NH F 0 0 KPU-35 NH/-N NH F 10 K N H / NH C 0 KPU-18 /-N NH Me 42 -90 0 KPU-19 /--N NH -C1 20 NH~.. H~ 0 KPU-38 /--N NH Me 45M NH. -' N -99- WO 2005/077940 PCT/US2005/003636 Compound Structure EC~ u nM) 0 F KPU-37 NH/--N NH - ~~ 21 N Hr

.

N H 0 KPU-41 NH/--N NH NH Br 31 0 0 KPU-29 /--N NH - 44 NH. X H Me 0 0 K-PU-16 NH/--NNH NH oM 42 o 0Me 0 Me KPU-32 NH/--N NH - 42 NH~~. ~ H 0 0 KPUJ-42 /--N NH 1 - 54 Nr __ - NH 0 O NO 2 KPU-46 NH/--N NH NH~ 44 0 0 KPU-44 /--N NH OE 43 NH~ - NH 0 -100- WO 2005/077940 PCT/US2005/003636 Compound Structure ECso (nM) 0 tBu-APLH /-N NH 13 (KPU-2) NH NH / O 0 KPU-69 NH/-N NH 16 NHNHO OF 0 KPU-80 /-N NH OCF 3 13 NH NH O' 0 0 F KPU-81 0 /N NH 19 0 OMe O KPU-90 N/--N NH NH 3 0 0 DehydroPL /-N NH 48 H (KPU-1) NH NH 0 2) Introduction of the methoxy groups to the phenyl ring [0386] Colchicine recognizes the same binding site on p-tubulin as PLH. Colchicine has four characteristic methoxy groups on its A and B rings. A series of substitutions with the single or multiple methoxy groups was performed and the results of cytotoxic activity are shown in Table 6. -101- WO 2005/077940 PCT/US2005/003636 Table 6. Effect of the methoxy group substitution on the proliferation of HT-29 cells Compound Structure EC50 (nM) 0 DehydroPLH /-=N NH 48 (KPU-1) NH / NH 0 0 tBuAPLH NH/-N NH - 13 (KPU-2) N NH O OMe KPU-8 /MN NH -6 89 0 0 KPU-9 N /-N NH OMe 31 NH~ ,NH I0 0 KPU-6 /-N NH O 6730 N NH OMe 0 o OMe KPU-10ON / -N NH NH ' 1350 0 OMe 0 OMe KPU-12 /-N NH O e 4980 N H

-

1 NH O M -102- WO 2005/077940 PCT/US2005/003636 Compound Structure EC50 (nM) 0 KPU-13 /-N NH OMe 2130 NH~ H ~ M 0 e o OMe KPU-14 /-N NH OMe 610 NH x N 0 OMe KPU-15 NH/-N NH 4430 NH~ x NH x MeO 0 0 KPU-16 /-N NH H OMe 42 NH. / NH o OMe 0 KPU-24 /-N NH N 7040 NH~ // N / O OMe [03871 The result demonstrated that substitutions at the m- or o-position increased cytotoxic activity against HT-29 cells. KPU-9 and 16 showed high activity. The methoxy derivatives with triple substitution (KPU-11, 17 and 45) also showed activity. The structure of KPU-24 was assigned by MASS analysis. 3) Modification with the electron-withdrawing groups [0388] To study more expanded structure-activity relationship on the phenyl ring, a series of different functional groups were introduced, which include both electron withdrawing and -donating groups. The result of cytotoxicity against HT-29 cells is shown in Tables 7 and 8, respectively. -103- WO 2005/077940 PCT/US2005/003636 [03891 Substitution at the o- or in-position effectively increased activity. These results were well consistent with the case of the methoxy group. Table 7. Effect of the electron-withdrawing group on proliferation of HT-29 cells Compound Structure

EC

5 o (nM) o C1 KPU-18 /=-N NH 42 NH / NH 0 0 KPU-19 /-N NH Cl 20 NH x N OCC 0 0 KPU-20 /-N NH 545 N H -.

-

NH 0 C KPU-21 NH/--N NH NH 51 O

NO

2 O NO 2 KPU-52 /-N NH 110 N NH O C1 O F KPU-37 / N NH 21 NH~ -rNb 0 0 KPU-35 NH/-N NH F 10 -104- WO 2005/077940 PCT/US2005/003636 Compound Structure

EC

50 (nM) 0 KPU-34 /-N NH 466 NH~ -NH F 0 o Br KPU-50 H/N NH - 38 NH~ // NH 0 0 KPU-41 NH/-N NH Br 31 NH~. x NH . 0 KPU-40 NH/--N NH - '623 NH~. NH - Br N1:5 Br62 0 o

NO

2 KPU-46 N /N NH NH 44 O 0 KPU-47 /-N NH NO 2 40 NH. t-NH 0 KPU-48 /N NH > 20 pM NH~ -NH

NO

2 0 -105- WO 2005/077940 PCT/US2005/003636 Compound Structure

EC

50 (nM) 0 KPU-49 /=:N NH CN 28 NH / / NH O 0 KPU-43 /-N CN > 20 pM :7 0 Table 8. Effect of the electron-donating group on proliferation of HT-29 cells Compound Structure EC5 0 (nM) o OMe KPU-8 /-N NH / 89 NH NH 0 0 KPU-9 NH/-N NH OMe 31 KP

-

N He 0 KPU-6 /--N NH - ".6730 NH~ o N H , Me 0 KPU-44 / N NH OE 43 NH CNH 0 -106- WO 2005/077940 PCT/US2005/003636 Compound Structure ECo (nuM) KPU-30 NH/--N NH NH 0~ 477 -l0 0 KPU-22 /N NH0 82 NH - NH o Me KPU-32 /NNH - ' Z- 42 NH~ NH 0 0 KPU-38 /-N NH Me 4 NH~ -NH x4 -l0 0 KPU-39 N /--NN NH Me"s 460 0 0 OH K.PU.-53 NH/--N NH NH > 20 RM 0 0 KPU-51 NH/--N NH OH 617 NH~tNH 0 -107- WO 2005/077940 PCT/US2005/003636 Compound Structure EC50 (nM) O OH KPU-23 NH/-N NH NH OMe 5870 0 0 OH KPU-58 NH/-N NH NH e >20 pM NH~ NH OMe 0 O OH KPU-54 /-N NH N >20pM O OMe 0 KPU-57 /-N NH H > 20 pM NH~ xNH OMe [0390] The present disclosure is not bound by or limited to any particular scientific theory. Nonetheless, it is appreciated that persons of skill in the art may interpret the results presented herein to suggest that a relatively smaller functional group, affecting less steric hindrance, may be preferred to elicit more potent activity, and slightly large groups such as the ethoxy group (when compared to the methoxy group) or the Br atom (when compared to the Cl atom) may affect steric hindrance unfavorable to interaction with, for example, the tubulin binding site. Moreover, because the electrical property of these substituents did not affect the activity, it is suggested that these relatively small substituents do not directly interact with the binding site of p-tubulin, but restrict the conformation of dehydroPLH suitable for the binding, Or, as another possible hypothesis, the hydrophobic property may be a more important factor at the binding site for o- or in-position on p-tubulin, since introduction of the hydrophilic hydroxyl group, which can form the hydrogen bonding as a hydrogen-donor, drastically decreased the activity. -108- WO 2005/077940 PCT/US2005/003636 [03911 As shown in Table 9, the effect of the substituents in the cytotoxic activity at the o-position may be ordered, as in the case of m-position, as shown in Table 10. The compounds having effective functional groups, which showed higher activity than tBu dehydroPLH, may also be further modified. And since the migration of the stereochemistry from Z to E under the visible light irradiation was observed, substituents that decrease the electron density in the conjugated double bonds may contribute to the reduction of Z to E migration by the light, results in more physicochemically stable structures. Temperature can also effect this migration. [03921 Modification at two parts of the ring can be preferred for the development of potent but also biologically stable compounds. The phenyl ring of phenylahistin is oxidized by cytochrome P-450. Double modification that reduces the electron density of the phenyl ring may therefore be effective to avoid P-450 oxidation. Thus, the combination of the small electron withdrawing group such as the fluorine atom to the element that can increase the activity such as -OMe, -Me, -Cl, -F and Br, may result in more potent and biologically stable drug compounds. Table 9. Summary of modification at the o-position Compound Structure

EC

5 o (nM) 0 KPU-2 /=-N NH 48 NH~ / x NH 0 o OMe KPU-8 H/-N NH 89 NH~ NH 0 0 F KPU-37 /=N NH / ' 21 NH~ / / NH / -109- WO 2005/077940 PCT/US2005/003636 Compound Structure

EC

50 (nM) O Cl KPU-18 NH/-N NH 42 N H

.

NH O Br KPU-50 /-N NH :-' 38 NH ~ .- NH / 0 O

NO

2 KPU-46 N/N NH 44 NH~ N NH O Me KPU-32 /-N NH / 1 42 NH. NH / O O OH KPU-53 / N NH / > 20 pM NH ~ x NH / 0 Table 10. Summary of modification at the m-position Compound Structure

EC

50 (nM) 0 KPU-2 NHN NH N 48 0 0 KPU-9 NH/-N NH N OM 31 0 -110- WO 2005/077940 PCT/US2005/003636 Compound Structure EC5 0 (nM) 0 KPU-35 /-N NH F 10 NH H K 0 0 KPU-19 / N NH -CI 20 NH N~ x H 0 0 KPU-41 /NHN NH Br 31 0 0 KPU-47 /-N NH NO 2 40 0 0 KPU-38 NH/-N NH Me 45 0 0 KPU-51 NH/-N NH OH 617 NH~ tNHx 0 0 KPU-49 /-N NH CN 28 NH -111 ,NH1 WO 2005/077940 PCT/US2005/003636 Compound Structure EC 50 (nM) 0 KPU-44 /-N NH OE 43 0 4) Substitution of the phenyl ring to aryl-heterocycles [0393] The phenyl ring may also be replaced by heteroaryl groups. The result of such replacements in terms of the cytotoxic activity is shown in Table 11. Since the arylic nitrogen atoms can form a hydrogen bonding with a NH group of the diketopiperazine ring and restrict the conformation of the molecule between pyridine and diketopiperazine rings to an uniplanar structure, the active conformation of dehydroPLH would be required a certain level of dihedral angle formed by the steric repulsion between an amide hydrogen atom of the diketopiperazine ring and an o-hydrogen atom of the phenyl ring (Figure 6). Table 11. Effect of the replacement with the heteroarlI ring on proliferation of HT-29 cells Compound Structure EC 50 (nM) 0 KPU-28 NH/-N NH >20 pM NH - NH NJ,, O 0 KPU-31 /-N NH 96 NH -NH N 0 0 KPU-25 /-N NH N 544 NH -112 -112- WO 2005/077940 PCT/US2005/003636 Compound Structure ECso (uM) 0 KPU-33 NH/--N NH - ~~>20 M NH~. ~NH N 0 Me 0 KPU-26 1--N NH 0 600 NH~ H" 0 0 KPUJ-60 /--N NH 0 -2 7 NH. NH C 2 7 0 0 KPU-42 /--N N -- s54 NH~ NH 0 0 K.PU-27 /-z:-N NH S Me 80 NH~. - NH 0 0 KPU-29 IN NH s 44/ NH~ NH Me 0 0 KPU-61 /--N NH s - 8 NH~ H~c 8 0 -113- WO 2005/077940 PCT/US2005/003636 Compound Structure

EC

50 (nM) o Me KPU-36 /~-N NH NH 2790 NH Y NH Nzz/NH o

CH

3 KPU-63 /-N NH N 105 NH NH [0394] Replacing the phenyl ring with a smaller furan or thiophene ring, for example, KPU-29 or -42, exhibited activity. The phenyl ring can be changed to other aromatic structure while maintaining the potent activity. 5) Metabolism of phenylahistin [03951 In the recent his study, (:)-phenylahistin was treated with rat hepatic microsome or human hepatic P450s. In human case at least seven metabolites were detected, and two of them, i.e., P1 and P3, were major metabolites, represented more than 60% of the recovered metabolites. [0396] Since there is no exo-olefin structure in tBu-dehydroPLH, present synthesized derivatives have no oxidization like P1 and P4. However, oxidizations such as P3 and P5 are formed during the hepatic metabolism. Various derivatives, which prevent such metabolism, are effective to avoid P450 oxidization at the phenyl ring. The imidazole ring can also be modified to avoid the unfavorable oxidation. 6) Physicochemical stability of dehydroPLH [0397] The physicochemical stability is one of the unfavorable problems of dehydroPLH. In phenylahistin, since there is no additional olefin structure at the benzyl part, there is no such problem. However, in dehydroPLH, the benzylidene moiety can be easily activated, probably with the visible light, and the Z to E migration frequently occurs due to the existence of longer conjugation of the double bond. This migration occurred even under normal room light. In the cytotoxic assay, some of the compounds migrate to E-form during the incubation, although this migration probably equilibrates at the 1 : 1 ratio in the case of -114- WO 2005/077940 PCT/US2005/003636 dehydroPLH. This migration can be controlled. The Z to E migration is also known in combretastatin A4, a same type of tubulin inhibitor, and a few studies for improving this problem were reported. 7) Prodrug Synthesis [0398] The E-form may also be used as a prodrug of dehydroPLH or of one or more of its analogs, including those analogs described herein. One of the undesired properties of anti-tubulin drugs involves its low selectivity between tumor and intact tissues, although these drugs belong to one of the molecular target therapies. This causes undesired side effects. However, if the compounds functions selectively only in tumor tissues, negative side effects of anti-microtubule drugs can be reduced. Since the dehydroPLH (Z-form) can be produced from its E-isomer by visible light irradiation, the E-form is administered and photo irradiation is performed only at the tumor site, then only. the tumor is damaged by photo-produced Z-form and the adverse effect to the intact tissues is reduced. [03991 The E-form can be protected chemically by the addition of a bulky but biodegradable acyl group, which is introduced into the diketopiperazine ring as a prodrug. This acyl group can be cleaved by the protease in the body. Therefore, the acylated-E compound is maintained before administration, then after administration it is changed to the real E-form, which can migrate to the bioactive Z-form by the local photo irradiation. [04001 The synthetic scheme of this acyl-E-form of tBu-dehydroPLH is summarized in Figure 9. EXAMPLE 7 Pharmaceutical Formulations of the Synthesized Dehydrophenylahistins 1) Formulations Administered Intravenously, by Drip, Injection, Infusion or The Like [04011 Vials containing 5 g of powdered glucose are each added aseptically with 10 mg of a compound synthesized by the method and sealed. After being charged with nitrogen, helium or other inert gas, the vials are stored in a cool, dark place. Before use, the contents are dissolved in ethanol and added to 100 ml of a 0.85% physiological salt water solution. The resultant solution is administered as a method of inhibiting the growth of a cancerous tumor in a human diagnosed as having such a tumor at between approximately 10 ml/day to approximately 1000 ml/day, intravenously, by drip, or via a subcutaneous or -115- WO 2005/077940 PCT/US2005/003636 intraperitoneal injection, as deemed appropriate by those of ordinary skill in the art. 2) Formulation to be Administered Orally Or The Like [04021 A mixture obtained by thoroughly blending 1 g of a compound synthesized by the method, 98 g of lactose and 1 g of hydroxypropyl cellulose is formed into granules by any conventional method. The granules are thoroughly dried and sifted to obtain a granule preparation suitable for packaging in bottles or by heat sealing. The resultant granule preparations are orally administered at between approximately 100ml/day to approximately 1000 mI/day, depending on the symptoms, as deemed appropriate by those of ordinary skill in the art of treating cancerous tumors in humans. 3) Formulation to be Administered Topically [0403] Administration to an individual of an effective amount of the compound can also be accomplished topically by administering the compound(s) directly to the affected area of the skin of the individual. For this purpose, the compound administered or applied is in the form of a composition including a pharmacologically acceptable topical carrier, such as a gel, an ointment, a lotion, or a cream, which includes, without limitation, such carriers as water, glycerol, alcohol, propylene glycol, fatty alcohols, triglycerides, fatty acid esters, or mineral oils. Other topical carriers include liquid petroleum, isopropyl palmitate, polyethylene glycol, ethanol (95%), polyoxyethylene monolaurate (5%) in water, or sodium lauryl sulfate (5%) in water. Other materials such as anti-oxidants, hurnectants, viscosity stabilizers, and similar agents may be added as necessary. Percutaneous penetration enhancers such as Azone may also be included. In addition, in certain instances, it is expected that the compound may be disposed within devices placed upon, in, or under the skin. Such devices include patches, implants, and injections which release the compound into the skin, by either passive or active release mechanisms. EXAMPLE 8 In vitro Pharmacology of KPU-2, KPU-35 and t-butyl phenylahistin [0404] The in vitro efficacy studies perfonned with KPU-2, KPU-35 and t-butyl phenylahistin included: A) a panel of six tumor cell lines, B) studies in multidrug-resistant tumor cells, and C) studies to determine the mechanism of action. -116- WO 2005/077940 PCT/US2005/003636 A). Study of KPU-2, KPU-35 and t-butyl phenylahistin in a panel of six tumor cell lines [0405] The following cell lines (source in parentheses) were used: HT29 (human colon tumor; ATCC; HTB-38), PC3 (human prostate tumor; ATCC; CRL-1435), MDA-MB 231 (human breast tumor; ATCC; HTB-26), NCI-H292 (human non-small cell lung tumor; ATCC; CRL-1848), OVCAR-3 (human ovarian tumor; ATCC; HTB-161), B16-FlO (murine melanoma; ATCC; CRL-6475) and CCD-27sk (normal human fibroblast; ATCC; CRL 1475). Cells were maintained at subconfluent densities in their respective culture media. [0406] Cytotoxicity assays were performed as described above in Example 4, using Resazurin fluorescence as an indicator of cell viability. [0407] The disclosed compounds are effective agents against a variety of different and distinct tumor cell lines. Specifically, for example, KPU-2 and KPU-35 were most effective on the HT-29 tumor cell line, both in terms of potency (active in the low nanomolar range) and efficacy (most responsive in terms of the maximum cytotoxic effect); t-butyl phenylahistin exhibited its greatest potency against the PC-3 tumor cell line, although the greatest efficacy was displayed against the HT-29 cell line; KPU-2 and KPU-35 were generally 10-40 fold more potent than t-butyl-phenylahistin whereas the efficacy was similar for all three compounds in the different tumor cell lines; the HT-29, PC-3, MDA-MB-231 and NCI-H292 tumor cell lines all responded similarly to the NPI compounds, whereas the B16-F10 appeared to be somewhat less sensitive. t-butyl-phenylahistin displayed a marked differential between normal fibroblasts and the tumor cell lines, with a ratio ranging from >20 - >100, except for the OVCAR-3 cell line. -117- WO 2005/077940 PCT/US2005/003636 Table 12 Activity of KPU-2, KPU-35 and t-butyl phenvlahistin in the Tumor Panel Screen Cell Line IPU-2 KPU-35 t-butyl-phenylahistin Mean SD n Mean SD n Mean SD n HT-29 Colon IC50 nM 9.8 2.4 4 8.2 2.0 4 420 473 3 % Cytotoxicity 82.5 5.3 4 81.3 4.0 4 88 0.2 3 PC-3 Prostate IC50.nM 13.4 0.7 4 13.2 2.5 4 174 - 2 % Cytotoxicity 60.3 2.1 4 56.8 1.0 4 59.5 - 2 MDA-MB-231 Breast 13.8 1.9 3 9.7 4.2 4 387 - 2 IC50 nM 56.7 7.2 3 59.3 5.6 4 65.5 - 2 % Cytotoxicity NCI-11292 Lung IC50 nM 17.5 1.1 4 15.9 1.1 4 384 194 3 % Cytotoxicity 70.5 2.9 4 68.5 2.9 4 65 5 3 OVCAR-3 Ovary IC50 nM >20,00 - 4 >20,000 - 4 >20,000 - 2 % Cytotoxicity 0 3.0 4 39 2.2 4 37 - 2 45.8 B 16-F 10 Melanoma IC50 nM 37.1 26.3 4 32.3 19.9 4 736 '650 3 % Cytotoxicity 71.8 2.5 4 72.0 2.2 4 74 2 3 CCD-27sk Fibroblast 9.2 2.9 4 7.4 2.6 4 >20,000 - 2 IC50 nM 64.3 2.4 4 60.8 1.9 4 45 - 2 % Cytotoxicity I I II I III B). Studies in Drug Resistant Cell Lines [04081 One of the major challenges in the use of chemotherapeutic agents in clinical oncology is the development of resistance to the drug effect by the tumor cells. There are several mechanisms for the development of resistance, each of which will have differential effects on chemotherapeutic drugs. These mechanisms include increased expression of ATP-dependent efflux pumps such as the P-glycoprotein encoded by MDR1 or the multidrug-resistance associated protein 1 encoded by MRP1. Reduced drug uptake, alteration of the drug's target, increasing repair of drug-induced DNA damage, alteration of the apoptotic pathway and the activation of cytochrome P450 enzymes are other examples of mechanisms by which cancer cells become resistant to anticancer drugs. The selected -118- WO 2005/077940 PCT/US2005/003636 compounds were studied in three different cell lines that exhibit two different mechanisms of resistance; the overexpression of the P-glycoprotein and altered topoisomerase II activity. 1) Human Uterine Sarcoma Tumor Cell Line Pair: MES-SA (Taxol Sensitive) and MES-SA/Dx5 (Taxol Resistant). [04091 This cell line expresses elevated mdr-1 mRNA and P-glycoprotein (an extrusion pump mechanism). Pretreatment with cyclosporin-A (CsA) blocks P-glycoprotein and reinstates activity in the resistant cell line for those compounds for which the resistance is due to elevated P-glycoprotein. [04101 As can be seen from Table 13, KPU-2, and KPU-35 have the same potency in the resistant cell line as in the sensitive line and the potency of t-butyl phenylahistin was only slightly reduced. Cyclosporin A (CsA) pretreatment did not alter the potency of the selected compounds. In contrast, taxol was virtually inactive in the MES SA/DX5 resistant cell line, whereas this compound was very potent in the sensitive cell line. CsA treatment restored the sensitivity to taxol of the MES-SA/DX5 cell line. The MES SA/DX5 cell line also showed reduced susceptibility to etoposide (60 fold), doxorubicin (34 fold) and mitoxantrone (20 fold). [0411] These data indicate that the effects of KPU-2, KPU-35 and t-butyl phenylahistin are not susceptible to the taxol-related resistance mechanism (p-glycoprotein) in this cell line, and that cross-resistance from taxol does not occur to these selected compounds in this model. -119- WO 2005/077940 PCT/US2005/003636 Table 13 Activity of KPU-2, KPU-35, t-butyl-phenylahistin and Taxol in MES-SA Taxol Sensitive and MES-SA/DX5 Taxol Resistant Human Uterine Sarcoma Tumor Cell Lines Compound MES-SA Sensitive MES-SA/DX5 Resistant Study No CsA Pretreat No CsA CsA Pretreat CsA IC50 IC50 Ratio IC50 Ratio IC50 Ratio nM nM No CsA nM MES-SA nM No CsA KPU-2 Study I 8.5 - - 10.5 1.2 - Study II 19.4 27.4 1.4 21.7 1.1 37.8 1.74 KPU-35 Study I 6.6 - 5.2 0.8 - Study III 3.9 2.0 0.5 2.5 0.6 6.7 2.7 t-butyl phenylahistin 144 - - 825 5.7 - Study I 122 162 1.3 694 4.3 622 0.9 Study III Taxol Study I 4.4 - - >20,000 >455 - Study II 13.3 7.6 0.6 >>100 >>8 40 <<0.25 Study III 7.3 2.8 0.4 >24,000 >3000 2.0 <<0.001 [04121 See also the additional data presented in Figure 43. 2) Human Acute Promyelocytic Leukemia Cell Line Pair: HL-60 (Mitoxantrone-Sensitive) and HL-60/MX-2 (Mitoxantrone-Resistant) [0413] This cell line is considered to have atypical drug resistance properties with altered topoisomerase II catalytic activity without overexpression of P-glycoprotein. [0414] As can be seen in Table 14, these results indicate that the potencies of the selected novel compounds are very similar in the sensitive and resistant HL-60 cell lines. In contrast, Mitoxantrone loses efficacy by a factor of 24-fold in the resistant HL-60/MX-2 cell line. [0415] Thus, KPU-2, KPU-35 and t-butyl-phenylahistin are not susceptible to the same resistance mechanisms as Mitoxantrone in this cell line, and there is no cross-resistance from Mitoxantrone to these selected novel compounds in this model. -120- WO 2005/077940 PCT/US2005/003636 Table 14. Activity of KPU-2, KPU-35, t-butvl-phenvlahistin and Mitoxantrone in the HL-60 Human Acute Promyelocytic Leukemia Tumor Sensitive and Resistant Cell Line Pair HL-60 Sensitive HL-60 Resistant Compound IC50 nM IC50 nM Ratio to Sensitive KPU-2 6.4 8.17 1.28 KPU-35 9.2 7.3 0.79 t-butyl-phenylahistin 255 175 0.69 Mitoxantrone 202 4870 24.1 3). Human Breast Carcinoma Cell Line Pair: MCF-7 (Taxol Sensitive) and MCF-7/ADR (Taxol Resistant) [0416] This study involved KPU-2 in comparison to taxol. KPU-2 demonstrated similar potencies in both the sensitive and resistant members of this cell line pair. In contrast, taxol was virtually inactive in the resistant cell line whereas there was low nanomolar potency in the sensitive cell line (Table 15). 104171 These studies confirm in a different human tumor cell line that taxol resistance does not transfer to KPU-2. Table 15. Activity of KPU-2 and Taxol in the MCF-7 Human Breast Carcinoma Sensitive and Resistant Cell Line Pair MCF-7 Sensitive MCF-7/ADR Resistant Compound IC50 nM IC 50 nM Ratio to Sensitive KPU-2 39.6 27.4 0.69 Taxol 2.6 >>100 >>38 C) Studies of the Mechanism of Action 1). Action on Microtubule Function [04181 Human umbilical vein endothelial cells (HuVEC from Cambrex) were used in this study, for evaluating the effects of KPU-2 and t-butyl-phenylahistin in comparison to colchicine and taxol on tubulin by staining for a-tubulin. [0419] Thirty minutes exposure to KPU-2, t-butyl-phenylahistin or colchicine (all at 2 pM) induced microtubule depolymerization as was indicated by the lack of intact microtubule structure in contrast to that observed in the DMSO Control and cell membrane blebbing (a clear indication of apoptosis) in the HuVEC cells, whereas taxol did not induce -121- WO 2005/077940 PCT/US2005/003636 microtubule depolymerization under these conditions. Colchicine is a known microtubule depolymerizing agent whereas taxol is a tubulin stabilizing agent. Similar results were obtained when CCD-27sk cells were exposed to KPU-2 or colchicine. 2). Induction of Apoptosis [04201 Apoptosis and its dysregulation play an important role in oncology; the selective induction of the programmed cell death cycle in tumor cells is the goal of many chemotherapeutic drug discovery programs. This induction of apoptosis can be demonstrated by different methods including the characteristic cell membrane blebbing, DNA fragmentation, hyperphosphorylation of the antiapoptotic factor Bcl-2, activation of the caspase cascade and cleavage of poly (ADP ribose) polymerase (PARP). [04211 The characteristic signs of apoptotic cell death include cell membrane blebbing, disruption of nuclei, cell shrinkage and condensation and finally cell death, very distinctive from necrotic cell death. KPU-2 induced the typical morphological changes associated with early stages of apoptosis in human prostate tumor cells. A similar finding was also clear in the treatment of HuVEC cells with KPU-2. 3). DNA Fragmentation [0422] A late stage characteristic of apoptosis is internucleosomal DNA cleavage that results in a distinctive ladder pattern that can be visualized by gel electrophoresis. This approach was used to study the effect of KPU-2 on DNA laddering in Jurkat cells (human T cell leukemia line) in comparison to halimide and dehydrophenylahistin (KPU-1). KPU-2 induced DNA laddering at the 1 nM concentration whereas halimide and KPU-1 were much less potent. 4). Activation of the Caspase Cascade [04231 Several enzymes in the caspase cascade are activated during apoptosis, including Caspase-3, -8 and-9. The activity of Caspase-3 was monitored in Jurkat cells following treatment with KPU-2, KPU-35 and t-butyl-phenylahistin. [0424] The results indicate that caspase-3 was activated in a dose-dependent manner by treatment with all three compounds in a manner similar to halimide. The caspase -122- WO 2005/077940 PCT/US2005/003636 3 activation occurred over a similar concentration range as for the IC50s for cytotoxicity in the Jurkat cell line (Table 16). Table 16 Cytotoxicity of KPU-2, KPU-35 and t-butyl-phenylahistin in Jurkat Cells Cytotoxicity NPI Compound Potency Efficacy IC50 nM % Cell Death KPU-2 11 94 KPU-35 5 93 t-butyl-phenylahistin 165 93 Mitoxantrone 41 99 5). Cleavage of Poly(ADP-ribose) Polymerase (PARP) in Jurkat Cells [04251 In order to assess the ability of these compounds to induce apoptosis in Jurkat cells, cleavage of poly(ADP-ribose) polymerase (PARP) was monitored. PARP is a 116 kDa nuclear protein that is one of the main intracellular targets of Caspase-3. The cleavage of PARP generates a stable 89 kDa product, and this process can be easily monitored by western blotting. Cleavage of PARP by caspases is one of the hallmarks of apoptosis, and as such serves as an excellent marker for this process. KPU-2 at 100 nM induced cleavage of PARP in Jurkat cells 10 hours after exposure of the cells to the compound. KPU-2 appeared to be more active than either halimide or KPU- 1. 6). Enhanced Vascular Permeability in HuVEC Cells [04261 Compounds that depolymerize microtubules (e.g. combretastatin A-4 phosphate, ZD6126) have been shown to induce vascular collapse in tumors in vivo. This vascular collapse is preceded by a rapid induction of vascular cell permeability initially to electrolytes and soon after to large molecules. The enhanced permeability of HuVEC cells to a fluorescent-labeled dextran is used as a proxy assay for vascular collapse. [04271 KPU-2, KPU-35 and t-butyl-phenylahistin all rapidly (within 1 hour) induced significant HuVEC monolayer permeability, to an extent similar to colchicine. The microtubule stabilizing agent taxol was inactive in this assay (Figure 12). 7). Profile in A Broad Kinase Screen [0428] KPU-2 was initially screened at a concentration of 10 JIM in a panel of 60 different kinases; the ATP concentration was 10 pM. Four kinases were inhibited by greater -123- WO 2005/077940 PCT/US2005/003636 than 50% in the primary screen and the IC50's determined in secondary screening are presented in Table 17. All of the IC50 values are in the low micromolar range, which indicates that inhibition of these kinases is not related to the low nanomolar activities observed for tumor cell cytotoxicity. Table 17. Activity of KPU-2 against Selected Kinases Kinase IC50 (pM) CDK1/Cyclin B (human) 10.1 c-RAF (human) 8.9 JNK3 (rat) 6.8 Lyn (mouse) 11.1 EXAMPLE 9 In vivo Pharmacology [0429] Preliminary studies with KPU-2 were performed using the MX-1 (breast) and HT-29 (colon) xenograft models and the P-388 murine leukemia tumor model, in the mouse. Other tumor models selected on the basis of activity in the in vitro tumor panel were the DU-145 (prostate), MCF-7 (breast), and the A549 (lung) cell lines. The human pancreatic tumor (MiaPaCa-2) was also included. The novel compounds were studied as monotherapy and in combination with a clinically-used chemotherapeutic agent. The doses of the selected novel compounds were determined from the acute tolerability testing (Maximally Tolerated Dose, MTD) and were adjusted if necessary during each study. The doses of the clinically-used chemotherapeutic agents were selected on the basis of historical studies. [04301 KPU-2 was the first compound to be studied in these five tumor models. Following the initial results from this study, all three compounds were compared in the HT 29 human colon tumor, the DU-145 human prostate and the MCF-7 human breast tumor xenograft models. [0431] The above models all use the subcutaneous xenograft implantation technique and are potentially subject to selective effects of a compound on the subcutaneous vasculature producing a magnified (or apparent) antitumor activity. In order to circumvent this possibility, two other tumor models have been incorporated in the research. One of these is the observation of lung metastases following the intravenous injection of B16-F10 mouse -124- WO 2005/077940 PCT/US2005/003636 melanoma tumor cells. The other model is the implantation of MDA-231 human breast tumor cells in the mouse mammary fat pad. While this latter model is a xenograft model, the subcutaneous vasculature does not play a role. Methods 1). Xenograft Models [0432] Animals used were (exceptions are indicated for individual studies): female nude mice (nu/nu) between 5 and 6 weeks of age (-20g, Harlan); group size was 9-10 mice per group unless otherwise indicated. [04331 Cell lines used for tumor implantation were: HT-29 human colon tumor; MCF-7 human breast tumor; A549 human non small cell lung tumor; MiaPaCa-2 human pancreas tumor; DU-145 human prostate tumor. [0434] Selected novel compounds were administered as monotherapy via the intraperitoneal (i.p.) route at the doses indicated for the individual study; for the combination studies the selected reference chemotherapy agents were injected 15-30 min prior to the compound. [0435] Vehicles used in these studies were: 12.5% DMSO, 5% Cremaphor and 82.5% peanut oil for the selected novel compounds; (1:3) Polysorbate 80:13% ethanol for taxotere; (1:1) Cremaphor:ethanol for paclitaxel; for CPT-11 each mL of solution contained 20 mg of irinotecan hydrochloride, 45 mg of sorbitol NF powder, and 0.9 mg of lactic acid, the-pH being adjusted to 7.4 with NaOH or HC1. Saline dilutions are used to achieve the injection concentrations used for the reference compounds. HT-29 Human Colon Tumor Model [04361 Animals were implanted subcutaneously (s.c.) by trocar with fragments of HT-29 tumors harvested from s.c. growing tumors in nude mice hosts. When the tumor size reached 5 mm x 5 mm (about 10-17 days) the animals were matched into treatment and control groups. Mice were weighed twice weekly and tumor measurements were obtained using calipers twice weekly, starting on Day 1. The tumor measurements were converted to estimated mg tumor weight using the formula (W 2 xL)/2. When the estimated tumor weight of the control group reached an average of 1000 mg the mice were weighed, sacrificed and the tumor removed. The tumors were weighed and the mean tumor weight per group was -125- WO 2005/077940 PCT/US2005/003636 calculated and the tumor growth inhibition (TGI) was determined for each group (100% minus the change in the mean treated tumor weight/the change in the mean control tumor weight x 100. [0437] In this model unless otherwise noted for the individual study, the selected novel compounds were injected intraperitoneally every third day for 15 days [1, 4, 8, 11 and 15 (q3dx5)]; CPT- 11 was administered intraperitoneally on days 1, 8 and 15 (qwx3). MCF-7 Human Breast Tumor Model [04381 Female nude mice (~20 g) were implanted s.c. with 21-day release estrogen (0.25 mg) pellets 24 hours prior to the s.c. implantation with MCF-7 tumor fragments (harvested from s.c. tumors in nude mice hosts). The study then proceeded as described for the HT-29 model, using taxotere as the standard chemotherapy agent. [0439] In this model unless otherwise noted for the individual study, the novel compounds were injected via the intraperitoneal route daily on Days 1-5, inclusive (qdx5); taxotere was administered intravenously on Days 1, 3 and 5 (qodx3). A549 Human Lung Tumor Model [04401 Animals were implanted s.c. by trocar with fragments of A549 tumors harvested from s.c. growing tumors in nude mice hosts. When the tumor size reached 5 mm x 5 mm (about 10-17 days) the animals were matched into treatment and control groups. The rest of the study proceeded as described for the HT-29 model, using taxotere and CPT-1 1 as the standard chemotherapy agents. [0441] In this model unless otherwise noted for the individual study, the tested compounds were administered via the intraperitoneal route on a q3dx5 dose schedule for the CPT- 11 combination or on a qdx5 dose regimen for the combination with taxotere; CPT- 11 was administered via the intraperitoneal route on a qwx3 schedule; taxotere was administered intravenously on a qodx3 dose regimen. MiaPaCa-2 Human Pancreas Tumor Model [04421 Animals were implanted s.c. by trocar with fragments of MiaPaCa-2 tumors harvested from s.c. growing tumors in nude mice hosts. When the tumor size reached 5 mm x 5 mm (about 10 -17 days) the animals were matched into treatment and control -126- WO 2005/077940 PCT/US2005/003636 groups. The rest of the study proceeded as described for the HT-29 model, using gemcitabine as the standard chemotherapy agent. [0443] In this model unless otherwise noted for the individual study, test compounds were administered every third day via the intraperitoneal route on Days 1, 4, 7, 10 and 15 (q3dx5); gemcitabine was administered via the intraperitoneal route on Days 1, 4, 7 and 10 (q3dx4). DU-145 Human Prostate Tumor Model [0444] Male mice were implanted s.c. by trocar with fragments of DU-145 tumors harvested from s.c. growing tumors in nude male mice hosts. When the tumors reached ~ 5 mm x 5 mm ( at about 13 -17 days) the animals were matched into treatment and control groups. The remainder of the study proceeded as for the HT-29 model, using taxotere as the standard chemotherapy agent. [04451 In this model unless otherwise noted for the individual study, test compounds were administered via the intraperitoneal route on Days 1, 3, 5, 8 and 11 (q3dx5); taxotere was administered intravenously on Days 1, 3 and 5 (q2dx3). 2). Non Subcutaneous Implantation Tumor Models [04461 The animals used were: female nude mice (nu/nu) (MDA-231 study) or B6D2F1 (B16-F10 studies) mice between 5 and 6 weeks of age (-20g, Harlan); group size was 10 mice per group unless otherwise indicated. [0447] The cell lines used were: MDA-MB-231 human breast tumor and B16-F10 murine melanoma cells. [0448] NPI compounds were administered as monotherapy via the intraperitoneal route at the doses indicated for the individual study; for the combination studies the selected reference chemotherapy agents were injected 15-30 min prior to the NPI compound. MDA-231 Human Breast Tumor [0449] Female nude mice were injected in the mammary fat pad with 2x 106 MDA-231 cells harvested from in vitro cell culture. When the tumor size reached 5 mm x 5 mm (about 14-28 days) the animals were matched into treatment and control groups. The study then proceeded as described for the HT-29 model, using paclitaxel as the standard chemotherapy agent. -127- WO 2005/077940 PCT/US2005/003636 [0450] In this model unless otherwise noted for the individual study, the test compounds were administered via the intraperitoneal route on Days 1, 4, 8, 11 and 15 (q3dx5); paclitaxel was administered via the intraperitoneal route on Days 1-5 (qdx5). B16-Fl0 Metastatic Murine Melanoma Model [04511 Mice received B16-F10 cells (prepared from an in vitro cell culture of B16-FlO cells) by the iv route on Day 0. On Day 1 mice were randomized into treatment and control groups and treatment commenced. Mice were weighed twice weekly, starting on Day 1. All mice are sacrificed on Day 16, the lungs removed, weighed and the surface colonies counted. Results are expressed as mean colonies of treated mice/mean colonies of control mice (T/C) x 100%). The metastasis growth inhibition (MGI) is this number subtracted from 100%. Paclitaxel was the standard chemotherapy agent used in this study. [04521 In this model unless otherwise noted for the individual study, the test compounds were administered via the intraperitoneal route on Days 1-5 (qdx5); paclitaxel was administered intravenously on Days 1-5(qdx5). [0453] When appropriate (n >_ 3), results are presented as means ± SEM. Statistical analysis of studies with several groups was performed using ANOVA with Neuman-Keuls post test, unless otherwise indicated. A one-tailed t-test was also used based on the hypothesis that the compound or drug, or the combination, would reduce tumor growth. Results Studies in the HT-29 Human Colon Tumor Xenograft Model 1. In Vivo Evaluation of KPU-2 +/- CPT-1 1 in the HT-29 Human Colon Tumor Xenograft Model [04541 This study assessed changes in dosage strength and dosing regimen for KPU-2 alone and in combination with a relevant chemotherapeutic CPT- 11 in the HT-29 model. [0455] KPU-2 was administered at doses of 7.5 mg/kg ip daily for five days (qdx5), 3.75 mg/kg ip bid for five days, 7.5 mg/kg ip every second day for 10 days (qodx5) and 7.5 mg/kg ip every third day for 15 days (q3dx5). The combination of CTP- 11 with NPI 2358 at a dose of 7.5 mg/kg ip q3dx5 resulted in a significantly greater effect than for either -128- WO 2005/077940 PCT/US2005/003636 compound alone, which lasted for the duration of the study (Figure 13). These observations during the in-life portion of the study were confirmed. by the mean group final tumor weights at autopsy for which only the combination group exhibited a statistically significant lower tumor weight than controls. In addition the difference between the mean tumor weights of the combination therapy and CPT- 11 monotherapy groups was statistically significant (Figure 14). When the individual final tumor weights at autopsy are examined the greater effect of cotherapy is clear (Figure 14). The TGI of cotherapy was 78% as compared to 38.9% for CPT-11 alone. The TGI for the combined therapy group exceeds the NCI criterion of 58% for a positive result. 2. Study of KPU-2 +/- Standard Chemotherapy vs. Five Human Tumor Xenograft Models 104561 This study consists of five different arms, each with its own protocol, timing, dosing regimen and reference compound. Each arm will be considered within the presentation of the particular tumor model. [04571 The aim of the HT-29 arm of the study was to investigate a slightly higher dose of KPU-2 (10 mg/kg ip q3dx5) in the HT-29 human colon tumor xenograft model as compared to those used in the study described above, in which a marked synergy was observed between KPU-2 (7.5 mg/kg ip q3dx5) and CPT-1 1 (100 mg/kg ip qwx3). [0458] As can be observed in Figure 15, the combination of KPU-2 and CPT- 11 in this model resulted in a marked synergy in the inhibition of tumor growth, with the tumor growth being almost completely inhibited up to Treatment Day 29 in the combination therapy group. The combined therapy maintained efficacy and the estimated tumor growth for this group was significantly lower than for either monotherapy group. Accordingly, administration of KPU-2 and CPT-1 1 inhibited tumor growth and is an effective anti-tumor treatment. [04591 The observations of the in-life portion of the study (estimated tumor growth, Figure 15) are supported by measurement of the weights of the tumors excised at autopsy (Figure 16). The tumor weights for the combination group was significantly less than the Controls (p<0.01), as were the tumor weights for CPT-1 1 alone (p<0.05). [0460] When the individual final tumor weights are considered (Fig 16), the tumor size for the combination group was generally smaller than for the other treated or -129- WO 2005/077940 PCT/US2005/003636 control groups. The TGI of the combination group was 65.8%, indicating a positive effect by the NCI criterion, while monotherapy did not reach the NCI criterion of TGI> 58%. 3. Study of activity of KPU-2, KPU-35 and t-butyl-phenylahistin in the HT-29 Human Colon Tumor Xenograft Study [0461] The results of this study are presented in Figure 17 and Table 18. The combination therapy groups all indicated a marked synergy between the novel compounds and CPT- 11. The individual tumor weights demonstrate the effectiveness of the cotherapy treatment (Figure 18). In each case the TGI for the combination group surpasses the NCI criterion for a positive effect, whereas the TGI for CPT- 11 monotherapy did not reach this level. -130- WO 2005/077940 PCT/US2005/003636 00 0n. 0 0 0 0 0 0 00 0I-. 0 0 00 00 cf) *! c ) c c >i 0~ 0 kC.. 4-~ 4-.4- 0 00 C) 0-m f ~ 0 WO 2005/077940 PCT/US2005/003636 4. Summary of the Effects of KPU-2,KPU-35 and t-butyl-phenylahistin in Combination with CPT-1 1 in the HT-29 Human Colon Tumor Xenograft Model [04621 When combined with CPT- 11, KPU-2 enhanced the effect of CPT- 11, the standard chemotherapeutic agent, to a level well in excess of the NCI criterion of a TGI 58% for a positive effect. The results generated in the three studies are very comparable for both the in-life observations (Figure 19) and for the weights of the tumors excised at autopsy (Figure 20). Studies in the DU-145 Human Prostate Tumor Xenograft Model [0463] Two studies have been completed with this model: the first study involved KPU-2 alone and in combination with taxotere; the second study compared KPU-2, KPU-35 and t-butyl-phenylahistin alone and in combination with taxotere. 1. Effect of KPU-2 in Combination with Taxotere in the DU-145 Human Prostate Tumor Xenograft Model [04641 As can be seen from the data obtained during the in-life portion of this study (Fig 21), the most effective treatment of the DU-145 human prostate tumor was the combined therapy of KPU-2 plus taxotere. The treatment effect was most pronounced at the beginning of the study and appeared to be reduced as the study progressed. From treatment Days 20 -27, the combination therapy did provide an apparent TGI that exceeded the NCI criterion (TGI 58%), and the estimated tumor weight of the combined therapy was significantly less than for either monotherapy. 2. Activity of KPU-2, KPU-35 and t-butyl-phenylahistin Alone or in Combination with Taxotere in the DU-145 Human Prostate Xenograft Model [0465] Based on the data obtained with KPU-2 in combination with taxotere in the Study described above a second study comparing KPU-2 to KPU-35 and t-butyl phenylahistin alone and in combination with taxotere was initiated. [0466] The observations made during the in-life portion of this study indicate that the combination of either KPU-2 or KPU-35 with taxotere has a greater reduction on tumor growth than for taxotere alone (Figure 22). The tumor growth was almost completely blocked by KPU-35 in combination with taxotere. -132- WO 2005/077940 PCT/US2005/003636 [04671 The excised tumor weights at autopsy confirmed the observations made during the in-life segment of the study. The combination of either KPU-2 (Figure 23) or KPU-35 (Figure 24) with taxotere was significantly more effective than taxotere alone in blocking tumor growth. In the case of KPU-35, three of ten mice showed evidence for tumor shrinkage. The tumor growth inhibition indices indicated a marked inhibition of tumor growth for KPU-2 (group mean = 74.1 %) and an almost total block for KPU-35 (group mean = 92.5%). Taxotere alone did not reach the NCI established criterion for a positive effect (TGA : 58%). 5. Studies in the MCF-7 Human Breast Tumor Xenograft Model [0468] This study compared the effects of KPU-2, KPU-35 and t-butyl phenylahistin in the MCF-7 human breast tumor xenograft model. The doses of the compounds were administered on Days 1, 2, 3, 4, and 7; Taxotere was administered on Days 1, 3 and 7. [04691 The selected novel compounds have early onset, statistically significant effects when used in combination with taxotere in this model, apparently almost completely blocking estimated tumor growth (Figure 25). Of the three compounds, KPU-2 appeared to be the most effective, with t-butyl-phenylahistin also exhibiting a significant potentiation of taxotere. 6. Studies in the A549 Human Non Small Cell Lung Tumor Xenograft Model [04701 The in-life observations during this study (Figure 26) indicated that the combination of KPU-2 (7.5 mg/kg ip, qdx5) with taxotere resulted in a marked inhibition of tumor growth as compared to the Control or either monotherapy group. This was confirmed by the autopsy tumor weights, as the mean of the cotherapy group was significantly less than that of taxotere alone or the Control group (Figure 27). The cotherapy group tumor weights form a cluster of low tumor weights, indicating the consistency of the effect. [0471] When the tumor growth index is calculated, the cotherapy group had a TGI of 74.4% as compared to the control group well in excess of the NCI criterion for a positive effect (TGI > 58%). Taxotere alone had a TGI of 26.1 %. -133- WO 2005/077940 PCT/US2005/003636 7. Studies in the MDA-231 Human Breast Tumor Orthotopic Xenograft Model [04721 This model involves the placement of the human tumor tissue into the mouse mammary fat pad, a surrogate of the natural environment. In this manner the possibility of a positive effect due to a specific action on the subcutaneous vascular bed is avoided. This study compared the effect of KPU-2 (7.5 mg/kg ip, q3dx5) alone and in combination with paclitaxel (16 mg/kg ip, qdx5). [0473] Three weeks into the study there was a significant inhibition of tumor growth in the combination therapy group, a highly significant effect. This effect appeared to be more marked than for taxotere alone (Figure 28). 8. Studies in the Murine Melanoma B16 F10 Metastatic Tumor Model [0474] This study examined the effect of KPU-2, KPU-35 and t-butyl phenylahistin alone and in combination with paclitaxel on the number of metastases appearing on the surface of the lung 16 days after the intravenous injection of B16 F10 melanoma cells to the mouse. This model is not a xenograft model; however, it does not involve a high degree of vascularization into the tumor mass. [0475] In this model the most effective treatment was KPU-2 alone (Figure 29), having a mean metastases count about 10% less than that for paclitaxel (MGIs of 41.6% and 35.0 %, respectively). While this study does not itself establish that combination therapy is more effective than monotherapy, it does indicate that KPU-2, KPU-35 and t-butyl phenylahistin are most effective in highly vascularized tumors. EXAMPLE 10 Assays For Activity Against Pathogenic Fungi [0476] Comparative activity of a dehydrophenylahistin or its analog against a pathogenic fungus, relative to known antifungal compounds recited above, for use in determining the dehydrophenylahistin or its analog's AF/IS value is measured directly against the fungal organism, e.g. by microtiter plate adaptation of the NCCLS broth macrodilution method described in Diagn Micro and Infect Diseases 21:129-133 (1995). Antifungal activity can also be determined in whole-animal models of fungal infection. For instance, one may employ the steroid-treated mouse model of pulmonary mucormycosis (Goldaill, L.Z. & Sugar, A.M. 1994 JAntimicrob Chemother 33:369-372). By way of illustration, in such -134- WO 2005/077940 PCT/US2005/003636 studies, a number of animals are given no dehydrophenylahistin or its analog, various doses of dehydrophenylahistin or its analog (and/or combinations with one or more other antifungal agents), or a positive control (e.g. Amphotericin B), respectively, beginning before, at the time of, or subsequent to infection with the fungus. Animals may be treated once every 24 hours with the selected dose of dehydrophenylahistin or its analog, positive control, or vehicle only. Treatment is continued for a predetermined number of days, e.g. up to ten days. Animals are observed for some time after the treatment period, e.g. for a total of three weeks, with mortality being assessed daily. Models can involve systemic, pulmonary, vaginal and other models of infection with or without other treatments (e.g. treatment with steroids) designed to mimic a human subject susceptible to infection. [0477] To further illustrate, one method for determining the in vivo therapeutic efficacies (ED 5 o, e.g. expressed in mg dehydrophenylahistin or its analog/kg subject), is a rodent model system. For example, a mouse is infected with the fungal pathogen such as by intravenous infection with approximately 10 times the 50% lethal dose of the pathogen (106 C. albicans cells /mouse). Immediately after the fungal infection, dehydrophenylahistin compounds are given to the mouse at a predetermined dosed volume. The ED 50 is calculated by the method of Van der Waerden (Arch Exp Pathol Pharnakol 195:389-412, 1940) from the survival rate recorded on 20th day post-infection. Generally, untreated control animals die 7 to 1 3 days post-infection. [04781 In another illustrative embodiment, C. albicans Wisconsin (C43) and C. tropicalis (C112), grown on Sabouraud dextrose agar (SDA) slants for 48 h at 28*C, are suspended in saline and adjusted to 46% transmission at 550 nm on a spectrophotometer. The inoculum is further adjusted by hemacytometer and confirmed by plate counts to be approximately 1 or 5 x 107 CFU/ml. CF-1 mice are infected by injection 1 or 5 x 106 CFU into the tail vein. Antifungal agents are administered intravenously or subcutaneously in ethanol:water (10:90), 4 h post infection and once daily thereafter for 3 or 4 more days. Survival is monitored daily. The ED 50 can be defined as that dose which allows for 50% survival of mice. -135- WO 2005/077940 PCT/US2005/003636 EXAMPLE 11 Evaluating Antimicotic Activity [0479] Benzimidazoles and griseofulvin are anti-tubulin agents capable of binding to fungal microtubules. Once bound, these compounds interfere with cell division and intracellular transport in sensitive organisms, resulting in cell death. Commercially, benzimidazoles are used as fungicidal agents in veterinary medicine and plant disease control. A wide variety of fungal species, including Botrytis cinerea, Beauveria bassiana, Helminthosporium solani, Saccharomyces cerevisiae and Aspergillus are susceptible to these molecules. Toxicity concerns and increasing drug resistance, however, have negatively impacted their usage. Griseofulvin is used clinically to treat ringworm infections of the skin, hair and nails, caused by Trichophyton sp., Microsporum sp., and Epidermophyton floccosum. Its antifungal spectrum, however, is restricted to this class of fungal organisms. Genotoxicity is also a significant side effect. Terbinafine, while an alternative first-line treatment, is more costly. Further, clinical resistance recently has been observed in Trichophyton rubrum (the major causative agent for all dermatophyte infections). [04801 In Candida albicans, microtubule/microfilament formation is affected where cells are exposed to the microtubule inhibitors nocodazole and chloropropham. These results further validate the exploration of cytoskeleton inhibitors as effective antimycotic agents. Accordingly, several of the compounds disclosed herein were evaluated for antimycotic activity. [0481] Specifically, disclosed compounds were evaluated alongside commercially available microtubulin inhibitors as well as recognized antifungal agents. The test compounds and controls used in this study: (-)-Phenylahistin, KPU-1, KPU-2, KPU- I1 and KIPU-17, KPU-35, t-butyl phenylahistin, Colchicine (commercial microtubulin inhibitor tested versus 3 Candida isolates), Benomyl (commercial microtubulin inhibitor tested versus 3 Candida isolates), Griseofulvin (commercial microtubulin inhibitor and antibiotic control for testing versus 6 dermatophyte isolates), Amphotericin B (antibiotic control for testing versus 3 Candida isolates), Itraconazole (antibiotic control for testing versus 2 Aspergillus isolates). -136- WO 2005/077940 PCT/US2005/003636 [0482] Microorganisms against which these compounds were tested included: Candida albicans, Candida glabrata, Aspergillus fumigatus, Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum. With the exception of Candida glabrata (one isolate), two isolates of each species were tested. [0483] Antifungal susceptibility testing was accomplished according to the methods outlined in the National Committee for Clinical Laboratory Standards, M38-A "Reference Method for -Broth Dilution Antifungal Susceptibility Testing of Conidium Forming Filamentous Fungi; Approved Standard." This includes testing in RPMI-1640 with glutamine and without bicarbonate, an inoculum size of 0.4 - 5 x 104, and incubation at 30 or 35*C for 48 hours. The minimum inhibitory concentration (MIC) was defined as the lowest concentration that resulted in an 80% reduction in turbidity as compared to a drug-free control tube. Drug concentrations were 0.03-16 pg/ml for the investigational compounds, 0.015-8 Rg/ml for itraconazole and griseofulvin. [04841 The minimum inhibitory concentration (MIC) at which a compound prevented the growth of the target microorganism was assessed according to the modified version of the NCCLS protocol. Minimum inhibitory concentrations (MIC) were determined at the first 24-hour interval where growth could be determined in the drug-free control tube. The defined MIC was the lowest concentration that exhibited an 80% reduction in turbidity as compared to the growth control. The minimum lethal concentration (MLC) was determined by plating 0.1 pl from the MIC concentration and each concentration above the MIC. The MLC was called at the first concentration that exhibited five or fewer colonies of fungal growth representing a 99.95% kill. When a MIC was obtained, a minimum fungicidal concentration (MFC) was determined to assess the fungistatic/fungicidal nature of the compound. This procedure entails diluting drug-treated cell samples (removed from test wells containing compound at and above the MIC) to compound concentrations significantly below the inhibitory concentration and depositing them on agar plates. The compound is scored as fungistatic if the cells are able to resume growth and fungicidal if no regrowth is possible because the compound had killed the organisms. -137- WO 2005/077940 PCT/US2005/003636 [0485] Compounds disclosed herein were shown to be effective against two Trichophyton species. T. rubrum is the principal causative agent for human dermatophytic infections, and would be the key organism to target in the development of a clinical agent. [0486] Compounds KPU-2, KPU-11 and KPU-17, KPU-35 & t butylphenylahistin were equivalent in potency or in some cases more potent than griseofulvin, a current, standard pharmaceutical agent used for treating dermatophytic infections. [0487] Compounds (-)-Phenylahistin and KPU-1 were significantly less potent than the other compounds when tested versus T. rubrum and weaker but more comparable to the others versus the sensitive T. mentagrophytes isolate. [0488] In those instances when an MFC could be determined, the results indicate that these compounds are fungistatic in nature (see Tables 19 and 20). -138- WO 2005/077940 PCT/US2005/003636 AA 6 00cc lC Cl 00 C> \0 ~ C 1 ~N o 0N - 00 00 C- No N Nl 'nCl 00 'o A A A A A 0 A( A A -4!1 - 139 - WO 2005/077940 PCT/US2005/003636 4 A0 -. 'A 0 ~A AA A A A -A -A - -- A "A \AAo AA -~ ~ B A A 0 0 C0 N 00 Cq \,o 0> ~ n in 'D0 00 '. oN . - 140 - WO 2005/077940 PCT/US2005/003636 EXAMPLE 12 Evaluating vascular targeting activity [04891 Tumors and neoplastic conditions can be treated using the compounds disclosed herein. The occlusion of the blood supply in tumors with vascular targeting agents (VTAs) induces regression of the tumors. The compounds disclosed herein, including NPU 02 and KPU-35, for example, can be as VTAs. Many VTAs exhibit their vascular effects by interacting at the colchicine-binding site on microtubules. This interaction induces a characteristic, rapid collapse and occlusion of established vasculature in the tumor and therefore compromises the integrity of existing vessels leading to necrosis. [04901 Vascular collapse can occur, for example, within 30-60 minutes of exposure to the VTA and involves changing the shape of the immature and proliferating, but not the quiescent and mature, endothelial cells in the central portion of the tumor. This differential effect on vascular cells provides a rationale for the selective effects on the tumor due to the higher percentage of proliferating immature endothelial cells in the tumor blood vessels versus normal blood vessels. VTAs can be classified into three overlapping spectra of activity: (1) potent vascular and cytotoxic effects, (2) potent vascular with weak cytotoxic effects, and (3) potent cytotoxic with weak vascular effects. In Vivo Vascular Targeting Activity of KPU-02 and KPU-35 [04911 Animal models are essential to investigate new therapies that inhibit tumor-induced angiogenesis, target the established tumor vasculature, and inhibit tumor growth. [04921 A murine syngeneic "pseudo-orthotopic" breast cancer model was used to address these issues. Torres Filho et al., Microvascular Research (1995)49, 212-226, which is incorporated herein by reference in its entirety. To create the "pseudo-orthotopic milieu," the coverslip of a dorsal skinflap chamber was removed and small pieces of mammary fatpad from donor mice were implanted into the chamber. On top of the fatpad graft, tumor spheroids containing N202 mammary tumor cells transduced with Histone (H12B)-green fluorescent protein (GFP) were applied. The use of H2B-GFP transduced cells allows for visualizing tumor growth and monitoring mitosis and apoptosis. -141- WO 2005/077940 PCT/US2005/003636 [0493] Fluorescence video microscopy allows for the relatively non-invasive study of tumor microcirculation in conscious mice. This model can provide data regarding the effects of compounds on tumor vasculature, tumor growth, mitosis and apoptosis, and is useful to examine the activity of compounds either alone or in combination with other therapeutics. Utilizing this model, KPU-02 and KPU-35 were shown to induce a rapid vascular collapse leading to central necrosis, and the regression of established tumors after a single i.v. administration. [04941 On day 12 of tumor growth, mice were treated i.v. with a 2-minute infusion of 5 mg/kg KPU-35, a 5 minute i.v. infusion of 10 mg/kg KPU-02, or bolus of vehicle (10% solutol (w/w) + 2% DMSO in water). On day 13, 5-minute infusions of 10 mg/kg KPU-02, KPU-35 or vehicle were administered. Treatments with KPU-02 or KPU-35 were well tolerated. Mice were observed for two additional days. Tumor area, blood flow rate, and vascular density within and surrounding the tumor were visualized. Real-time observations were recorded at various time-points using still photos and video microscopy. [0495] This study demonstrates the rapid collapse of the central vasculature after the single i.v. treatment with either KPU-02 or KPU-35. The changes in vascular functions resulted in a significant central tumor necrosis, without an observed effect on the vasculature in the surrounding fat pad or skin (Figure 30). These observations support the selectivity and specificity of KPU-02 and KPU-35, which both individually can disrupt established tumor vasculature. In Vivo Activity of KPU-02 in Human Tumor Xenografts [0496] When KPU-02 was administered with CPT- 11 (Irinotecan), Taxotere or Paclitaxel, marked antitumor activity was seen in the human colon (HT-29), breast (MCF-7; MDA-MB231) and lung (A549) tumor xenograft models (Table 21). The effect of KPU-02 in the HT-29 model was robust, reproducible in three studies, and showed a dose-dependent effect i.e., 7.5 mg/kg was statistically greater than 2.5 mg/kg (Figures 32, 33). In vitro Activity of KPU-02 and KPU-3 5 in HuVEC cells [04971 The above-described in vivo effects of KPU-02 and KPU-35 on tumor vasculature were supported by the in vitro effects of the same compounds in HuVEC cells. Human umbilical vein endothelial cells are considered a good in vitro model of tumor -142- WO 2005/077940 PCT/US2005/003636 endothelium, which is considered "immature". Tumor endothelium lacks supporting vascular mural cells and is increasingly reliant on microtubule network for integrity of the tumor vasculature. Therefore, disruption of the microtubule network tumor causes vascular collapse. KPU-02 induces rapid tubulin depolymerization in HuVEC cells. [0498] Human umbilical vein endothelial cells (HuVECs; Cambrex CC2519A) were maintained at subconfluent densities in EGM-2 (Cambrex) media. The cells were cultured in an incubator at 37'C in 5% CO 2 and 95% humidified air. For tubulin staining assays, HuVEC cells were seeded at a density of 3x10 4 cells/ml in EGM-2 on tissue culture compatible coverslips (Fisher). The plates were returned to the incubator for 2 days. [0499] Stock (20 mM) solutions of the test compounds were prepared in 100% DMSO. 400X concentrated dilutions of the compounds were prepared in 100% DMSO. 5 pl volumes of the dilutions were added to individual wells resulting in a final concentration of 200 nM. The final concentration of DMSO was 0.25% in all samples. The plates were returned to the incubator for 30 minutes. HuVEC cells were treated for 30 min with 200 nM KPU-02 or KPU-35. [0500] The cells were rinsed in dPBS before fixation in 10%(v/v) neutral buffered formalin for 10 minutes at room temperature. Following fixation, a-tubulin was visualized by indirect immunofluorescence. Specifically, the cells were permeabilized in 0.2%(v/v) triton X-100/dPBS for 10 minutes. The cells were washed prior to transferring the coverslips to a humidified chamber, the coverslips were blocked for two hours in antibody buffer (2%(w/v) BSA/ 0.1%(v/v) Tween 20/ dPBS). The coverslips were incubated with 50 1Ll of 0.1 ptg/ml mouse a-tubulin (Molecular Probes) in antibody buffer for 1 hour before washing and incubation with 50 pl of 1 pg/ml goat anti-mouse FITC (Jackson ImmunoResearch Laboratories) for one hour in the dark. Finally, the cells were washed and treated with 2 ptg/ml DAPI (Molecular Probes) for 10 minutes before rinsing in H20 and mounting with Vectashield (Vector Labs) mounting media. The cells were imaged using a 60x oil immersion objective on an upright microscope (Olympus BX51). The images were digitally captured using a CCD camera and Magnafire 2.0 software (Olympus). Post image processing was performed in Photoshop Elements 2.0 (Adobe) and in Microsoft Powerpoint. -143- WO 2005/077940 PCT/US2005/003636 105011 Figure 33 shows that KPU-02 and KPU-35 rapidly induce tubulin depolymerization in HuVEC cells. KPU-02 induces dose dependent monolayer permeability in HuVEC cells. [05021 Human umbilical vein endothelial cells (HuVECs; Cambrex CC2519A) were maintained at subconfluent densities in EGM-2 (Cambrex) media. The cells were cultured in an incubator at 371C in 5% CO 2 and 95% humidified air. For monolayer permeability assays, HuVEC cells were seeded at 1x10 5 cells/ ml in EGM-2 media on Fibronectin-coated 3.0 tm Fluoroblok inserts (Becton Dickinson) in 24-well plates. The plates were returned to the incubator for 4 days to allow the cells to reach confluency. [0503] Stock solutions (20 mM) of the test compounds were prepared in 100% DMSO. 1OX concentrated serial dilutions of the compounds were prepared in EGM-2. 10 pl volumes of the serial dilutions were added to the test inserts in duplicate resulting in final concentrations ranging from 2 pM to 2 nM. The final concentration of DMSO was 0.25% in all samples. The cells were treated with 2 nM-2 pM KPU-02 for 15 minutes. [0504] FITC-Dextran (50 mg/ml) in dPBS (38.2 kDa; Sigma) was diluted 2.5 fold in EGM-2, 10 ptl of FITC-Dextran was added to each insert. The final concentration of FITC-Dextran was 1 mg/ml. The plates were returned to the incubator and 30 minutes later the fluorescence of the lower chambers of the 24 well plates was read using a Fusion fluorimeter (Packard Bioscience) with , = 485 nm and Xem = 530 nm filters. [0505] Figure 34 shows that KPU-02 is able to induce monolayer permeability in a dose dependent manner. The results shown in Figure 34 represent the mean ± S.D. of three independent experiments. Blood Flow in the P22 Rat Sarcoma Model with 1 25 1-IAP [0506] Tumor blood flow was assessed in a model using a quantitative 12__ iodoantipyrine (IAP) technique in rats bearing a P22 rat sarcoma. KPU-02 (15 mg/kg, IP) markedly and selectively reduced tumor blood flow to 23% of vehicle at 1 hour after administration; blood flow remained markedly reduced 24 hours later (59% vehicle). In contrast, blood flow in non-tumor tissues was affected to a much lesser extent at 1 hour (see Figure 35). -144- WO 2005/077940 PCT/US2005/003636 [0507] The reduction in blood flow at 24 hours post-dose was more variable between tissues for KPU-02 compared to vehicle, as shown in Figure 36. The blood flow to the tumor was the most affected. other tissues exhibited a small. reduction in blood flow. skeletal muscle blood flow appeared to be increased at 24 hours post-dose. [05081 The effects of KPU-02 observed at 1 hour appear to be longer lasting and more selective for tumor blood flow than that previously reported for CA4P using the same technique. [05091 In an experiment with the P22 rat sarcoma model, it was demonstrated that KPU-02 7.5 and15 mg/kg IP (n=2 per dose) produced a dose-dependent tumor necrosis by 24 hours post-dose, with the highest dose resulting in an almost total necrosis of the tumor as shown in Figure 37. All tumors in the KPU-02-treated rats showed evidence of necrosis, whereas tumors in vehicle-treated rats did not. The VTAs that have entered into the clinic (e.g., CA4P, ZD6126, AVE8062) show similar qualitative effects on tumor blood using the IAP methodology (or similar technology) to demonstrate reduced blood flow in the P22 rat sarcoma tumor and in humans using the dce-MRI technique. See Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al., "Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow," J Clin Oncol 2003;21(23):4428-38; Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, et al., "Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126," Clin Cancer Res 2004; 10(1 1):3650-7; and Gadgeel SM, LoRusso PM, Wozniak AJ, Wheeler C. "A dose-escalation study of the novel vascular targeting agent, ZD6126, in patients with solid tumors," Proc Am Soc Clin Oncol 2002;21:abstract 438; each of which is hereby incorporated by reference in its entirety. Combination Therapy with Microtubule Targeting Agents [05101 The findings that VTAs selectively damage the vasculature in the central part of the tumor versus the periphery, which recovers functionality, support using these agents in combination with chemotherapeutics (Taxol, Vinblastine and Cisplatin), radiation and angiogenesis inhibitors directed against VEGF and EGF. The new VTAs will -145- WO 2005/077940 PCT/US2005/003636 supplement rather than supplant these therapies and should provide for greater antitumor activities. Treatment of other conditions [05111 In addition to cancer, other diseases may be treated using the VTAs disclosed herein. Conditions include other neoplasms, retinopathies, and any other condition or disease that relies upon blood supply, preferably blood supply from new vasculature in order to remain viable and/or proliferate. [05121 Many conditions are associated with excessive or inappropriate vasculature. Examples of conditions associated with excessive vasculature include inflammatory disorders such as immune and non-immune inflammation, rheumatoid arthritis, chronic articular rheumatism and psoriasis; disorders associated with inappropriate or inopportune invasion of vessels such as diabetic retinopathy, neovascular glaucoma, retinopathy of prematurity, macular degeneration, corneal graft rejection, retrolental fibroplasia, rubeosis, capillary proliferation in atherosclerotic plaques and osteoporosis; and cancer associated disorders, including for example, solid tumors, tumor metastases, blood born tumors such as leukemias, angiofibromas, Kaposi sarcoma, benign tumors such as hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, as well as other cancers which require vascularization to support tumor growth. Additional examples of vasculature-dependent diseases include, for example, Osler-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints and wound granulation. Furthermore, excessive vasculature is also associated with clinical problems as part of biological and mechanical implants (tissue/organ implants, stents, etc.). The instant compounds and compositions can be used to target vasculature, in preferably to preferentially target disease vasculature over non disease tissue vasculature, and thus the compounds and compositions can be used in the treatment of such conditions. Other diseases in which vascularization plays a role, and to which the instant compounds and compositions can be used, are known by those of skill in the art. [0513] Examples of retinopathies include age-related macular degeneration (ARMD), diabetic retinopathy, and the like. Pathological angiogenesis is a major contributing factor to a number of retinopathies that collectively are major cause of blindness -146- WO 2005/077940 PCT/US2005/003636 in the developed world. Kahn and Hiller Am J Ophthalmol (1974) 78, 58-67, which is incorporated herein by reference in its entirety. For example, retinal and disk neovascularization occurs in 30-50% of patients with diabetic retinopathy for more than 20 years. Yanko et al Retina (2003) 23, 518-522, which is incorporated herein by reference in its entirety. Furthermore, subretinal neovascularization is a serious complication in -10% of patients with macular degeneration. Ferris et al Arch Ophthalmol (1984), 102, 1640-1642, which is incorporated herein by reference in its entirety. [05141 Vascular targeting agents such as Combretastatin A-4 (CA-4) have been shown to cause the disruption of neovessels in non-neoplastic tissue. Griggs et al Br J Cancer (2001) 84, 832-835, which is incorporated herein by reference in its entirety. Additionally, CA-4P was shown to inhibit the retinal neovascularization that occurs during proliferative retinopathy. Griggs et al Am J Path (2002) 160, 1097-1103, which is incorporated herein by reference in its entirety. Finally, CA-4P Phosphate was demonstrated to suppress the development of VEGF induced retinal neovascularization and inhibit the development and/ or cause partial regression of choroidal neovascularization. Nambu et al Invest Ophthalmology & Visual Sci (2003) 44, 3650-3655, which is incorporated herein by reference in its entirety. The compounds disclosed herein can be used to treat retinopathies. For example, the methodologies of Griggs (2001 and 2002) and Nambu are used to treat retinopathies. Furthermore, the compounds and compositions disclosed herein can be used to treat such retinopathies by applying the compounds and/or compositions to the target area in an effective amount for reducing vascular density and/or vascular proliferation. -147- WO 2005/077940 PCT/US2005/003636 N,+ +1 0 0 4 00 00 knC 00 i'3 - n U 06 40- 75 In -148 WO 2005/077940 PCT/US2005/003636 EXAMPLE 13 Structure-Activity Relationship [0515] The effect of activity from various modifications on the phenyl ring of tBu-dehydroPLH is illustrated by the data in Figure 38. It is apparent that substitution with relatively hydrophobic and smaller functional groups at the m- or o- position increased or maintained the cytotoxic activity at HT-29 cells while substitutions at the p- position decreased activity. While not being bound to any particular theory, this data suggests a rigorous recognition of the phenyl ring by tubulin. [0516] 3D-QSAR (CoMFA) analysis (see Figure 39) also supports the existence of sterically favorable fields at m- and o- positions and sterically unfavorable fields exist at the p- position. X-ray crystal analysis (see Figure 40) indicates that the conformation of potent derivatives require a certain amount of dihedral angle between the phenyl ring and the pseudo-tricyclic cor template formed by DKP and imidazole rings. Thus, modification with the appropriate conformational restriction of the phenyl ring may elicit potent activity. While not being bound to any particular theory, it may be that the binding mode of PLH derivatives at the chochicine binding site of tubulin is different from that of colchicines and its known homologues. EXAMPLE 14 In Vitro Action on Microtubules Purification of Microtubule Protein and Tubulin [0517] Microtubule protein (MTP) was prepared as previously described (Farrell KW and Wilson L. (1987) Tubulin-colchicine complexes differentially poison opposite microtubule ends. Biochemistry 23(16):3741-8, which is incorporated herein by reference in its entirety). MTP preparations consisting of 70% tubulin and 30% microtubule-associated proteins (MAPs) were isolated from bovine brain by three cycles of warm polymerization and cold -depolymerization in PEM100 (100 mM 1-4 piperazinediethansulfonic acid (Pipes), 1 mM MgSO 4 , 1 mM EGTA, pH 6.8) and 1 mM GTP. MTP was drop-frozen in liquid nitrogen and stored at -70*C until use. Tubulin was purified from microtubule protein by phosphocellulose chromatography (PC-tubulin) and stored in PEM50 (50 mM Pipes, 1 mM -149- WO 2005/077940 PCT/US2005/003636 MgSO 4 , 1 mM EGTA, pH 6.8). Protein concentration was determined by a Bradford assay (Sigma Chemicals, St. Louis, MO) using bovine serum albumin as the standard (Bradford, 1976). Test Agents [0518] Stock solutions of KPU-02 were prepared at a concentration of 20 mM in DMSO. Stock solutions of Combretastatin A4 (National Cancer Institute, Bethesda, MD) (CA4) was prepared at a concentration of 5 mM in DMSO. Colchicine (Sigma Chemicals, St. Louis, MO) (CLC) was prepared at a concentration of 3 mM in water. All agents were shielded from ambient light with amber Eppendorf tubes. Serial dilutions were made in DMSO and/or PEM50 to the desired concentrations. Determination of Steady-State Microtubule Polymer Mass [05191 MTP (2 mg/ml) was polymerized into microtubules in the presence of a range of drug concentrations in PEM100 containing 1 mM GTP and a final DMSO concentration of 0.5%. Samples were monitored by light scattering at 350 nm at 37*C for 75 minutes. [0520] Polymerization reactions were centrifuged and the microtubule protein concentrations in the supernatant, a measure of the soluble tubulin at steady state, and the pellet, a measure of the microtubule polymer, were used to calculate the inhibition of polymerization. After incubation, polymerized microtubules were separated and sedimented from unpolymerized MTP by centrifugation (150,000 x g, 45 minutes, 37*C). The supernatant was removed, and the microtubule pellets were depolymerized in deionized H20 (24 hours, 0*C) before protein determination by the Bradford assay. [0521] The percent inhibition was calculated in two ways and the values obtained from the two ways were compared. In one way, a ratio of the microtubule protein in the pellet, drug to no drug, was calculated. Another ratio of microtubule protein in the pellet to the supernatant, drug to no drug, was also calculated. The numbers were in close agreement and the former values were used because they were subject to less variance and experimental perturbation. -150- WO 2005/077940 PCT/US2005/003636 Microtubule Mean Length Distributions [05221 Transmission electron microscopy was used to determine the mean length distribution of microtubules in the absence or presence of tested agent. At 75 minutes and prior to sedimentation, 10 1l aliquots from the polymer mass experiments were fixed by dilution into 290 tl PEM100-buffered 0.2% glutaraldehyde. Thirty microliters of fixed sample was settled onto formvar-coated 150 ICG mesh electron microscope grids for 90 seconds. Excess sample was wicked off with Whatman filter paper. Thirty microliters of cytochrome C (1 mg/ml) was applied for 30 seconds to enhance protofilament resolution and facilitate negative staining. Uranyl acetate (1.5%) was applied for 20 seconds and the excess was wicked off. Grids were viewed in a Jeol electron microscope-1200 EX1 1 at 2000X and 30,OOOX magnification. The Zeiss MOPIII was used to determine microtubule length distributions and mean lengths for at least 100 microtubules per sample. CLC Competition Assays [0523] PC-tubulin (0.2 mg/ml) was incubated in PEM50 with 1 mM GTP, 1% DMSO, 10 iM of tested agent and 7-25 gM [3H] CLC for 120 minutes at 37*C. Measurement of [3H] CLC binding was followed by DEAE-cellulose filter-binding assay as described previously (Wilson, 1970). This method depends on the adsorption of tubulin to filter paper impregnated with DEAE-cellulose. Whatman DE81 filter paper was pre-wet with PEM50 prior to sample application. The total 100 gl reaction volume was applied to 2.5 cm disks of filter paper, over parafilm, on ice. The paper disks were washed by immersion in five successive 50 ml changes of PEM50, 5 min/wash, 4'C, to remove all unbound colchicine. The paper disks with adhering tubulin-bound colchicine were then counted directly in a scintillation vial containing 2 ml of Beckman Coulter Ready Protein solution (Fullerton, CA). All of the disks were washed together. Negligible binding of unbound CLC to the paper disks occurred in controls, either in the presence of absence of tubulin. [0524] The Ki values were calculated by linear regression of a double reciprocal plot of the experimental data in Microsoft Excel. The Km. value of tubulin for CLC under the experimental conditions was first determined, with x intercept equal to -1/Km. Km app, Km in -151- WO 2005/077940 PCT/US2005/003636 the presence of drug, was determined experimentally. The Ki was determined using the relationship Km app = a Km, and for competitive inhibition a = Km(1 + [I]/Ki). Fluorescence Spectroscopy [0525] Fluorescence measurements were performed using a Perkin-Elmer LS50B spectrofluorimeter. PC-tubulin (0.2 mg/ml) was incubated in PEM50, 2 mM GTP, 3% DMSO, with 0 - 30 [tM KPU-02. The interaction of KPU-02 with tubulin was reported by 4,4'-dianilino- 1,1'-binaphthyl- 5,5'-disulfonic acid, dipotassium salt (bis-ANS; Molecular Probes, Eugene, OR) fluorescence, with an excitation wavelength of 395 nm and an emission wavelength maximum of 487 nm. Excitation and emission band passes were 10 nm. This experiment was performed twice. [05261 The bis-ANS fluorophore probes the hydrophobic surface of proteins and a change in intensity of the bis-ANS fluorescence signal is a result of a change in the solvent accessible surface area of a protein. If there is some conformational change that changes the tubulin-bis-ANS interaction upon ligand binding, then bis-ANS can be used to report binding. [05271 PC-tubulin (0.2 mg/ml) was incubated with 0 - 30 pM KPU-02 at 25*C for 20 minutes. Bis-ANS (25 gM) was then added and relative fluorescence intensities of samples were measured at 25*C within 15 minutes. Buffer blank spectra were collected and showed that KPU-02 plus bis-ANS produced negligible fluorescence in the experimental wavelength range. [05281 The Kd was determined by fitting experimental data in Sigmaplot and Microsoft Excel using the equation F = ((-Fmax x L)/(Kd + L)) + F 0 where F is the fluorescence intensity of bis-ANS-tubulin in the presence of total ligand concentration L, Fmax is the bis-ANS fluorescence intensity of fully liganded tubulin, and FO is bis-ANS fluorescence in the absence of drug. Fmax was determined by plotting 1/(Fo-F) versus I/L and extrapolating to i/L = 0. The fraction of binding sites B occupied by KPU-02 was determined using the following relationship: B = (Fo-F)/(Fo-Fmax). The concentration of free ligand was determined with Lfree = L - B[C] in which [C] is the molar concentration of ligand-binding sites, assuming a single binding site per tubulin dimer. -152- WO 2005/077940 PCT/US2005/003636 Inhibition of microtubule polymerization by KPU-02 [0529] KPU-02, CA4, and CLC were assayed for their ability to alter the polymerization of MAP-rich tubulin (MTP) (2 mg/ml) in a cell-free system in vitro. Initially, inhibition of polymerization was assayed using phosphocellulose-purified, microtubule associated protein-free tubulin (data not shown). KPU-02 was a more potent inhibitor towards MTs assembled with glycerol and DMSO seeds as compared to MTs assembled in the presence of MAPs that copurify with tubulin. Although microtubule polymer in the absence of stabilizing MAPs did not reach steady state over a 2-hour period, these assays demonstrated that KPU-02 interacts directly with purified tubulin and that it does not exert its primary effect through a MAP. [05301 KPU-02 and CA4 inhibited MT polymerization more powerfully than CLC as measured by light scattering (Figure 44) and sedimentation analysis (Figure 45). MTP (2 mg/ml) was polymerized into microtubules in the presence of a range of drug concentrations and allowed to reach steady state as monitored by light scattering at 350 nm. Figure 41 depicts turbidity spectra of microtubule protein polymerization in the presence of DMSO drug vehicle (0), 1.25 piM (o), 2.5 pM (-), and 5 pLM (o) NPI-2358 (a), CA4 (b) and CLC (c).KPU-02 and CA4 inhibited MT polymerization with comparable potencies. Figure 45 depicts inhibition of microtubule polymerization in the absence or presence of a range of KPU-02 (o),CA4 (o), and colchicine (0) concentrations. The total polymer mass after 75 minutes of assembly was determined by sedimentation. Error bars are standard deviation values from three experiments. The concentration at which polymerization was inhibited 50% (ICso), is 2.4 ± 0.4 RM for KPU-02, 2.2 + 0.3 gM for CA4, and 7.6 ± 2.4 gM for CLC (Table 22). (Variances obtained by statistical analysis are reported as standard deviation values unless stated otherwise). At concentrations over the IC 50 for in vitro polymerization of MAP rich tubulin, MTP displays aggregation kinetics, suggesting that KPU-02 and CA4 sequester protein to prevent microtubule assembly. -153- WO 2005/077940 PCT/US2005/003636 Table 22. Microtubule polymerization inhibition concentrations. Compound Polymer Mass n Ave. IC50 ± sd (RM) KPU-02 2.4 ±0.4 4 CA4 2.2 ±0.3 3 CLC 7.6 ±2.4 3 [05311 As shown in Figure 44, all three of the tested agents produced a concentration dependent inhibition of the extent of microtubule polymerization from 1.25 - 5 gM. There are two important differences to note among the spectra. First, the initial rate of increase in absorbance over time decreases with increasing drug concentration (Figure 44A and 44B). The spectra indicate that there is a lag period for MT formation in the presence of KPU-02 and CA4. Drugs that significantly and rapidly reduce the soluble, assembly competent pool of tubulin would decrease the initial rate of polymerization. In contrast, the initial rate of polymerization is unchanged at all concentrations of CLC (Figure 44C). Second, MTP in the presence of KPU-02 or CA4 does not reach steady state at high drug concentrations (above 5 jaM), as shown by the absorbance values that increase linearly with time (Figure 44A and 44B). In contrast, MTP in the presence of CLC reaches steady state at high drug concentrations (Figure 44C). [0532] The amount of drug required to inhibit polymerization by 50% (ICso) was determined from the analysis of the linear relationship between the decrease in microtubule polymer sedimented by centrifugation with the increase in drug concentration (Figure 45). The error bars in Figure 45 represent standard deviation values from at least three independent experiments. Decrease in mean microtubule length measured by transmission electron microscopy [0533] Transmission electron microscopy was performed on agent-microtubule polymerization reactions to describe the polymer formed at steady state and to evaluate conclusions drawn from the light scattering spectra. KPU-02, CA4, and CLC all decreased -154- WO 2005/077940 PCT/US2005/003636 the lengths of the microtubules formed at steady state. MTs were progressively shorter with increasing drug concentration (Figures 46, 47 and 48). Figure 46 depicts frequency histograms of mean microtubule lengths in vitro at steady state in the presence of (A) KPU 02, (B) CA4, and (C) CLC. The Zeiss MOPIII was used to determine microtubule length distributions and mean lengths. At least 100 microtubules per drug concentration were counted. Figure 47 depicts electron microscopy used to record microtubules in the absence or presence of tested compounds. At 75 minutes, samples from polymer mass experiments were fixed and stained and viewed in a Jeol electron microscope-1200 EX1 1 at 2000x magnification. Representative electron micrographs of MAP-rich microtubules formed in vitro at steady state in the presence of (A) KPU-02, (b) CA4, and (C) CLC. Scale bar, 10 RiM. Figure 48 depicts a graphical summary. of MT length decrease at steady state in the presence of KPU-02, CA4, and colchicine. Black bars, 1.25 gM, and shaded bars, 2.5 gM drug. In the presence of KPU-02, and CA4, MTs are progressively shorter with increasing drug concentration, until the drug concentration at which MTP displays aggregation kinetics as detected by turbidity, and no MTs are observed. Error bars are standard deviation values from the measurement of at least 100 microtubules. [05341 KPU-02, CA4 and CLC did not affect MT nucleation. The numerous, short microtubules formed in the polymerization reactions evidence that the presence of KPU-02, CA4, or CLC does not affect nucleation. If nucleation were affected, then fewer, longer microtubules, as opposed to numerous, shorter microtubules would have been observed in drug-treated versus control samples. [0535] KPU-02 and CA4 were comparably potent in decreasing the average MT length. At 1.25 [tM, the lowest drug concentration analyzed by electron microscopy, KPU-02 and CA4 decreased mean MT length by approximately 70%, and CLC by 40% (Figure 48). [0536] At drug concentrations over the IC 5 0 for in vitro microtubule polymerization, microtubules are not observed by electron microscopy for KPU-02 and CA4. In contrast, microtubules were observed by electron microscopy for all concentrations of CLC assayed. At concentrations over the IC 50 , microtubule protein in the presence of KPU 02 and CA4 displays aggregation kinetics, characterized by a linear increase in light absorbance over time (Figure 44A and 44B), whereas in the presence of CLC, light scattering -155- WO 2005/077940 PCT/US2005/003636 polymer reaches steady state (Figure 44C). Despite the observation that MTP with KPU-02 or CA4 increases absorbance at 350nm over time, drug-specific protein aggregates were not observed. Fluorescence Spectroscopy [0537] Tubulin (0.2 mg/ml) was incubated with a range of KPU-02 concentrations for 20 minutes at 25*C in PEM50 and 2 mM GTP. KPU-02 quenched bis ANS fluorescence in a concentration-dependent manner (Figure 49A). For KPU-02 and tubulin as measured by non-linear regression analysis of bis-ANS fluorescence intensity at the emission maximum, Kd = 10 + 1.6 gM (standard error) (Figure 49B). The double reciprocal plot of the binding data, assuming a single binding site for KPU-02 per tubulin dimer, yielded a dissociation constant of 6.4 pM (Figure 49C). The two different Kd values obtained by nonlinear and linear regression analysis methods were sufficiently close and the values were considered approximately equivalent. Figure 49A depicts fluorescence emission spectra of tubulin in the presence of increasing KPU-02. Drug binding results in quenching of bis-ANS fluorescence. Figure 49B depicts fluorescence emission maxima at 487 nm fit to obtain the Kd of tubulin for KPU-02, 10 sM, standard deviation 1.6 f1M. Inset, residuals. Figure 49C depicts the double reciprocal transformation of the binding data assuming a one mole drug/mole tubulin. dimer. Competitive Inhibition of CLC Binding [05381 KPU-02 and CA4 competitively inhibited CLC binding to tubulin (Figure 50). Figure 50 depicts the results of an inhibition assay where phosphocellulose-purified tubulin (0.2 mg/ml) was incubated with various concentrations of [ 3 H]CLC in the absence (0), or presence of 10 jiM KPU-02 (o) or 10 pM CA4 (o). Tubulin-CLC Km was 11 ± 4.4 ptM and inhibition constants for KPU-02 and CA4 were 3.2 + 1.7 RM and 2.4 ± 0.3 pM, respectively. Constants were calculated from three independent experiments. The colchicine-tubulin binding reaction is time and temperature dependent and the binding dissociation constant is Kd = 0.1-1 FM, depending on the conditions of the assay (Wilson L and Meza L (1973) The mechanism of action of colchicine. Colchicine binding properties of -156- WO 2005/077940 PCT/US2005/003636 sea urchin sperm tail outer doublet tubulin. Journal of Cell Biology 58(3):709-19, which is incorporated herein by reference in its entirety). Under the test conditions, the Km of tubulin for CLC is 11 + 4.4 gM. The Km may be considered the overall Kd of tubulin for CLC, however, due to the time-dependence of CLC binding, the Km is greater than the reported values for the Kd. The Ki for KPU-02 and CA4 was 3.2 + 1.7 gM and 2.4 + 0.3 ptM, respectively. The Ki is defined as the amount of drug required to inhibit CLC binding by 50% and it is based on the amount of radioactive CLC bound to tubulin. The Ki is a measure of the drugs' ability to compete with CLC; it is not a direct measurement of drug-tubulin binding dissociation because of the method in which binding affinity is reported. Results At all concentrations of CLC assayed, MAP-rich tubulin reached steady state. In contrast, at higher KPU-02 or CA4 drug concentrations, MAP-rich tubulin did not polymerize to steady state and microtubules were not observed by electron microscopy. KPU-02 and CA4 effectively decreased the concentration of available tubulin. This decrease in the pool of soluble tubulin increased the MT critical concentration and prevented polymerization. The stoichiometric amounts of KPU-02 and CA4 required to decrease in vitro polymer mass coupled with the data that microtubule protein did not reach steady state above those concentrations, suggesting that KPU-02 and CA4 act by a sequestering mechanism in which soluble tubulin is bound and prevented from polymerization. Observations by electron microscopy on the steady state, MAP-rich microtubules formed in the presence of the tested agents were consistent with the proposed mechanism that KPU-02 and CA4 sequester tubulin. There was a concentration-dependent decrease in the average microtubule length in the presence of KPU-02, CA4, and CLC. In the presence of KPU-02 and CA4, there was a drug concentration dependent decrease in the initial rate of polymerization, indicating that these drugs reduce the tubulin available for elongation. This decrease in the initial polymerization rate was not seen with CLC due to its slow association with tubulin. Furthermore, microtubules were formed at CLC concentrations over its IC 5 o for polymerization, but microtubules were not formed at KPU-02 or CA4 concentrations over their IC 5 0 for polymerization. While not being bound by any particular theory, the -157- WO 2005/077940 PCT/US2005/003636 concentration of soluble tubulin bound by KPU-02 or CA4 must be under the critical concentration required for tubulin polymerization to proceed. [0539] Binding studies indicated that tubulin has a lower affinity for KPU-02 than it has for CLC. Inhibition of CLC binding to tubulin by KPU-02 and CA4 occurred within a 20-minute incubation period, indicating that KPU-02 and CA4 association with tubulin approaches equilibrium relatively faster than for CLC (data not shown). KPU-02 competitively inhibited CLC binding to tubulin at a site overlapping with the CLC-binding site, consistent with studies characterizing phenylahistin (halimide) (Kanoh K, Kohno S, Kataka J, Takahashi J and Uno I. (1999) (-)-Phenylahistin arrests cells in mitosis by inhibiting tubulin polymerization. The Journal of Antibiotics 52(2):134-141, which is incorporated herein by reference in its entirety). CA4, a structural analog of CLC, also competitively inhibited CLC binding. Without being bound to any particular theory, it appears that despite sharing a tubulin binding region with CLC, KPU-02 and CA4 interact with tubulin and inhibit microtubules by a mechanism distinct from that of CLC. EXAMPLE 15 In Vivo Action on Microtubules Cell culture studies [0540] MCF7 human breast carcinoma cells (American Type Culture Collection, Manassas, VA) stably transfected with GFP-alpha-tubulin (Clontech, Palo Alto, CA) were cultured in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum, 0.1% penicillin/streptomycin and nonessential amino acids (Sigma) in 250-ml tissue culture flasks or 35-mm six-well plates (doubling time, 29 hours) at 37 0 C in 5% CO 2 . Cells were incubated with KPU-02, CA4, or CLC, prepared as described in Example 14, by replacing the original medium with an equal volume of medium containing the required concentration of tested agent or DMSO vehicle, and incubation was continued at 37*C for 20 hours. Mitotic Progression [0541] The fraction of cells in mitosis at a given drug concentration (mitotic index) was determined in the breast cancer cell line MCF7. Cells were plated at a density of -158- WO 2005/077940 PCT/US2005/003636 3 x 104 cells/ml in six-well plates. After 24 hours, cells were incubated in the absence or presence of drug over a range of concentrations (1 nM to 1 gM) for 20 hours. Media were collected and cells were rinsed with versene (137 mM NaCl, 2.7 mM KC1, 1.5 mM KH 2

PO

4 , 8.1 mM Na 2

PO

4 , and 0.5 mM EDTA), detached with trypsin, and added back to the media to ensure that floating and poorly attached mitotic cells were included in the analysis. Cells were fixed with 10% formalin in PBS overnight at 37*C, permeabilized in methanol for 10 minutes, and stained with 4,6-diamidino-phenylindole (DAPI) to visualize nuclei. Stained cells were spread on coverslips in Vectashield mounting media (Burlingame, CA) and sealed onto slides with nail polish. Fluorescence microscopy was used to determine mitotic indices. Results were the mean and standard deviation of 4-7 experiments in which 300 cells were counted for each concentration. The IC 50 was the drug concentration that experimentally induced 50% of the maximal mitotic accumulation at 20 hours. Immunofluorescence microscopy [0542] Cells were prepared as for mitotic progression, except that cells were seeded onto poly-L-lysine (50 [tg/ml, Sigma) treated coverslips. On the day of staining, cells were rinsed in PBS and fixed in 10% formalin overnight at 37*C. Cells were rinsed in PBS, permeabilized in methanol at -20'C, and hydrated with PBS. Coverslips were treated with 20% normal goat serum in PBS/ BSA (1%) for 1 h at room temperature. Cells were incubated in a mouse monoclonal cocktail of anti-alpha- and beta-tubulin, DM1A /DM1B diluted in PBS/BSA for 1 hour at room temperature, then stained with FITC-conjugated secondary antibody and DAPI. Coverslips were mounted using Prolong antifade media (Molecular Probes, Eugene OR). Preparation of cells for analysis of microtubule dynamics 105431 Cells were prepared as for mitotic progression, except that to promote cell spreading, cells were seeded onto glass coverslips that had been pretreated with poly-L-lysine (50 ptg/ml, Sigma) for 2 hours, followed by laminin and fibronectin (10 pg/ml, Sigma) for 1 hour at 37 0 C. Cells were incubated with drug or DMSO for 20 hours and serum-starved. Before analysis, coverslips were transferred to recording media (culture media lacking phenol -159- WO 2005/077940 PCT/US2005/003636 red and- sodium bicarbonate buffered with 25 mM HEPES and supplemented with 3.5 g/L sucrose). To prevent photobleaching, Oxyrase (30 pl/ml, Oxyrase Inc., Mansfield, OH) was added to the recording media immediately before sealing cells in a double coverslip-enclosed chamber. Time-lapse microscopy and image acquisition [0544] Microtubules were observed using a Nikon Eclipse E800 fluorescence microscope with a plan apochromat 1.4 N.A. x 100 objective lens. The stage was enclosed in a Pyrex box and maintained at 36 L 1*C by a forced air heating system. Thirty images of each cell were acquired at 4-s intervals using a Photometrics CoolSNAP HQ digital camera (Tucson, AZ) driven by Metamorph software (Universal Imaging, Media, PA) at 10 MHz, with a 300 ms exposure time, a gain of 2, and 2 x 2 binning to enhance brightness. Analysis of microtubule dynamics [05451 The positions of the plus ends of microtubules over time were tracked using the Metamorph Track Points application exported to Microsoft Excel and analyzed using Real Time Measurement software. The lengths of individual microtubules were graphed as a function of time. Individual growth and shortening rates were determined by linear regression. Changes of > 0.5 ptm between two points were considered to be growth or shortening events, and changes of < 0.5 Rm between two points were considered to be periods of attenuated dynamics or pause. At least 25 microtubules were analyzed for each condition. Results are the mean and standard deviation of at least three independent experiments. [0546] The time-based catastrophe frequency for each microtubule was calculated by dividing the number of catastrophes per microtubule by the time spent in growth or attenuation. The time-based rescue frequency per microtubule was calculated by dividing the total number of rescues per microtubule by the time spent shortening. The distance-based catastrophe and rescue frequencies were calculated similarly by dividing the number of transitions by the length grown or shortened, respectively. Microtubules that were visible for < 2 min were included in the frequency analysis. Dynamicity per microtubule was calculated -160- WO 2005/077940 PCT/US2005/003636 as the length grown and shortened divided by the total life span of the microtubule. Microtubules that were visible for >_ 0.3 min were included in the dynamicity analysis. Cell cycle progression blocked at prometaphase [0547] The concentration range for KPU-02, CA4 and CLC over which cells accumulate in mitosis were determined. After 20 hours, 60-70% of cells were inhibited at prometaphase, compared to 30-40% of cells at metaphase in studies on MT depolymerizers such as the vinca alkaloids and 2-methoxyestradiol, and MT stabilizers such as taxol, epothilone B, and discodermolide (Jordan MA (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Current Medicinal Chemistry - Anti Cancer Agents 2: 1-17, which is incorporated herein by reference in its entirety). The drug concentration necessary for 50% maximal mitotic block (IC 50 ) was evaluated between 1 nM and 1 pM drug (Figure 51). Figure 51 depicts log [Drug] response curves for mitotic progression inhibition by KPU-02, CA4, and CLC. MCF7 cells were cultured in the presence of NPI-2358 (o), CA4 (o), and colchicine (0). To evaluate mitotic indices, MCF7 cells were plated at a density of 3 x 10 4 cells/ml in six-well plates. After 24 hours, cells were incubated in the absence or presence of drug over a range of concentrations (1 nM to 1 gM) for 20 hours. Cells were fixed and stained with DAPI to visualize nuclei. Fluorescence microscopy was used to determine mitotic indices. Results are the mean and standard deviation of three or four experiments in which 300 cells were counted for each drug concentration. The mitotic block IC 50 for KPU-02 was 17.4 + 1.2 nM, CA4 was 5.4 + 0.7 nM, and CLC was 23.8 3.1 nM (Table 23). Table 23. Inhibition of mitotic progression. Compound Mitotic block Ave. n IC50 ±sd (nM) KPU-02 17.4 1.2 4 CA4 5.4 ±0.7 3 CLC 23.8 3.1 4 -161- WO 2005/077940 PCT/US2005/003636 [0548] Most MT-targeting agents block mitosis at the metaphase to anaphase transition. Mitotic block at the metaphase to anaphase transition is associated with suppression of MT dynamics. Without being bound to any particular theory, the earlier prometaphase block, together with the depletion of MT polymer, suggests a distinct mechanism of action for KPU-02 as compared with other MT depolymerizing drugs, e.g., vinblastine, which at low concentrations stabilize MT dynamics. Depolymerization of the mitotic spindle and the interphase array MTs [0549] KPU-02, CA4, and CLC were observed to be potent microtubule depolymerizers in MCF7 cells. Although mitotic spindle microtubules are more susceptible to depolymerization and/or inhibition of polymerization than interphase array microtubules, both microtubule populations were affected (Figure 52). Figure 52 depicts immunofluorescence microscopy images of MCF7 cells. Interphase arrays are relatively more stable to depolymerization by KPU-02, CA4 and CLC than mitotic spindles.. Cells were prepared and seeded as for mitotic progression and treated with the mitotic block IC 5 0 for each drug for 20 hours. Cells were incubated in a mouse monoclonal cocktail of anti alpha- and beta-tubulin, DM.1A/DM1B then stained with FITC-conjugated secondary antibody and DAPI. a-d, Tubulin in control (a), KPU-02 (b), CA4 (c), and CLC (d) treated cells, and e-h, DNA in control (e), KPU-02 (f), CA4 (g), and CLC (h) treated cells. Narrow arrows indicate mitotic spindle polymer and mitotic chromosomes and thicker arrows indicate interphase arrays and nuclei. [0550] At the IC 25 for mitotic block, KPU-02 dramatically altered spindle morphology. Figure 53A-C depicts immunofluorescence microscopy images of MCF7 cells treated with KPU-02 (A), CA4 (B), and CLC (C) for 20 hours. Mitotic spindle destruction with increasing drug concentration. 1-4, Alpha and beta tubulin in control (1), a concentration of IC 25 for mitotic block (2), the IC 50 for mitotic block (3), and twice the IC 50 for mitotic block (4); 5-8, corresponding images of DNA for the adjoining panels. There were no normal, bipolar spindles at the IC 2 5 for KPU-02 or CA4 (Figures 53A and B). Compound-treated cells had monopolar or bipolar spindles with uncongressed chromosomes. In contrast, normal bipolar spindles persist at the IC 25 for CLC (Figure 53C). At the IC 5 o for -162- WO 2005/077940 PCT/US2005/003636 KPU-02, 75% of the mitotic cells contained asters or foci of tubulin, and the remaining cells had no detectable mitotic polymer. In the presence of CLC, half of the cells were bipolar with uncongressed chromosomes and the remaining half were monopolar. At concentrations of twice the IC 50 for mitotic block, there was little detectable MT polymer in mitotic cells treated with KPU-02, CA4, or CLC. [05511 Microtubule interphase arrays were more resistant to depolymerization than mitotic spindles for all of the compounds examined (Figure 52). However, a qualitative decrease in polymer was observed in a dose-dependent manner for all three compounds (Figure 54 A-C). Figure 54A-C depicts immunofluorescence microscopy images of MCF7 cells treated with KPU-02 (a), CA4 (b), and CLC (c) for 20 hours. Interphase MT depolymerization with increasing drug concentration. 1-4, Alpha and beta tubulin in control (1), a concentration of IC 25 for mitotic block (2), the ICso for mitotic block (3), and 2XIC 50 for mitotic block (4); 5-8, corresponding images of DNA for the adjoining panels. Presumably, tubulin is sequestered in these interphase cells, despite the presence of intracellular stabilizing MAPs, just as MAP-rich tubulin is sequestered in in vitro polymer mass assays. Lack of suppression or modulation of MT dynamic instability in living MCF7 cells [0552] KPU-02, as well as CA4, did not have a measurable effect on MT dynamic instability at concentrations effecting 25% (Table 24) or 50% (Table 25) of the maximal mitotic block in MCF7 cells. Without being bound by any particular theory, these data suggest that the antiproliferative mechanism of action of KPU-02 (and CA4) is primarily due to inhibition of MT polymerization, rather than suppression of microtubule dynamics. -163- WO 2005/077940 PCT/US2005/003636 Table 24. MT dynamic instability at the mitotic block. Control sd NPI-2358 sd CA4 sd CLC sd Mean rates (pm/min) Growth 9.03 4.66 11.89 6.23 10.59 4.75 11.31 8.46 Shortening 32.85 18.06 31.87 15.12 40.21 18.90 29.17 17.13 Mean duration (min) Growth 0.41 0.27 0.31 0.15 0.27 0.12 0.26 0.14 Shortening 0.20 0.07 0.20 0.07 0.21 0.09 0.23 0.29 Attenuation 0.58 0.38 0.73 0.36 0.45 0.32 0.56 0.43 % time spent Growth 41.83 29.66 35.31 33.07 Shortening 18.57 20.63 25.19 25.96 Attenuation 39.60 49.81 39.50 40.97 Freq. of (min-1) Catastrophe 1.15 1.27 1.52 1.57 Rescue 3.05 2.79 1.90 2.95 Dyn. (pm/min) 9.87 10.07 13.87 11.31 MTs/cells 16/30 11/33 13/39 8/26 Minutes 40.66 43.69 39.62 35.29 Table 25. MT dynamic instability at the mitotic block. Control sd NPI-2358 sd CA4 sd Mean rates (pm/min) Growth 9.03 4.66 10.63 6.78 11.21 5.64 Shortening 32.85 18.06 34.06 12.84 29.88 18.87 Mean duration (min) Growth 0.41 0.27 0.30 0.18 0.33 0.18 Shortening 0.20 0.07 0.22 0.08 0.22 0.08 Attenuation 0.58 0.38 0.61 0.41 0.55 0.44 % time spent Growth 41.83 33.02 43.64 Shortening 18.57 20.92 20.13 Attenuation 39.60 46.06 36.23 Freq. of (min-1) Catastrophe 1.15 1.22 1.09 Rescue 3.05 2.60 2.79 Dynamicity (pm/min) 9.87 1 10.64 10.91 MTs/cells 30/16 25/11 29/9 Minutes 40.66 33.13 39.14 10553] The examples described above are set forth solely to assist in the understanding of the invention. Thus, those skilled in the art will appreciate that the disclosed methods and compounds encompass and may otherwise provide further derivatives of dehydrophenylahistins. -164- WO 2005/077940 PCT/US2005/003636 [0554] One skilled in the art would readily appreciate that the present invention is well adapted to obtain, for example, the ends and advantages mentioned, as well as others inherent. The methods and procedures described herein are presently representative of preferred embodiments and are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention. [0555] It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. [05561 As noted above, all patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are hereby incorporated by reference herein to the extent allowable by law, such that each individual patent and publication may be treated as specifically and individually indicated to be incorporated by reference. [0557] The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions indicates the exclusion of equivalents of the features shown and described or portions thereof. It is recognized that various modifications are possible within the scope of the invention. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be falling within the scope of the invention. -165-

Claims (20)

1. A method for treating a condition by reducing vascular proliferation or vascular density, comprising administering a compound of formula (I) to an animal in need, wherein said compound has the following structure: R 1 1 Rl- ,R Z R 2 N Z 3N N (I) wherein RI, R 4 , and R 6 , are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated CI-C 2 4 alkyl, unsaturated CI-C 2 4 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, -CO-0-R 7 , cyano, alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl CCO-R 7 , wherein R 7 is selected from a hydrogen atom, a halogen atom, and saturated Ci C 2 4 alkyl, unsaturated CI-C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups; R 1 ' and RI" are each independently selected from the group consisting of a hydrogen atom, a halogen atom, and saturated CI-C 2 4 alkyl, unsaturated CI-C 2 4 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, -CO-O-R 7 , cyano, alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl CCO-R 7 , wherein R 7 is selected from a hydrogen atom, a halogen atom, and saturated Cj C 2 4 alkyl, unsaturated Ci-C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups; 166 AMENDED RI' and RI" are either covalently bound to one another or are not covalently bound to one another; R 2 , R 3 , and R 5 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated CI-CI 2 alkyl, unsaturated CI-C 1 2 alkenyl, acyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups, sulfonyl and substituted sulfonyl groups; X, and X 2 are separately selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom, each either unsubstituted or substituted with a R 5 group, as defined above; Y is selected from the group consisting of a nitrogen atom substituted with R 5 , an oxygen atom, a sulfur atom, an oxidized sulfur atom, a methylene group and a substituted methylene group; n is an integer equal to zero, one or two; Z, for each separate n, if non-zero, and Zi, Z 2 , Z 3 and Z 4 are each separately selected from a carbon atom, a sulfur atom, a nitrogen atom or an oxygen atom; and the dashed bonds may be either single or double bonds; wherein the condition is selected from the group consisting of immune and non immune inflammation, psoriasis, a retinopathy, neovascular glaucoma, macular degeneration, corneal graft rejection, retrolental fibroplasia, rubeosis, and capillary proliferation in atherosclerotic plaques.

2. The method of claim 1, wherein the condition is retinopathy.

3. The method of claim 2, wherein the retinopathy is diabetic retinopathy.

4. The method of claim 2, wherein the retinopathy is due to age-related macular degeneration.

5. The method of claim 1, wherein the condition is associated with hypervascularization.

6. A method of preferentially targeting tumor vasculature over non-tumor tissue vasculature, comprising administering a compound of formula (I) to an animal in need, wherein said compound has the following structure: 167 AMENDED R 1 Z R N R4 Z1/ R 2 ZRN Nz z 6 wherein RI, R 4 , and R 6 , are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated CI-C 2 4 alkyl, unsaturated CI-C 2 4 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, -CO-0-R 7 , cyano, alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl CCO-R 7 , wherein R 7 is selected from a hydrogen atom, a halogen atom, and saturated C 1 C 2 4 alkyl, unsaturated CI-C 2 4 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups; R 1 ' and RI" are each independently selected from the group consisting of a hydrogen atom, a halogen atom, and saturated CI-C 24 alkyl, unsaturated CI-C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, -CO-O-R 7 , cyano, alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl CCO-R 7 , wherein R 7 is selected from a hydrogen atom, a halogen atom, and saturated C 1 C 24 alkyl, unsaturated CI-C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups; RI' and R 1 " are either covalently bound to one another or are not covalently bound to one another; R 2 , R 3 , and R 5 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated CI-CI 2 alkyl, unsaturated CI-C 1 2 alkenyl, acyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted 168 AMENDED heteroaryl, amino, substituted amino, nitro, and substituted nitro groups, sulfonyl and substituted sulfonyl groups; X, and X 2 are separately selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom, each either unsubstituted or substituted with a R 5 group, as defined above; Y is selected from the group consisting of a nitrogen atom substituted with R 5 , an oxygen atom, a sulfur atom, an oxidized sulfur atom, a methylene group and a substituted methylene group; n is an integer equal to zero, one or two; Z, for each separate n, if non-zero, and ZI, Z 2 , Z 3 and Z 4 are each separately selected from a carbon atom, a sulfur atom, a nitrogen atom or an oxygen atom; and the dashed bonds may be either single or double bonds; wherein the non-tumor tissue is selected from the group consisting of skin, muscle, brain, kidney, heart, spleen, and gut.

7. The method of claim 6, wherein the tumor vasculature is preferentially targeted over non-tumor tissue vasculature by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90%.

8. The method according to any one of the preceding claims, wherein each of R 2 , R 3 , R 5 and R 6 is a hydrogen atom.

9. The method according to any one of the preceding claims, wherein each of X, and X 2 is an oxygen atom.

10. The method according to any one of the preceding claims, wherein R 4 is a saturated CI-C 1 2 alkyl.

11. The method according to claim 10, wherein said saturated CI-CI 2 alkyl is a tertiary butyl group.

12. The method according to any one of the preceding claims, wherein R, comprises a substituted phenyl.

13. The method according to claim 12, wherein said substituted phenyl group is methoxybenzene.

14. The method according to any one of the preceding claims, wherein n is equal to zero or one. 169 AMENDED

15. The method according to any one of the preceding claims, wherein n is equal to one.

16. The method according to any one of the preceding claims, wherein n is equal to one and Z, ZI, Z 2 , Z 3 and Z 4 are each a carbon atom.

17. The method according to any one of claims 1-9 and 12-16, wherein R 4 is selected from the group consisting of a halogen atom, tert-butyl, unsaturated Ci-C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, -CO-0-R 7 , cyano, alkylthio, halogenated alkyl including polyhalogenated alkyl, halogenated carbonyl, and carbonyl -CCO-R 7 , wherein R 7 is selected from a hydrogen atom, a halogen atom, and saturated Ci-C 2 4 alkyl, unsaturated CI-C 2 4 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups.

18. The method according to any one of the preceding claims, wherein the compound 0 /--N NH / N NH ~ .- NH / O has the structure:

19. The method according to any one of the preceding claims, wherein the compound is used with a pharmaceutically acceptable carrier.

20. The method according to any one of the preceding claims, wherein the animal is a human. 11670558 072911 170